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Abstract 
Background:  The global incidence of end-stage renal disease (ESRD) continues to rise 
annually.  Accompanying this rise is an increase in the number of patients on hemodialysis. 
These trends are being driven by an unprecedented burden of hypokinetic, non-communicable 
diseases, and particularly the type 2 diabetes-obesity pandemic.  The progression of kidney 
disease is associated with an exponential increase in atherosclerotic cardiovascular disease 
(CVD) and associated mortality.  CVD is the leading cause of hospitalization and death in this 
cohort.  As the ESRD patient population continues to grow, greater efforts must be directed 
toward improving patient outcomes in this cohort, including morbidity, mortality and health-
related quality of life (HRQoL).  
Aims:  This thesis addresses several gaps related to the investigation and application of 
progressive resistance training (PRT) in the hemodialysis setting.  The specific aims were: (i) to 
systematically review the extant literature on PRT in patients with ESRD, and to outline 
recommendations for robust clinical trials; (ii) to assess the feasibility and efficacy of including a 
novel customized resistance training device within a comprehensive intradialytic PRT 
intervention in a conventional hemodialysis unit; (iii) to investigate the effect of a 12-week 
intradialytic PRT intervention on measures of CVD risk, specifically, arterial stiffness (i.e. pulse 
wave velocity; PWV) and associated outcomes (i.e. hemodynamic, anthropometric, and 
hematologic).  
Research Program:  The research program was undertaken from March 2011 to March 2015 
and culminated in a clinical trial enrolling 22 participants conducted across four dialysis centers 
in Adelaide, South Australia.   
vii 
Overview of Chapters (Key Findings):  Chapter 1 presents the background and aims of the 
research program.  Chapter 2 and 3 present a general review of the literature and the general 
methodology for the clinical trial, respectively.  Chapter 4 presents a systematic review of the 
extant literature.  The evidence gathered suggests that PRT can induce muscle hypertrophy and 
improve aspects of physical functioning and HRQoL in this population.  There is also 
preliminary evidence to suggest that PRT may reduce protein-energy malnutrition and CVD risk 
factors, including CRP, total cholesterol, triglyceride, and measures of insulin resistance in 
patients with or at-risk of comorbid type 2 diabetes. Chapter 5 presents on the development, 
feasibility and efficacy of a novel resistance exercise device used to deliver 12 weeks of 
intradialytic PRT.  The device was developed to enable the performance of 2 upper and 3 lower 
body exercises, unilaterally and bilaterally, both before and during dialysis with loads of 2.5 to 
59 kg. The PRT intervention was delivered without serious adverse events, resulted in 71.2 ± 
23.3% adherence and significant adaptation of all training loads from pre to mid to post training 
(83.8% to 185.6%, all p<0.05).  Lower body strength (p<0.001) and HRQoL sub-scales (Role-
Physical, Social Functioning, Role-Emotional) significantly increased (all p<0.01) and a trend 
toward reduced depression was noted (p=0.06).  No significant changes were noted in other 
outcomes. Chapter 6 presents on the effect of a 12-week intradialytic PRT intervention on PWV, 
hemodynamic and associated biomarkers in patients with end stage renal disease (ESRD).  
Twenty-two patients with ESRD (59% men, 71.3 ± 11.0 years, 28.5 ± 5.67 kg/m2, 7 mo. to 13.5 
years on hemodialysis) performed supervised full-body PRT (3 sets, 11 exercises, moderate 
intensity) three times per week during routine hemodialysis treatment. No significant change in 
log-PWV was detected between control and intervention periods [mean difference = 0 (95% CI = 
-0.1 to 0.1); P=0.58].  Similarly, no significant change was noted in any of the secondary 
outcomes between the control and intervention periods.  
Conclusions:  Chapter 7 presents general conclusions to the thesis, as follows:  (i) According to 
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the systematic review of the extance literature (Chapter 4) clinical trials are required to 
investigate a range of novel research questions related to the benefits and application of PRT in 
this cohort and its patient subgroups (e.g. diabetes, depression, dyslipidemia, etc.).  Future studies 
must be of high methodological quality to inform clinical practice guidelines.  (ii)  According to 
the study presented in Chapter 5, PRT using the novel training device was feasible and improved 
measures of physical and psychological health and HRQoL. This device can be utilized in most 
dialysis centers. Future studies are required to evaluate dose-response effects of PRT 
prescriptions in subpopulations, and the application of PRT in standard dialysis practice. (iii) 
According to the study presented in Chapter 6, 12 weeks of low-to-moderate intensity 
intradialytic PRT did not change PWV, hemodynamic, anthropometric or hematologic measures 
in patients with ESRD. More research is needed to determine whether different intensities or 
durations of PRT can affect vascular health or other outcomes related to survival in this patient 
group. 
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1.1 Background 
 
The global incidence of end-stage renal disease (ESRD) continues to rise annually (1).  
Accompanying this rise is an increase in the number of patients on hemodialysis (1). These 
trends are being driven by an unprecedented burden of hypokinetic, non-communicable diseases, 
and particularly the type 2 diabetes-obesity pandemic (2).   
The progression of kidney disease is associated with an exponential increase in 
atherosclerotic cardiovascular disease (CVD) and associated mortality (3).  CVD is the leading 
cause of hospitalization and death in patients with ESRD receiving maintenance hemodialysis 
(1).  Data suggest a 10-30 fold higher risk of CVD-related mortality versus the general 
population (4).  As the ESRD patient population continues to grow, greater efforts must be 
directed toward improving patient outcomes in this cohort, including morbidity, mortality and 
health-related quality of life (HRQoL).  
Progressive resistance training (PRT) is an anabolic form of exercise that involves 
challenging the skeletal muscles with unaccustomed loads, usually in the form of free- or 
machine weights.  Clinical trials in other cohorts have consistently shown that chronic PRT 
interventions (>6 weeks) can counteract many impairments that accrue as a consequence of 
ageing and hypokinetic diseases (5).  PRT is the exercise modality of choice for inducing skeletal 
muscle hypertrophy and enhancing bone mineral density (6, 7).  These adaptations often underlie 
improvements in physical functioning (e.g. muscular strength), activities of daily living (8-10) 
and HRQoL (11-13).  Accumulating evidence from other chronically diseased cohorts suggests 
 12 
that PRT can also attenuate CVD risk factors [e.g., hypertension, blood lipids, visceral fat, insulin 
resistance, and circulating C-reactive protein (CRP)] (14-18).  
1.1.1. Systematic review of the extant literature  
In 2002, Headley et al (19) conducted the first study of isolated PRT in patients with 
ESRD.  Ten hemodialysis patients were prescribed 12 weeks of PRT during non-dialysis time.  
Each training session consisted of 9 machine-weight exercises targetting all major muscle groups.  
Participants significantly improved several measures of physical functioning, including six-
minute walk, maximal walking speed, sit-to-stand movement time and leg extension strength 
from pre to post training.  Since this initial study (19), 16 clinical trials have shown that isolated 
PRT (>6 weeks) prescribed within or outside of routine hemodialysis treatment is safe, and can 
induce clinically important adaptations in patients with ESRD (20-22).   Despite an accumulating 
evidence base, PRT and exercise training in general are not routinely prescribed in clinical 
practice to enhance health outcomes in this cohort.  This shortcoming of clinical practice may be 
due to the lack of widespread awareness of the PRT in ESRD literature.  Hence, a systematic 
review of the extant evidence base is warranted.    
1.1.2  Refining the delivery of intradialytic PRT  
Early studies evaluating the efficacy of PRT in patients with in ESRD prescribed PRT 
interventions during non-dialysis time and resulted in low participant enrollment and compliance 
(23).  More recently, since 2006 (24), many PRT interventions have been prescribed during 
dialysis (25-27) in an attempt to overcome some of the barriers to exercise participation in this 
cohort, including lack of access and time (23). To date, the exercise equipment used to deliver 
intradialytic PRT interventions within clinical trials has been largely been rudimentary (28).  
Lower body exercises have typically been prescribed using weighted ankle cuffs (24, 27, 29-32), 
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and upper body exercises have either been avoided due to perceived difficulty (26), or prescribed 
unilaterally during dialysis in the non-fistula containing arm using elastic bands (32) or 
dumbbells (31), with the fistula-containing arm trained with the same exercises just prior to each 
dialysis session.  Utilizing these rudimentary forms of equipment is cost-effective, but can 
compromise PRT effectiveness (28).  For example, ankle cuffs typically have a low loading 
capacity (up to 10kg), and patients who have achieved the maximum load will experience no 
further overload or adaptation (28).  Moreover, the use of dumbbells during dialysis restricts a 
patient to performing only a few exercises that do not effectively target the major muscle groups 
of the upper body, e.g. pectorals or latissimus dorsi (28).  Experts have previously suggested a 
need to develop and evaluate the effects of more robust, custom-designed resistance training 
devices to enhance the delivery of PRT interventions in the hemodialysis setting (33).  There is 
currently a need to develop and test the feasibility and efficacy of more refined resistance 
exercise equipment in the hemodialysis setting.  
1.1.3 Arterial stiffness and associated biomarkers of CVD risk 
Pulse wave velocity (PWV) is a measure of arterial stiffness that can be assessed non-
invasively using applanation tonometry (34).  Elevated PWV reflects greater arterial calcification 
or arteriosclerosis (i.e., lower arterial compliance) and is a strong predictor of cardiac events and 
CVD mortality in ESRD (35, 36) and other clinical cohorts such as non-dialysis CKD, 
hypertension and coronary artery disease (37).  Previous studies have shown that intradialytic 
aerobic training can significantly reduce PWV (38). This improvement in arterial stiffness could 
be partially mediated by enhanced vascular repair reflected in the increased number and/or 
function of progenitor cells (PCs) and endothelial progenitor cells (EPCs) (39, 40).  
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Interventions that decrease arterial stiffness (increase arterial compliance) and increase 
circulating EPCs may contribute to better CVD-related survival in patients with ESRD (35, 36, 
41). Current evidence suggests that PRT may mitigate CVD risk in patients with ESRD by 
mitigating risk factors such as blood lipids (i.e. total cholesterol and triglyceride)(42), CRP (30, 
31, 43, 44), and body adiposity (27, 42)  However, to date, there has been no investigation of the 
effect of PRT on arterial stiffness, associated biomarkers (e.g., PCs and EPCs) and other CVD 
risk factors in patients with ESRD.  
1.2 Research Program  
This research program was undertaken from March 2011 to March 2015 and culminated 
in a clinical trial conducted across four dialysis centers in South Australia, including the 
Payneham Dialysis Center, the Wayville Satellite Dialysis Center, the Hartley Dialysis Center 
and the Queen Elizabeth Hospital’s dialysis ward.   
All study procedures were completed within one center before proceeding to the next 
given that only the principal investigator was involved in the collection of data (i.e. recruitment 
of participants, assessments, and delivery of the intervention).   
The customized resistance exercise device tested in this clinical trial was co-designed by 
the candidate based on several years of experience working as a healthcare professional in a 
setting that routinely prescribed intradialytic PRT with a variety of exercise equipment.   
The candidate was also involved as a co-author during his candidature on two published 
 15 
manuscripts: (i) a book chapter (22) on the safety and benefits of PRT across the chronic kidney 
disease continuum published in the first textbook on PRT in the prevention and treatment of 
chronic diseases (45) (candidate’s authorship contribution = 50%1), and  (ii) a systematic review 
and meta-analysis of randomized controlled trials evaluating changes in muscle mass, strength 
and HRQoL across the chronic kidney disease continuum (published in Sports Medicine, Impact 
Factor: 5.2; candidate’s authorship contribution = 30%2).      
1.3 Aims  
The overall aim of this research program was to advance the investigation and application 
of PRT in the hemodialysis setting.   
The specific aims were:  
1) To systematically review the extant literature on PRT in patients with ESRD, and to outline 
recommendations for robust clinical trials to investigate a range of novel research questions 
related to the benefits and application of PRT in patients with ESRD. 
2) To assess the feasibility and efficacy of including a novel customized resistance training 
device within a comprehensive intradialytic PRT intervention in a conventional hemodialysis 
unit.  
3) To investigate the effect of a 12-week intradialytic PRT intervention on PWV and secondary 
relevant outcomes (i.e. hemodynamic, anthropometric, and hematologic).  
                                                
 
1 Note that the candidate could not be listed as first author on this book chapter at the request of the book editors, J.T. Ciccolo and 
2 Other author contributions:  B.Cheema 30%, P.Fahey 20% and E. Atlantis 20% 
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Chapter 2 
General Review of the Literature
 22 
 2.1 Classifications of Renal Disease 
Chronic kidney disease (CKD) is diagnosed according to the presence of kidney damage 
and/or decreased kidney function for 3 months or more, irrespective of the underlying cause 
(K/DOQI, 2002; KHA 2012; CARI, 2012).  Kidney damage is determined by the presence of 
albuminuria, proteinuria, haematuria or structural abnormalities of the kidney determined by 
imaging (CARI, 2012).  The classification of kidney function ranges from Stage 1 to 5 and is 
based on glomerular filtration rate (GFR).  A reduction in GFR to less than 60 ml/min/1.73m2 
that persists for 3 months or more is an indicator used to diagnose CKD. At end-stage renal 
disease (ESRD) which is Stage 5 CKD, the GFR is less than 15 mL/min/1.73 m2, indicating that 
the level of kidney function can no longer sustain life (1). The individual with ESRD therefore 
requires renal replacement therapy in the form of hemodialysis, peritoneal dialysis or a successful 
kidney transplant (1).  
 
2.2 Incidence and mortality rate in ESRD 
The incidence of end-stage renal disease (ESRD) continues to rise within Australia and 
other developed nations. Although there has been an increasing number of renal transplant 
operations performed in the past five decades, the number of new patients diagnosed with ESRD 
still exceeds the number of renal transplants by approximately four-fold (2, 3). In 2009, 772 
transplant operations were performed (3), while over 2,300 individuals in Australia commenced 
hemodialysis treatment for the management of ESRD, raising the total number of dialysis 
patients to over 10,000 (4). Only 11% of all who are dialysing were on the transplant waiting list 
(5).  
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The primary factors contributing to the rising tide of ESRD include the aging 
demographic and chronic disease epidemics. Burgeoning rates of type 2 diabetes mellitus 
(T2DM), hypertension, cardiovascular disease (CVD) and underlying cardiometabolic 
impairments (e.g. atherosclerosis, dyslipidaemia, etc.) have increased the incidence of ESRD 
within Australia and worldwide (2, 6-8). 
As the incidence of ESRD continues to increase, greater efforts must be directed toward 
improving the morbidity and mortality in this patient population. The mortality rate in 
hemodialysis patients is 7 times higher than in the general population (7), and two times higher 
than in patients with diabetes, cancer, congestive heart failure, cerebrovascular accident, transient 
ischaemic attack or acute myocardial attack (7).  The five year life expectancy in hemodialysis 
patients is 34% (7). 
 
2.3 Cardiovascular morbidity and mortality in ESRD 
Atherosclerotic CVD is highly prevalent and remains a leading cause of death in patients 
with ESRD (9, 10). Recent data suggest that among patients commencing renal replacement 
therapy, approximately 34% have diagnosed coronary artery disease and 19% have diagnosed 
peripheral artery disease (2).  The incidence rates for both myocardial infarction and stroke are 5 
to 15 times higher in hemodialysis patients versus the general population (11). CVD accounts for 
at least one-third of deaths in hemodialysis patients (9) and cardiovascular mortality is generally 
10 to 30 times higher in dialysis patients than in the general population (12-15).  Hence, the 
prevention, management and/or treatment of CVD is essential to improving the life expectancy 
and HRQoL of this patient population. 
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2.4 Cardiovascular disease risk factors in ESRD 
Traditional CVD risk factors include older age, male gender, diagnosis of T2DM, history 
of tobacco use, dyslipidaemia, hypertension and left ventricular hypertrophy. Many of these risk 
factors independently predict cardiovascular and all-cause mortality in patients with ESRD (16).  
However, the evidence also suggests that these risk factors alone may not identify those patients 
at highest risk of cardiovascular events or mortality.  Interestingly, Cheung et al. (10) determined 
that these traditional risk factors predict a similar burden of CVD events or mortality in patients 
with ESRD as in the general population. However, notably, the data indicate a 3 to 8 times higher 
prevalence of coronary heart disease in ESRD (10, 12, 17, 18).  Thus, the data obtained by 
Cheung et al. (10) suggest that the traditional CV risk factors may be insufficient to account for 
the higher CVD risk in patients with ESRD.  For example, it has been suggested that renal-
specific risk factors including uremia, acidosis, proteinuria, fluid overload, electrolyte 
imbalances, anaemia and a higher prevalence of thrombogenic factors contribute significantly to 
the elevated CVD risk in this cohort (10, 19). 
 
2.5 Management of ESRD complications with exercise  
Due to renal anaemia and muscle weakness complications associated with ESRD, patients 
are prone to  fatigue and sedentariness which accelerate declines in exercise capacity (20-22). 
Patients with CKD, including ESRD, have a higher prevalence of physical inactivity than the 
non-CKD population (23, 24). When compared to established norms, ambulatory patients new to 
hemodialysis score below the 5th percentile for all age and gender categories (23). There is a 
corresponding decline in maximal exercise capacity characterised by peak oxygen uptake (VO2) 
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and increased muscle wasting with deteriorating renal function over time in patients with CKD 
(25-27). Patients starting dialysis treatment have a physical fitness and functioning of about 50% 
to 70% of that of healthy subjects (28-30), thus negatively impacting even their capacity to 
perform activities of daily living and occupational tasks (31).  
In the past four decades, substantial advances in medicine and research to reverse these 
complications have been achieved. In particular, the use of recombinant human erythropoietin 
(EPO) since the early 1990s has been successful in correcting renal anaemia; however, this 
treatment does not normalise peak exercise capacity (32-35).  By contrast, studies investigated 
the efficacy of intradialytic exercise training have yielded consistent and significant effects on 
exercise capacity and other clinically relevant outcome measures.    
In 1986, Painter et al. (36) conducted the first study that prescribed aerobic training (AT) 
during routine hemodialysis treatment. Fourteen patients performed up to 30 min of cycling three 
times per week during dialysis sessions. Their VO2 improved at 3 and 6 months of training, to a 
similar extent (23%) as in previous studies (17.8–21%) that prescribed a longer training duration 
of training (8–12 months) on non-dialysis days (36). Since this seminal study by Painter et al 
(36), several studies have further examined the effects of AT such as intra-dialytic cycling or 
walking on non-dialysis days and these elicited many positive adaptations, including increased 
VO2 (37-41). Studies that prescribed 2 to 6 months of AT showed improvement in VO2 by an 
average of 17% with or without the administration of EPO (22, 42). In more recent times, several 
prospective studies observed that both low physical activity level and exercise capacity are 
associated with increased risk of mortality in CKD (23, 43-45), thus suggesting that AT may 
improve survival rate by improving VO2 directly and through modifications of various 
cardiovascular risk factors.  
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There also appears to be a shift in focus in researching the effect of exercise on maximal 
oxygen uptake to other physiological markers of cardiovascular health. Several intradialytic AT 
trials have been successful in reducing the use of anti-hypertensive medications, and improving 
other clinical markers including: blood pressure (46, 47), B-type natriuretic peptide (48), C-
reactive protein (49), cardiac baroreflex sensitivity (50), epicardial fat layer, and serum alkaline 
phosphatase (a risk factor for vascular calcification) (51). These studies generally enrolled more 
participants and had higher rates of exercise adherence versus studies that prescribed exercise 
during non-dialysis time. Furthermore, intradialytic AT has been shown to significantly increase 
weekly phosphate removal (52) and reduce the rebound of urea, creatinine and potassium (53). 
The increased clearance of solutes during intradialytic AT is due to the acute dilation of the 
vasculature in skeletal muscle (54). These metabolic adaptations to intradialytic exercise may 
contribute to improve cardiovascular health. 
Consequently, there is strong support to prescribe exercise during dialysis for 
hemodialysis patients to achieve higher exercise adoption and adherence (55, 56). Low 
motivation, lack of equipment, bad weather, fear of falling, a lack of time are commonly cited 
psycho-social barriers to participation that can be overcome by the provision of exercise advice 
and supervision during hemodialysis sessions (57-60). However, it should be noted that patients 
can be at risk of hypotension due to fluid removal during intradialytic exercise, thus precluding 
them from completing the amount of exercise achievable during a non-dialysis day (50). 
Otherwise, exercise for hemodialysis patients is generally safe, as indicated by over 28,400 
patients-hours of exercise in research studies recently reviewed by Smart et al (42); no deaths due 
to exercise have been reported and the benefits derived from exercise outweights the low risk of 
adverse events with appropriate exercise screening and prescription. Common adverse events 
include hypotensive or ischemic events.  
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Systematic reviews of exercise training in CKD, particularly patients on hemodialysis  
had reported significant improvements in aerobic capacity, muscle strength, physical functioning 
and HRQoL in response to intradialytic exercise (20, 42, 61). Due to the ease of prescribing 
aerobic exercise, particularly cycling, during hemodialysis treatment, the majority of research 
generated to date has been focussed on the effects of AT (20, 61).  
 
2.6 Progressive resistance training in ESRD 
PRT is an anabolic exercise modality that involves exercises which challenge the skeletal 
muscle to work against a resistance for a limited number of repetitions.  PRT is the exercise 
modality of choice for inducing skeletal muscle hypertrophy, maintaining and enhancing bone 
health, and eliciting strength adaptations in healthy and chronically diseased populations (62).  
Moreover, PRT is especially important in preventing and reversing sarcopaenia and osteoporosis 
in older adults (63, 64).  The increase in muscle strength and endurance due to PRT is associated 
with reduced myocardial oxygen and metabolic demand during submaximal exercise (62, 65). 
Consequently, time to exhaustion during a bout of submaximal aerobic exercise can increase 
despite a modest or no improvement in maximal aerobic capacity (65).   
A systematic review conducted by Smart et al (42) also concluded that combined AT plus 
PRT interventions seem to produce a larger improvement in peak VO2 compared with AT alone.  
Improvements in muscular strength and endurance through PRT can also potentially contribute to 
higher levels of physical activity, including greater involvement in activities of daily living, 
which could enhance cardiovascular and overall health and functioning (63, 66).  Further, the 
American Heart Association (62, 65) highlighted accumulating evidence showing PRT can 
induce a range of adaptations that reflect improved cardiovascular health and reduced risk of 
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mortality. PRT prescribed in isolation has been shown to improve glucose tolerance, insulin 
insensitivity, blood lipid profile, blood pressure and body composition, particularly in individuals 
with values outside the recommended ranges (62, 65); however, additional robust studies are 
required to confirm these findings in patients with ESRD specifically.  
Most studies that have prescribed supervised PRT during hemodialysis treatment have 
reported a high compliance rate of between 70% to 87%, with either nil or few acute 
complications during exercise (67, 68).  These findings show that intradialytic PRT is safe and 
beneficial and contribute to better adherence than exercise prescribed during non-dialysis time 
(55). Further, regarding the safety of PRT in terms of cardiovascular risk, a review conducted on 
the use of RPT in patients with stable coronary heart disease found no reported anginal 
symptoms, ischemia, abnormal hemodynamics, complex ventricular dysrhythmias or other 
cardiovascular complications (69). 
A systematic review of studies that have investigated the effect of chronic PRT 
interventions in patients with ESRD is presented in Chapter 4.  This systematic review suggest 
that there is currently a lack of research on the effect of PRT on traditional cardiovascular risk 
factors, including both hemodynamic and hematological outcome measures pertinent to 
cardiovascular health. Thus, future research should focus on filling this gap of understanding the 
holistic physiological effects of RT in ESRD.  
 
2.7 Progressive resistance training during hemodialysis treatment  
Early studies evaluating the efficacy of PRT in patients with ESRD prescribed PRT 
interventions during non-dialysis time and resulted in low participant enrollment and adherence a 
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(55). More recently, since 2006 (70), a number of PRT interventions have been prescribed during 
dialysis (67, 71, 72) in an attempt to overcome some of the barriers to exercise participation in 
this cohort, including lack of access and time (55). This evidence base suggests that intradialytic 
PRT can improve many important aspects of health status (61). However, the delivery of the PRT 
in this setting must be refined to elicit better health adaptations in patients and enable more 
seamless translation to standard clinical care (73). 
To date, the exercise equipment used to deliver intradialytic PRT interventions within 
clinical trials had been largely rudimentary (73). Lower body exercises have typically been 
prescribed using weighted ankle cuffs (67, 72, 74), and upper body exercises have either been 
avoided due to perceived difficulty (71), or prescribed unilaterally during dialysis in the non-
fistula containing arm using elastic bands (75) or dumbbells (76), with the fistula-containing arm 
trained with the same exercises just prior to each dialysis session.  Utilizing these rudimentary 
forms of equipment is cost-effective, but can compromise PRT effectiveness (73). For example, 
ankle cuffs typically have a low loading capacity (up to 10kg), and patients who have achieved 
the maximum load for a PRT exercises will experience no further overload or adaptation (73). 
Moreover, the use of dumbbells during dialysis restricts a patient to performing only a few 
exercises that do not effectively target the major muscle groups of the upper body, e.g. pectorals 
or latissimus dorsi (73). Experts have previously suggested a need to develop and evaluate the 
effects of more robust, custom-designed resistance training devices to enhance the delivery of 
PRT interventions in the hemodialysis setting (77).  
To our knowledge, there have been only two studies that have implemented the use of 
novel resistance training equipment in the hemodialysis setting (71, 78). However, both devices 
were limited to targeting the lower body musculature only with either one (71) or a few 
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movements (78). Upper body musculature was not targeted by these devices, and this has been 
identified as a major limitation of PRT interventions prescribed to date (73).  
 
2.8 Arterial stiffness in ESRD 
Arteriosclerosis and atherosclerosis are pathological conditions and antecedents to CVD. 
Arteriosclerosis is the stiffening of the arteries and/or arterioles while atherosclerosis refers to the 
deposition of fats, cholesterol and other substances resulting in intimal plaque formation that can 
restrict blood flow (79, 80). Unlike atherosclerosis, arteriosclerosis affects both the intimal and 
medial layers of the arteries, characterised by fibrous intimal thickening and calcification of the 
media and internal elastic lamina (79). The arterial hypertrophy and narrowing of the arteries due 
to these pathological states contributes to hypertension, left ventricle hypertrophy and congestive 
heart failure, ultimately predisposing individuals to cardiovascular events and mortality (79, 81). 
Both traditional and renal-specific CVD risk factors contribute to arteriosclerosis and 
atherosclerosis in patients with ESRD (82). Therefore, assessing the severity of arteriosclerosis 
and atherosclerosis may be essential to assessing and abating CVD in this cohort. 
Although arteriosclerosis and atherosclerosis commonly co-exist (83, 84), arteriosclerosis 
can exist without clinically evident atherosclerosis and its early detection is important for 
averting CVD (85, 86). The extent of arterial calcification or arteriosclerosis is directly 
proportional to arterial stiffness which can be measured non-invasively by using applanation 
tonometry (87). This method for evaluating arterial stiffness yields two parameters: the pulse 
wave velocity (PWV) and the augmentation index (AI) (88). PWV is a measure of arterial 
stiffness derived through the Moens-Korteweg equation, PWV = √ (Eh/2Rρ), where E is Young 
modulus in the circumferential direction, h is wall thickness, R is vessel radius, and ρ is the 
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density of fluid (89).  The PWV is related to vessel distensibility and a faster PWV denotes a 
stiffer vessel.  The AI is a composite measure of arterial stiffness and timing of wave reflection 
(89). It is quantified as the rise in pressure from the first systolic shoulder to the peak systolic 
shoulder as a proportion to the pulse pressure (i.e. the difference between systolic and diastolic 
blood pressure). This rise in pressure is known as augmentation pressure and it is mainly due to 
the reflected waves of the forward pressure pulse generated by ventricular ejection. A higher AI 
denotes a stiffer vessel.   
The assessment of PWV has been well-validated in patients with ESRD (88), and PWV is 
a strong, independent predictor of cardiovascular and all-cause mortality in this cohort (90-93). 
For example, Blacher et al. (90) divided their ESRD study population into 3 tertiles based on the 
aortic PWV and found that the upper third tertile had nearly 6 times (95% CI, 2.3 to 15.5) the 
incidence of cardiovascular mortality as compared to the lower third. Further, Guerin et al. (92) 
found the aortic PWV to be a better predictor of mortality than blood pressure (BP) in patients 
with ESRD. Notably, many of the patients in this study who died during the follow up period 
were characterised by elevated PWV despite a reduction in mean BP due to anti-hypertensive 
medication usage.  
 
2.9 Effect of aerobic training on arterial stiffness in ESRD 
Three recent clinical trials that prescribed AT showed preliminary evidence that exercise 
can improve the PWV and the AI in patients with ESRD (94-96). One of these studies prescribed 
AT during non-dialysis time (95), while the other two prescribed AT during routine hemodialysis 
treatment (94, 96). 
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Mustata et al. (95) conducted an uncontrolled trial that prescribed AT during non-dialysis 
time in 11 hemodialysis patients.  All patients performed AT on recumbent bikes and/or 
treadmills at an intensity of 60 to 80% of the maximal heart rate elicited during a baseline stress 
test.  Exercise sessions were completed twice weekly for 3 months and each session was one hour 
in duration, including a 5-10 minute warm-up and cool-down period.  The patients who 
completed the intervention significantly improved their AI (17±3 to 12.2±3, p=0.01).  The 
improvement in AI was accompanied by an improvement in pulse pressure (64±7 to 57±6, 
p<0.05) with both adaptations indicating reduced arterial stiffness. However, in a follow-up 
assessment completed one month after the cessation of the AT intervention, AI and pulse 
pressure regressed to baseline values (95). Mustata et al. (95) concluded that patients with ESRD 
who engaged in an ongoing AT program could derive reductions in arterial stiffness, as indicated 
by reductions in AI and pulse pressure. PWV was not measured in their study.   
In another study, Toussaint et al. (94) conducted a prospective, crossover trial in 19 
hemodialysis patients. The exercise program consisted of 30 minutes of intradialytic exercise 
cycling performed three times per week.  The patients were randomised into an exercising group 
and a non-exercising group for an initial 3-month training period.  This was followed by 1-month 
of detraining (wash out) and a second 3-month, cross-over period. The patients were instructed to 
exercise for approximately 30 minutes at a self-selected exercise intensity (i.e. to tolerance). 
After the initial 3-month period, a near-significant improvement in the PWV (p=0.07) was noted 
in the exercising patients while the non-exercising patients showed no change (p=0.31). 
Following the second 3-month training period, the patients now allocated to the exercise 
intervention showed a trend toward improved PWV (p=0.11) while the patients allocated to no 
exercise showed a trend toward regression (p=0.19). When the whole study cohort was analysed, 
the mean PWV was significantly improved (9.04 vs 10.16 m/s, p=0.008) with 3-month of AT 
compared with no training. The magnitude of this improvement in the PWV (1.0 m/s) was 
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considered clinically significant (92), and this improvement was concomitant with a trend toward 
improved AI (p=0.062). The authors concluded that prescribing AT during hemodialysis should 
be a standard practice in order to maintain improvements in arterial compliance (i.e. reduce 
arterial stiffness) and reduce CVD risk and mortality. 
Koh et al. (96) conducted a RCT by allocating 46 patients to intra-dialytic exercise 
(n=15), home-based exercise (n=15) or usual care (n=16).  Both exercising groups performed 
exercises three times per week for 6 months, while the usual care group did not exercise. The 
intradialytic exercise group engaged in an exercise cycling intervention and progressively 
increased the duration of each session from 15 to 45 minutes. The intensity of AT was prescribed 
at a rating of perceived exertion (RPE) of 12 – 13. Resistance of the cycle ergometer was 
increased if heart rate was low relative to the prescribed RPE. Similarly, the home-based exercise 
group performed a walking intervention that progressed from 15 min to 45 min per session at an 
RPE of 12 to 13.  Arterial stiffness measures, including PWV and AI did not significantly 
improve in either of the exercise groups over time when compared to the usual care control group 
(all p>0.05). In addition, the exercising patients did not significantly improve the secondary 
outcome measurements, which included surrogate markers of cardiovascular health such as the 
six-minute walk.  
Study design limitations may have contributed to the disparate findings of these three 
studies (48, 95, 96).  Among the three studies, only Koh et al. (96) showed no effect of AT.  
However, it should be noted that in this study (96), the authors provided information about the 
benefits of physical activity to the control group (citing ethical reasons), which may have 
contributed to the documented 36% increase in physical activity in the control group.  This could 
have compromised the nature of the control group (i.e. no exercise) making it unreasonable to 
draw conclusions about the effectiveness of the AT intervention.   
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Due to the small sample size of the randomised crossover study of Toussaint et al. (94), a 
significant change in the arterial stiffness measurements between the exercise period to the non-
exercise period was only noted when both groups were analysed as a whole. However, no 
significant change was found between the exercise group and the non-exercise group during the 
first 3 months. On the contrary, Mustata et al. (95) conducted a non-controlled trial that found 
positive changes in arterial stiffness characterised by improved AI. Their patients were on the 
average older than those in the other two studies and this could be a factor of the greater 
improvement in arterial stiffness as older participants may have greater potential for exercise-
induced adaptation than younger participants.  
The difference in their findings may also be attributed to differences in exercise protocols. 
Koh et al’s (96) progressed the exercise volume and intensity at a slower rate than the other 
studies and this may have limited the potential cardiovascular benefits. Both Mustata et al. (95) 
and Toussaint et al. (94) prescribed a longer duration of training per session (i.e. 30 to 50 min). 
Mustata et al. (95) had the patients exercise at a higher intensity level than Koh et al. (96) while 
Toussaint et al. (94) had the patients self-select the intensity level. When Koh et al. (96) 
compared the average work performed per session by their exercising patients, it was lower than 
the exercise group in the study by Toussaint et al. (94). Thus, the patients of Toussaint et al. (94) 
could have exercised at a higher intensity on average when compared to the patients of Koh et al. 
(96).  
Given the heterogeneity of exercise protocols and the lack of robust clinical trials, further 
investigations with sufficient sample sizes, and appropriate modalities, quantity and intensity of 
exercise need to be conducted to elucidate more clearly the effects of AT on measures of arterial 
stiffness (i.e. AI and PWV) in patients with ESRD. The limited number of studies available to 
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date do however suggest that arterial stiffness can be altered favourably by AT prescribed at a 
moderate intensity for a minimum duration of 3 months.  
 
2.10 Effect of resistance training on arterial stiffness in apparently healthy adults 
Although RT has consistently been shown to elicit muscle hypertrophy, and increase 
muscular strength, functional fitness and HRQoL in ESRD (97), no study has yet investigated the 
effect of RT on arterial stiffness and the burden of CVDs in this cohort.  However, several studies 
have investigated the effect of RT on arterial stiffness in the general population and in patients 
with diabetes and chronic heart failure.   
Recently, a meta-analysis was conducted on randomised controlled trials that examined 
the effect of moderate and high intensity RT on arterial stiffness in healthy adults (98). Eight 
studies (n=193) were included in the meta-analysis, with five of these studies enrolling 
participants younger than 40 years. The findings of the review indicated that RT significantly 
increased measures of arterial stiffness (PWV or carotid beta index) by a pooled mean difference 
of 10.7% change  (p<0.001). Subgroup analysis revealed only high intensity RT (>70% 1RM) 
and not moderate intensity (40-70% 1RM) RT was associated with an increase in arterial 
stiffness measures.  All four studies that prescribed high intensity PRT induced increases in 
arterial stiffness and these might be due to a high sympathetic vasoconstrictor activity elicited 
during heavy, loaded exercise (99). Further, when performing high intensity training, participants 
are often obliged to lift slowly, due to the heavy resistance, if not given instruction to do 
otherwise. Okamoto et al. (100) found that high intensity RT with slow lifting increases the PWV 
but this effect is not seen when the lifting phase of the movement is performed quickly, followed 
by a slow lowering (eccentric) phase. As most studies did not report the muscular contraction 
 36 
duration (i.e. time under tension), it can only be speculated that this is a confounding variable that 
could affect vascular adaptation.  
Although this meta-analysis indicated a negative effect of RT, the authors suggest that the 
magnitude of the increase in arterial stiffness is unlikely to be clinically adverse, especially in 
young adults with low baseline levels of arterial stiffness. Moreover, two out of three reviewed 
studies that had middle-aged (>40 years old) adults performing moderate intensity RT did not 
show any effect (positive or negative) on arterial stiffness (101-103). The increase in arterial 
stiffness associated with RT has been shown to revert to baseline values after detraining (104, 
105). Other studies conducted by Okamoto et al have shown that healthy adults who performed 
low intensity RT (50% 1RM for 10 weeks) (106) or lower-limb training instead of upper-limb 
training (107) can either improve or have null effect on arterial stiffness measured by brachial-
ankle PWV.   
Further, combined AT and RT has been shown to have no effect on measures of arterial 
stiffness in young men (105).  It is important to note that this meta-analysis was limited to the 
healthy general population and did not include studies that prescribed light intensity RT (<30% 
1RM) or RT in older adults (>65 years). The findings of the review should therefore not be 
extrapolated to chronically diseased populations without direct investigation.  
 
2.10 Effect of progressive resistance training on arterial stiffness in chronic diseased 
patients 
A few recent research studies have investigated the effect of RT on vascular function or 
vascular dimensions in patients with overt cardiovascular diseases and risk factors apart from 
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ESRD. A RCT conducted by Maiorana et al (108) randomised 36 patients with chronic heart 
failure (NYHA class 1-3) to 12 weeks of RT, AT or a no training (control) group. Thrice weekly 
exercise training was prescribed in the RT and AT groups. For RT, the intensity ranged from 50 
to 70% with work-rest ratio at 2:1 (60:30 seconds) for the first 6 weeks to 1:1 (45:45 seconds) for 
the second 6 weeks. Both exercise training modes increased maximal exercise capacity (peak 
VO2) and brachial diameter, but only RT reduced brachial artery wall thickness with a 
consequent reduction in wall:lumen ratio. Since the RT exercises prescribed were predominantly 
for the lower limbs, the findings suggest that RT can induce a positive effect on systemic 
vascular health. Whether this translates to a reduction in aortic or brachial-ankle arterial stiffness 
need to be confirmed. 
In overweight adults with T2DM, an intervention consisting of an initial 2-month 
supervised laboratory-based RT program, followed by random allocation to 12 months of RT in 
either a community fitness center or at home has shown promising preliminary results on 
endothelial function (109). The endothelium secretes vasoactive substances, primarily vasodilator 
nitric oxide, to regulate vascular smooth muscle tone and blood pressure in coronary and 
peripheral arteries (110, 111). Consequently, a degree of arterial stiffness or atherosclerosis may 
be mediated or precipitated by endothelial dysfunction (111, 112). The initial 2 month supervised 
RT program was performed twice weekly and involved 8 exercises targetting the major muscles 
groups. The intensity (loading) was progressively increased from 50% to 85% of 1RM. Three 
sets of 8 repetitions were performed for each exercise. The participants who were allocated to a 
fitness center continued with a similar RT program 2 to 3 times weekly while participants in the 
home-based group were given one hand weight to perform upper body RT with the same 
frequency as the other group. Endothelial function, measured using a laser Doppler flow 
technique, improved in both exercise groups with no between-group differences observed after 
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the 14-month training programs. Endothelial function was also assessed after the first 2 months 
but no significant change was detected in either group. There was no control group in this study.  
 
2.11 Effect of resistance training on blood pressure in ESRD 
Although prevention of renal function decline is no longer necessary in patients with 
ESRD, blood pressure continues to be closely managed clinically to curb the high risk of CVD 
and related cardiovascular morbidity and mortality in this population. Hypertension in ESRD is 
associated with higher relative risk of left ventricular hypertrophy (LVH), chronic heart failure 
(CHF) and ischaemic heart disease while low blood pressure is also independently associated 
with mortality (113). Drugs that inhibit the renin and/or angiotensin II production.have been 
shown to be effective in clinical trials (114) and are currently recommended within clinical 
practice guidelines in ESRD due to their positive cardiovascular effects including improvements 
in endothelial function, reduction in PWV and sympathetic nerve activity, and regression of LVH 
(115). The other key factor in blood pressure management in this cohort is fluid status and the 
National Kidney Foundation has suggested that predialysis and postdialysis blood pressure goals 
should be <140/90 mmHg and <130/80 mmHg, respectively (115).   
In the Cochrane review on the efficacy of exercise in CKD (20) it was determined that no 
study to date has specifically assessed the effect of isolated RT on resting systolic and diastolic 
blood pressure. More recently published RT intervention studies have also not done so (74, 116, 
117). However, the review found that 5 studies prescribing a combined AT plus RT intervention 
significantly decreased both resting systolic BP (186 participants: mean difference 5.80 mmHg, 
95%CI=1.19, 10.41) and diastolic BP (229 participants: mean difference 3.77 mmHg, 
95%CI=1.61, 5.94). The review also reported that exercise training with an intensity level of 
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greater than 60% of maximal effort significantly reduced both SBP and DBP. In normotensive 
and hypertensive populations with no other concomitant disease, a meta-analysis of RCTs that 
prescribed RT revealed a mean difference in resting SBP of -6.0 mmHg (95% CL -10.4 to -1.6) 
and resting DBP of -4.7 mmHg (95% CL -8.1 to -1.4) when weighted by the reciprocal of the 
variance for the blood pressure change (118).  
In patients with ESRD, the impact of RT prescribed in isolation on blood pressure and the 
underlying mechanisms contributing to blood pressure regulation remains unclear. A known 
complication of ESRD is cardiac autonomic neuropathy which may be characterised by increased 
plasma dopamine and norepinephrine, reduced heart rate variability and abnormal l-
metaiodobenzylguanidine, which suggest increased cardiac sympathetic and decreased 
parasympathetic activity at rest (119). As hypertension can be due to elevated sympathetic tone 
(120), a potential way exercise training can affect blood pressure in patients with ESRD is it’s 
effect on autonomic activity. In a 10 month study of thrice weekly, 90 minutes, moderate 
intensity (RPE 13/20) AT conducted by Kouidi et al (121), there was a significant reduction in 
heart rate variability which indicates increased cardiac vagal activity. Similar increase in heart 
rate variability was also shown in a 6 month AT study conducted by Deligiannis et al (122). 
However, it was unclear whether these results were associated with a change in systolic or 
diastolic blood pressure, as these outcomes were not assessed.  
 
2.12 Effect of resistance training on inflammation in ESRD 
Inflammation is recognised to underlie the inception and development of atherosclerosis, 
from the expression of adhesion molecules by endothelial cells, adherence and penetration of 
leukocytes into the intima, development of fatty streaks and complex plaque, blocking of creation 
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of new collagen fibers, stimulating the destruction of existing collagen that contributes to an 
increased risk of thrombosis (123). Unlike acute inflammation which is a normal immune 
response to contain infection or trauma, chronic and systemic inflammation is harmful and can 
lead to end organ and vascular damage (124). Systemic inflammation is also linked to 
malnutrition, protein-energy wasting, endocrine disorders, depression and vascular calcification 
(125); these conditions are prevalent in uremia, CKD and ESRD (126). Furthermore, 
inflammation is also a strong prognostic indicator of sudden death in ESRD patients (127).  
In general, CKD patients are characterised by elevations in markers of chronic 
inflammation such as CRP, IL-6 and TNF-!. In hemodialysis patients, these markers strongly 
predict survival (126, 128). CRP is a biochemical by-product that hepatocytes produce in 
response to IL-6 elevations during acute inflammation. It is the most widely used and accepted 
inflammatory marker of CV risk and due to its 19-hour half-life, it is easy to measure in 
circulating blood (125). CRP is a strong predictor of cardiovascular morbidity and mortality in 
patients receiving hemodialysis (128).  
Preliminary observations of ESRD cohorts showed that inflammatory marker CRP is 
inversely correlated with self-reported (129) and objectively measured physical activity level 
(130). However, it remains unclear whether the level of CRP is a causative or the result of muscle 
catabolism and subsequent change in physical function and activity level (125). Among studies 
that have prescribed RT in isolation, Kopple et al (131), who prescribed only lower body RT, 
showed no change in CRP while two studies by Cheema et al (76, 132) that prescribed full body 
RT showed significantly decreased CRP. However, despite a reduction in CRP, a subsequent 
analysis of the same cohort of patients found no change in pro- and anti-inflammatory cytokines, 
including IL-1β, TNF-α, IL-6, IL-8, IL-10 and IL-12. Similarly, AT studies in ESRD have shown 
conflicting results, with some studies reporting no change in inflammatory cytokines IL-6 (133) 
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and CRP (51, 94, 134) while others found a significant decrease in CRP after training (49, 135, 
136). There was no obvious indication to identify whether patient characteristics, study design, 
exercise duration or intensity level prescribed between these studies were the cause of the 
conflicting results. Nevertheless, the observed relationship between CRP level and physical 
activity level (PAL) suggest that higher physical functioning or physical activity level may result 
in lower CRP level. Thus, future studies should consider prescribing an RT regimen that is 
comprehensive and targets the major muscle groups of the upper and lower body, similar to the 
intervention prescribed by Cheema et al (76).  
 
2.13 Effect of resistance exercise training on endothelial progenitor cells in ESRD 
Endothelial function is crucial to regulating arterial vascular tone, permeability and 
angiogenesis (137). Endothelial dysfunction is a major factor that contributes to increased arterial 
stiffness and the development of atherosclerosis (138). The integrity and function of the 
endothelial cells are dependent on a critical balance between the cells’ degeneration and 
regeneration. Circulating cells derived from bone marrow that are identified as endothelial 
progenitor cells (EPCs) are a key factor to the maintenance and repair process of the damaged 
endothelium (139-141). EPCs are mobilised from bone marrow during cytokine stimulation and 
ischemic injury, homing in on the ischemic tissue, and contribute to neovascularisation and 
angiogenesis (139, 141-143).  
When metabolic and cardiovascular risk factors are present, the integrity and function of 
the vascular endothelium are compromised (144-146). In patients with cardiovascular risk 
factors, higher levels of circulating EPCs are associated with cardiovascular event-free survival, 
and lower risk of cardiovascular morbidity and mortality (147, 148).  
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Several studies have reported either or both decreased numbers of circulating EPCs and 
impaired angiogenic function in patients with ESRD (149-153). Most notably, Choi et al (149) 
determined that patients with ESRD have a lower number of circulating EPCs, lower endothelial 
colony forming units (e-CFU), and impaired EPCs mobilisation and incorporation into 
endothelium when compared to healthy peers (149).  
No data currently exist on the effect of RT on circulating EPCs in healthy adults or 
patients with chronic diseases, including ESRD. The possibility of RT increasing EPCs numbers 
can only be drawn from preliminary findings of AT effect on EPCs, especially in patients with 
ESRD. Several studies have emerged in the past decade showing that AT can have a positive 
influence on EPCs, both acutely and chronically, in healthy people and patients with coronary 
artery disease (154-159).  
Only one study to date has investigated the effect of AT on EPCs in patients with ESRD. 
In a non-randomised control study by Manfredini et al (160), hemodialysis patients (n=14) were 
prescribed a 6-month moderate intensity AT intervention. The exercise protocol consisted of two 
10-minute walking sessions per day at 50% of the patient’s maximum treadmill speed, performed 
at home on at least the non-dialysis days of the week (i.e. at least 3 times per week). Maximum 
treadmill speed was re-evaluated and updated every month and walking speed was adjusted 
accordingly. When the exercise group was compared to a control group (n=8), no difference was 
found in circulating EPCs (CD34+AC133+VEGFR2+) and e-CFU from pre- to post-intervention 
although the exercise group significantly increased e-CFU within-group from baseline. e-CFU 
was also significantly correlated with 6-minute walking distance (r=0.75, p=0.002).  
The lack of change in circulating EPCs numbers and e-CFU between groups in the 
Manfredini et al study (160) may be explained by the detrimental effect of uraemia in vivo. 
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Jourde-Chiche et al (161) demonstrated 24-hour incubated myeloid EPCs apoptosis increased by 
81% (p<0.01) after incubation with uremic serum from HD patients compared with normal serum 
from healthy subject. Among other uremic toxins tested, indole-3 acetic acid was identified to 
increase apoptosis of CD133+ cells in vitro by 38% and was negatively correlated with 
CD34+CD133+ immature progenitor cell numbers (161). The results indicated that EPCs number 
can be reduced by the detrimental effect of uremia on progenitor cells and hence its 
differentiation into EPCs.  As e-CFU is enumerated in a non-uraemic in vitro condition in 
Manfredini et al’ study, there is a possibility that exercise could have improved EPCs capacity to 
proliferate if it is in a non-uraemic environment. However, Jourde-Chiche et al  (161) also 
showed that the addition of EPO in vitro completely reverse the effect of indole-3 acetic acid on 
myeloid EPCs apoptosis. In their HD patients, EPO ‘good responders’ (defined as patients with a 
lower ratio of EPO weekly dose to hemoglobin level and less than the median value) had more 
CD34+CD133+ progenitor cells than EPO ‘poor responders’.  Since EPO therapy may reduce 
anemia associated with kidney disease and hence improve maximal exercise capacity (54), this 
may be a contributory factor for the significant correlations shown by Manfredini et al (160, 162) 
between circulating EPCs and physical function measures including a 6-minute walk test, 
maximal treadmill speed and physical functioning score. It reminds unclear whether exercise 
training can further increase EPCs numbers. Future research is necessary to determine also 
whether RT can have a similar positive effect on EPCs numbers and related outcomes including 
arterial compliance.  
 
2.14 Effect of resistance exercise training on blood lipids in ESRD 
Most research has measured the effect of AT, rather than RT, on lipid profile in patients 
with CKD or ESRD. The results of studies on the effect of AT have been mixed. Goldberg et al 
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(163, 164) reported decreased triglycerides in two non-controlled trials (NCT). Both Goldberg et 
al’s studies and a separate study conducted by Eidemak et al (165) have also reported increased 
HDL cholesterol. A recent controlled trial enrolling patients with early stage CKD has shown 
improvements in HDL cholesterol, LDL cholesterol and triglycerides but both its AT and control 
groups also received diet therapy which may have amplified the effect of exercise on lipid profile 
yama (166). Conversely, other uncontrolled studies (36, 167, 168) and RCTs (165, 169) that 
prescribed AT in patients with CKD or ESRD reported no change in triglycerides (165, 169), 
total cholesterol (TC) (165, 169), and HDL cholesterol (169). There is little indication that RT 
can positively alter the lipid profile in ESRD.  A recent small study that randomly assigned male 
HD patients to either AT (10-30min of intradialytic cycling at RPE 12-16) or RT (knee 
extension-flexion and hip abduction-adduction at RPE 15-17) for 8 weeks did not find any 
change in lipid profile and BMI when in either training group compared to the control group.   
One speculated reason for the lack of change in lipid profile secondary to RT may be due 
to a lack of change in body composition or mass.  A meta-analysis of RCTs on the effect of RT 
on lipids in adults with and without chronic diseases (including diabetes and CVD) found 
significant improvements in TC, TC to HDL-C ratio, non-HDL-C, LDL-C and triglyerides but 
not HDL-C (170). The meta-analysis also reported that reduced BMI was associated with 
improvements in triglycerides, HDL-C, TC to HDL-C ratio and non-HDL-C (TC minus HDL-C). 
Positive association between changes in HDL-C and lean body mass and negative associations 
between changes in upper body strength with both TC and non-HDL-C were also found. Hence, 
the current evidence suggests that unless RT results in changes in body composition or body 
weight, lipid profile is unlikely to be altered. Such associations need to be verified in patients 
with ESRD. 
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2.15 Effect of resistance training on skeletal muscle and physical function in ESRD 
Patients with ESRD are commonly found to suffer skeletal muscle wasting and 
dysfunction,  and lower cardiorespiratory fitness compared to healthy individuals, thus resulting 
in reduced exercise tolerance (59, 171). Consequently, these physiological maladaptations 
promote or reinforce a sedentary lifestyle in this population which can lead to further muscle 
atrophy (172, 173) and other physiological and functional impairments (22). The potential causes 
of skeletal muscle wasting in ESRD are complex with multiple contributing factors such as 
metabolic acidosis, comorbidities, corticosteroid usage, proinflammatory cytokines, oxidative 
stress, insulin resistance and dialysis treatment  (174-176).  
Protein-energy malnutrition or wasting, characterised by skeletal muscle wasting and low 
visceral protein stores, is strongly associated with a high mortality risk in patients with ESRD 
receiving hemodialysis treatment (177-179). Low cardiorespiratory fitness (43), low PAL (44) 
and low exercise frequency (45) have all been associated with lower survival rate. These 
observed relationships thus suggest that by exercise training, these parameters can be altered 
favorably, which may result in increased survival.  
A 2011 Cochrane review by Heiwe et al (20) on exercise training for adults with CKD 
analysed and found that regular RT significantly increased muscle strength (4 studies, 153 
participants, SMD -0.6, p=0.0003) (61, 68, 72, 180) while cardiovascular exercise training (4 
studies, 165 participants, SMD -0.23, p=0.19)(96, 181, 182) and mixed cardiovascular with RT 
(183, 184) did not. 
Despite the physiological limitations associated with ESRD, studies have consistently 
shown that muscular strength and muscle composition can be altered positively and 
simultaenously through the prescription of RT. A recent RCT conducted by Kirkman et al (71) 
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prescribed 12-week intradialytic leg press resistance exercise, thrice per week, for ESRD patients 
using a novel machine which utilised a series of elastic bands to provide a maximum resistance 
equivalent to 200 kg. The participants were prescribed three sets of eight to ten repetitions at 80% 
of their predicted 1-repetition maximum load with 2-minute rest period between sets. Training 
load was progressively increased with strength adaptation. The HD patients who received RT 
showed clinically and statistically significant improvements in both thigh muscle volume 
(evaluated via magnetic resonance imaging (MRI)  (Mean Difference = 193 [95% CI = 63 to 324 
cm3) and knee extensor strength (Mean Difference= 56 [95 % CI = 15 to 98 N) compared to 
control. The changes in strength and muscle volume in response to RT were of similar magnitude 
in HD patients as in healthy participants.  
In another RCT that prescribed 12-week, thrice per week, high intensity intradialytic RT 
involving most major muscle groups in upper and lower extremities, Cheema et al. (67, 76, 185) 
found statistically significant improvement in total body muscular strength, mid-thigh muscle 
quality (evaluated by muscle lipid content, i.e. attenuation), mid arm circumference and clinically 
significant improvement in mid-thigh muscle cross-sectional area (CSA) (evaluated by computed 
tomography) in the exercise group compared to control group. Their exercise protocol was 
comprised of two sets of eight repetitions for each exercise performed at a RPE of 15-17/20 
(“hard” to “very hard”). Free weights dumbbells were utilised for upper body exercises while 
weighted ankle cuffs and elastic tubing were utilised for lower body exercises. The limb 
containing the vascular access was exercised just prior to the dialysis session while all other 
exercises were performed while the patient was in a seated or supine position receiving dialysis. 
In a follow up study, Cheema et al. (67) had also noted that an additional 12-week of intradialytic 
RT can induce greater gains in muscle CSA.    
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In another intradialytic exercise trial, Johansen et al. (70) double-blinded and randomised 
79 patients with ESRD into four groups. The patients would receive weekly anabolic steroid 
(nandrolone decanoate) or placebo injections, with or without 12 weeks of RT intervention. The 
intervention involved performing five lower limbs exercise using ankle weights, thrice weekly 
while on dialysis. Training intensity began at two to three sets of 10 repetitions at 60% of 3 RM 
and was progressed as patients’ strength improved. Quadriceps muscle CSA (evaluated by MRI) 
increased in the two groups of patients that completed 12 weeks RT (RT + placebo (p=0.02) and 
RT + nandrolone (p<0.0001)) compared to the control group. There was no signficant 
improvement in total lean body mass (evaluated by DEXA) which may be attributed to the 
prescribed RT targetting only the lower limbs. The effect of RT on muscle and body composition 
was ascertained by Chen et al. (72) who prescribed a similar lower-body intradialytic RT 
intervention but beginning with an intensity of 60% of 1RM noted significant increases in leg and 
whole body fat-free mass after approximately six months of twice weekly RT.  
It is important to note that several studies that prescribed RT with even lower intensity RT 
compared to Johansen et al. (68) and Chen et al. (72) did not find any significant change in 
maximum strength (measured as 1RM) (116), total lean body mass (116, 131) or physical 
function measures such as 6 minute walk (6MW) (75, 186). Thus, with the current evidence, 
positive muscle adaptations can occur in ESRD. The level of exercise duration, intensity, volume 
and progression similar to the study of Johansen et al. (68) may be the minimum dosage required 
to elicit positive adaptation.  
Although muscle quantity and strength, and muscle oxygen extraction are associated with 
functional capacity in HD patients (187-190), elicited improvements in muscle strength or muscle 
volume due to RT may not necessarily translate to an improvement in  physical function outcome 
measures per se. Kirkman et al. (71) reported improvements in thigh muscle volume and leg 
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extensor strength but no significant change in 30 s sit-to-stand (STS) and 6MW. By contrast, 
Chen et al. (72) reported concurrent improvements in knee extensor strength, STS time, self-
perceived physical functioning and activities of daily living versus a sham exercise group 
whereas, Cheema et al. found an increasing trend but no significant change in 6MW (76). The 
lack of change despite the high intensity of RT may be due to the functional measures being less 
sensitive to direct measures or that the measures are also dependent on other physiological factor 
such as aerobic capacity (e.g 6 MW), muscular endurance (e.g 30s STS), and agility and dynamic 
balance (e.g 8-ft up and go)  rather than only muscle strength (191). Therefore, traditional 
progressive RT does not appear to improve these other outcomes consistently in ESRD. 
However, in studies combining RT with AT (59, 183, 184), surrogate measures of cardiovascular 
fitness such as 6MW (67, 192-194), and other measures of physical functioning such as gait 
speed (193) and STS movement time (181, 193, 194) seem to consistently improve, thus 
suggesting the efficacy of AT as an adjunt to RT.  
There is also preliminary evidence that when RT is combined with balance training, falls 
risk can be reduced. Bennett et al. (195) prescribed eight weeks of hip, knee and ankle 
strengthening exercises, static and dynamic balance exercises to 24 hemodialysis patients. The 
strength exercises were performed while on dialysis while the balance exercises were performed 
before or after dialysis. The short form Physiological Profile Assessment (196), which is a 
battery of tests on factors considered most crucial to falls risk, was utilised pre- and post-
intervention. The factors evaluated include vision edge contrast sensitivity, hand reaction time, 
knee joint proprioception, quadriceps strength and standing postural sway on foam board. The 
study found significant improvements in the Physiological Profile Assessment overall score, 
reaction time and quadriceps strength (195). As the falls injury rate in dialysis patients is four 
times higher and post-hip fracture mortality is twice as high compared to age-matched 
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population, there is strong incentive for dialysis patients to perform strength and balance 
exercises to improve physical function and reduce falls risk.  
It is unclear whether the form of resistance applied is a factor that affects the efficacy of 
RT in modifying muscle. Elastic resistance band/tubing (186), pneumatic resistance (116), 
weights machine (71, 192), and free-weights (including ankle cuff weights) (67, 68, 72, 76) have 
all been utilised in previous studies with the latter two being the common mode of RT 
prescriptions in most studies successfully inducing improvements in muscle strength or 
composition.  
 
2.16 Effect of resistance training on quality of life and depression in ESRD 
HRQoL is commonly defined to include three domains of health (physical, psychological 
and social), with each domain consisting of diverse components (197). Broader aspects of 
HRQoL in populations with chronic illnesses can also include perceptions of illness burden, 
happiness and life satisfaction, satisfaction with care (198, 199) and spirituality in coping (200, 
201). It is relevant for health professionals to measure HRQoL due to its good prognostic value 
of hospitalisation, morbidity and mortality, especially in elderly dialysis patients (202, 203). The 
association between better HRQoL and survival rate is especially prominent in elderly dialysis 
patients. De Oreo et al. (204) assessed HRQoL of 1,000 dialysis patients using Medical 
Outcomes Trust Short-Form 36 (SF-36) and found that, with each five-point increase in physical 
component summary (PCS) score of SF-36, the possibility of survival after 2 years was increased 
by 10%. Further, a five-point increase in mental componenet summary score resulted in a 2% to 
5.8% increase in survival. This showed that the domains of health are interdependent of one 
another and HRQoL  can be considered a composite assessment of broad aspects of health 
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perception that may be otherwise overlooked by physiological or physical assessments. The 
measurement of HRQoL is therefore applicable in determining the efficacy of treatments or 
therapies, such as exercise, and their net benefits beyond physiological improvements (203). The 
myriad benefits due to exercise and physical activity in ESRD that translate to higher HRQoL are 
well reflected in observational and interventional studies. Kutner et al. (205) showed that in 226 
dialysis patients, physical activity was associated with the most number of HRQoL measures 
compared to any other variables. Positive association were found between physical activity and 
the HRQoL questionnaire SF-36 perceived physical functioning, overall PCS score, vitality, 
general health, mental health and social functioning domains (205).  
Intervention studies that have prescribed AT (182, 206, 207), RT (68, 72, 76) or a 
combination of both (208-210) can improve some domains of HRQoL, particularly in the 
physical functioning domain and/or the PCS score of SF-36 (68, 72, 76, 209, 210). No research 
has compared and elucidated any differential effects of AT versus RT on self-reported HRQoL. 
Studies investigating isolated RT, however, have reported some positive findings.  Cheema et al. 
(76) reported improved vitality in hemodialysis patients after high intensity RT while. Similarly, 
Chen el al. (72) reported their low-intensity strength training can improve self-reported physical 
functioning (p=0.02). Segura-Orti et al. (194) reported no change in HRQoL measured with SF-
36 and this may be due to the low intensity of their exercise program, which consisted of 4 lower 
extremities exercises using a mixture of ankle weight, elastic bands, human resistance and 
isometric muscle contraction. 
In a study that prescribed a combination of 30 minutes of cycling and 30 minutes of 
strengthening and flexibility exercises, the effects of the intervention on HRQoL were assessed 
with several methods including SF-36 questionnaire, Quality of Life Index (Spitzer Index) and 
Scale of Life Satisfaction (209). The mean score of Quality of Life Index significantly improved 
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by 38.4%, Life Satisfaction score improved by 18.3% and the PCS score of SF-36 improved by 
9.9% (209). A study conducted by Molsted et al. (208) used five months of high intensity, 
combined AT plus RT twice a week and showed that SF-36 physical functioning, bodily pain and 
PCS score were improved. Similarly,  van Vilstern et al. (183) prescribed 12 weeks of exercise 
consisting of pre-dialysis RT and intradialytic cycling and showed an improvement in patient 
vitality and general health. Apart from these studies, there is a lack of comparative research to 
determine whether RT has a distinctive benefits to HRQoL in relation to AT. Nevertheless, the 
evidence does show that RT with and without AT can improve objectively measured physical 
functioning and consequently HRQoL.  
To date, there has been little investigation on the efficacy of RT on other clinically 
important psychological outcomes in patients with ESRD including mental health and 
depression. Depression is perceived as a common psychopathology and under recognised in 
patients with ESRD (211, 212). The Dialysis Outcome and Practice Patterns Study Program 
(DOPPS) analysed 12 countries’ patients with ESRD and found a 13.9% prevalence rate of 
physician-diagnosed depression and 43% when using a Center for Epidemiologic Studies 
Depression (CES-D) scale cut-off of ≥10 (213). Depression symptoms are also strongly linked to 
many HRQoL measures (203, 214) and were shown by the DOPPS to be inversely associated 
with aerobic physical activity but not with muscle strength/flexibility activity (215). Neither AT 
nor RT have shown any effect on the mental component summary (MCS) score of SF-36 (68, 72, 
76, 194). One RT trial that was conducted by Cheema et al. (76) assessed depression level using 
the Geriatric Depression Scale (GDS) but did not find any significant change in response to 12 
weeks of intradialytic RT intervention.   
The results from mixed intervention studies of AT plus RT have been equivocal. Ouzouni 
el al. (209) did not observe a change in the SF-36’s MCS score; however, depression level 
 52 
measured by Beck Depression Inventory decreased by 39.4% (p<0.001) and the number of 
depressed patients was reduced after their 10-month mixed AT plus RT intervention. In another 
mixed intervention, Oh-Park et al. (210) found significant improvements in the MCS scores of 
SF-36 after 3-month of 2-3 times per week AT plus RT intervention. Conversely, De Paul et al. 
(184) reported no change in SF-36’s MCS score. Depression level measured by Standard 
Depression Scale was not significantly different in van Vilsteren’s (183) mixed intervention 
study too. More studies are therefore necessary to assess the isolated and/or additive effect of RT 
on depression symptoms in patients with ESRD. 
 
2.17 Conclusion 
There is sufficient evidence to support the prescription of intradialytic RT to patients with 
ESRD to improve a range of health outcomes (20, 42, 61, 97). However, there has been no 
investigation of the  efficacy of PRT for improving arterial stiffness in this cohort, and how this 
adaptation is associated with other physiological changes to cardiovascular health, including 
markers such as EPCs, CRP and lipids.  The majority of research generated to date has focussed 
on the effects of intradialytic AT on arterial stiffness and other cardiovascular risk factors (20, 
61). To better understand the role PRT can play in improving cardiovascular health of patients 
with ESRD, there is a need to elucidate the concurrent effects of PRT on arterial stiffness and 
associated physiological, functional and psychological outcome.   In addition, there is a need to 
develop novel, customized resistance training equipment to enhance the delivery of PRT in the 
hemodialysis setting to elicit better health adaptations in patients and enable more seamless 
translation to standard clinical care.  
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Chapter 3 
General Methods
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3.1 Study Design 
This study utilised a within-subjects non-randomised crossover trial design.  The trial 
compared the outcomes of an initial 12-week usual care control period to a 12-week intradialytic 
RT intervention period in a single group of patients with ESRD (Table 3.1). Primary and 
secondary outcome measures were assessed at baseline (week 0), after the control period (week 
12) and after the intervention period (week 26).  
Table 3.1. Phases of the study 
Phase Testing Control period Testing Intervention period Testing 
Week        0            1 – 12        13      14 – 25          26 
 
The duration of the intradialytic RT intervention (12 weeks) was considered appropriate 
as previous clinical trials prescribing 12 weeks of AT have been successful in eliciting a 
reduction in arterial stiffness of hemodialysis patients (1, 2).  Moreover, studies of RT have been 
shown to induce positive physiological adaptations, including improvements in inflammation and 
muscle mass and quality after 12 weeks of training (3-5). The University of Western Sydney 
Human Research Ethics Committee (Research Code: H9651) and the Central Northern Adelaide 
Health Service (RAH Protocol No.: 120507) approved all research procedures. Written informed 
consent was obtained from all patients prior to study participation (Appendix 5).  The trial was 
registered with the Australia and New Zealand Clinical Trials Registry (ANZCTRN: 
12612000496819) upon receipt of ethics approval on the 8/05/2012.   
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3.2 Participants 
3.2.1 Recruitment Sites 
The participants were recruited from four dialysis centers in South Australia, including 
the Payneham Dialysis Center, the Wayville Satellite Dialysis Center, the Hartley Dialysis Center 
and the Queen Elizabeth Hospital’s dialysis ward.  All study procedures were completed within 
one dialysis center before proceeding to the next given that only the principal investigator was 
involved in the data collection (i.e. recruitment of participants, assessments, and delivery of the 
intervention). 
3.2.2 Medical Screening 
All patients regularly attending the dialysis centers for maintenance hemodialysis 
treatment (i.e. three sessions per week) were screened for eligibility.  The screening process 
involved review of the medical and clinical records of the patient, clearance from the 
nephrologist of the patient (Appendix 3), and interview of the patient by the principal 
investigator.  Eligibility criteria:  (1) adult aged ≥40 years, (2) medically stable and adequately 
dialysed (Kt/V ≥1.2) for greater than three months, (3) able to ambulate independently or with an 
assistive device for ≥50m, (4) no limb amputation, (5) no acute or chronic medical condition that 
contraindicated or prevented the performance of RT during hemodialysis treatment, (6) cognition 
and English language sufficient to understand research procedures and provide written informed 
consent, (7) sedentary (i.e. less than 120 minutes of moderate intensity physical activity per 
week) (6), (8) no current participation in an exercise regimen involving RT.  
3.2.3 Participant Recruitment  
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Hemodialysis patients are typically highly sedentary and reluctant to participate in 
exercise programs (7).  Therefore, eligible participants were approached individually by the 
principal investigator (D.C.) in an attempt to build rapport by addressing any fears, concerns and 
queries about study participation. A video recording which promoted intradialytic exercise 
performance and perceptions of patients enrolled in existing exercise programs at the Hampstead 
Dialysis Unit in Adelaide were shown to patients during their dialysis sessions via a laptop  
computer (Available at: 
https://www.dropbox.com/s/68s6o3zcwvndbsr/Dialysis%20Ex%20Promo-2012.m4v?dl=0).  
In addition, a participant information sheet (Appendix 4) was provided to patients to read, 
consider and discuss with their family members for a one-week period prior to re-approaching 
the participant regarding participation.  
 
3.3 Outcome measures 
3.3.1  Physiological Outcomes 
3.3.1.1 Pulse wave velocity (PWV) and secondary haemodynamic outcomes  
Participants were first instructed to fast from food and caffeinated drinks for a minimum 
of 4 hours prior to testing. The brachial and posterior tibialis arteries sites were palpated and 
marked. The height of brachial artery site and sternal notch were measured using a stadiometer 
and the distance from the base of the foot to posterior tibialis site was measured using a large 
bone caliper. From these measures, distance between brachial artery site to sternal notch and 
distance between posterior tibialis artery to sternal notch were calculated.  
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The following measurements were collected with participants in a supine position. 
Resting brachial blood pressures were evaluated after 15 min supine rest using an aneroid 
sphygmomanometer (1512 Riester Ri-san, Germany) and stethoscope. Three blood pressure 
measures were taken 1 minute apart with the average of two closest measures recorded. 
Applanation tonometry using the SphygmoCor System and Program (AtCor Medical Pty, 
Sydney, Australia) was then applied to measure the primary outcome PWV, and the 
augmentation index (AI).  
A hand-held, high fidelity tonometer (Millar Instruments, Houston, Texas) was applied at 
the radial artery to measure the AI. The SphygmoCor algorithm also normalizes AI to a heart rate 
of 75 beats per minute since AI is affected by factors such as ejection fraction and heart rate (8). 
The SphygmorCor Program is able to derive aortic blood pressure parameters using a validated 
and reproducible generalised transfer function (9, 10). Pulse pressure was calculated by 
deducting the diastolic pressure from systolic pressure. To measure PWV, the tonometer was 
applied to the brachial artery and posterior tibialis artery that give clear waveforms. If there are 
differences between the positions of the tonometer to the palpated sites, the distances measured 
earlier were corrected according to the differences and entered into the SphygmoCor Program for 
PWV data collection. The SphygmoCor device has been used in three previous trials which 
investigated the effect of AT in patients receiving maintenance hemodialysis treatment for the 
management of ESRD (2, 11, 12). AI and PWV measured using the device  is highly 
reproducible in this cohort (9). Due to fluid shifts unique to hemodialysis patients as a 
consequence of hypervolaemia and thrice weekly dialysis treatment, PWV and AI can fluctuate 
within a week (13).  However, the affect of such fluid shifts on indices of arterial stiffness was 
minimised by conducting the measures on the same non-dialysis day of the week for the baseline 
and follow-up assessments (week 13 and 26) (9, 14).  According to Di Iorio et al, this may be the 
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best approach to evaluate arterial stiffness over time in this patient population (13).  Post 
intervention testing was completed at least 72 hours after the completion of the final exercise 
session to ensure that changes were independent of acute effects. The detailed procedure for 
conducting PWV and AI assessments is detailed in Appendix 6.  
A total of 16 patients agreed to have their arterial stiffness measures assessed twice by the 
same investigator during baseline assessment to determine reliability. AI was not measured in 1 
patient due to difficulty in detecting the patient’s radial arterial pulse. Duplicate measures of 
PWV measures were not collected from 4 patients due to difficulty in capturing clear pulse 
waveforms and lack of time. The reliability of the measures was determined based on coefficient 
of variability percentage (CV%) and intra-class correlation coefficient (ICC) of the arterial 
stiffness measures (i.e. PWV, AI and normalised AI) were established prior to the study (Table 
3.2). The coefficient of variation percentage (CV%) was defined as the percentage of the 
standard deviation divided by the mean; the average CV% of the total cohort was reported. Table 
3.3 showed the individual data of the repeated measures.  
 Table 3.2. Reliability of PWV and AI measures 
Variable Mean CV% ICC (Single measure) ICC (Average measure) 
PWV (n=12) 13.9 7.2 0.883 0.938 
AI (n=16) 35.6 4.8 0.973 0.987 
Normalised AI (n=12) 31.5 6.2 0.931 0.964 
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Table 3.3. Repeated measures of AI and PWV of participants 
Participant ID  AI  
Measure 1 
AI  
Measure 2 
AI-75bpm  
Measure 1 
AI-75bmp  
Measure 2 
PWV  
Measure 1 
PWV 
Measure 2 
3 39 35 32 28   
4     14.5 15.6 
6 19 16 16 12 9.2 10.8 
7 46 45 36 34 17.5 16.9 
8 20 21 19 20 10.2 11.4 
9 26 24 28 25 11.3 11.2 
11 44 43 42 41 14.9 15.8 
12 49 47 40 37 12.3 15.5 
14 33 37 29 31   
15 44 41 40 37   
16 48 50 34 37 20.8 22.1 
19 35 35 36 38 10 11.2 
23 22 27 23 28   
25 27 26 35 35 15.5 12.4 
31 41 42 30 30 14.7 13.8 
32 26 29 27 31   
33 51 51 37 39 12.3 13.4 
AI-75bmp, Augmentation index normalised to 75 beats per minute. PWV is presented in ms-1. AI and AI-
75bmp is in percentage.  
3.3.1.2 Haematological Outcomes  
Endothelial progenitor cells (EPCs) 
Peripheral blood samples were taken from each patient just prior to each participant’s first 
hemodialysis session of week 0, week 13 and week 26. 20mls of blood was collected via 
venepuncture into 10ml lithium heparin coated Vacuette tubes (Greiner Bio-One, 
Kremsmuenster, Austria). Samples were diluted 1:1 with sterile phosphate buffered saline (PBS) 
and mononuclear cells (MNCs) were isolated via Lymphoprep™ (Axis-Shield, Oslo, Norway).   
Cells were washed two times in HUVE media (Media 199 (Sigma); containing 20% FCS 
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(Hyclone, Utah, USA), 1.5% sodium bicarbonate, 2% HEPES buffer solution, Penicillin 
Streptomycin, sodium pyruvate (all Gibco Invitrogen, Gaithersburg, MD, USA) and non-
essential amino acids (Sigma) before flow cytometry staining. 
MNCs were analysed for cell surface expression of various markers by flow cytometry. 
Cells were blocked with 10ul of human FcR blocking reagent (Miltenyi Biotec, Bergisch 
Gladbach, Germany) for 10 minutes. Cells were then incubated in 100 µl HUVE media with 
either mouse anti-human DSG2 (1 µg, Abcam, MA, USA) or mouse IgG1 isotype control (1ug, 
BD Bioscience) for 30 minutes on ice. Following a wash with HUVE media cells were incubated 
with goat anti mouse DyLight® 650 (1:100, Abcam) in 100 µl HUVE wash for 30 minutes on 
ice. The cells were blocked with 5ul normal mouse serum (Sigma-Aldrich, MO, USA) ) then 
immediately incubated with panels of mouse anti-human conjugated antibodies; anti CD14 PE-
Cy7, anti CD144 FITC, anti CD34 Percp-Cy5.5, anti CD45 Amcyan, anti CD31 V450 (all BD 
Biosciences) and anti-CD133-PE (Miltenyi Biotec) used as per manufacturers instructions for 
flow cytometry along with fixable viability dye eFlour®780 (1:1000, eBioscience, CA, USA) in 
a final volume of 80ul of HUVE media for 30 minutes on ice. The cells were then resuspended in 
FACS fix (1% formaldehyde, 20g/L glucose, 5mM sodium azide, made up in PBS) prior to 
analysis using a FACS Aria II (BD Biosciences) with FACS DIVA software (BD Biosciences). 
Further analysis was performed using FCS Express 4 Flow Cytometry: Research Edition (De 
Novo Software, CA, USA). The analysis of EPCs was performed by a research assistant in the 
Vascular Biology and Cell Trafficking Laboratory, Center for Cancer Biology, SA Pathology. 
Progenitor cells (CD133+CD34+) and endothelial progenitor cells (CD133+CD34+CD31+) are 
presented as percentage of MNCs. 
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C-Reactive Protein (CRP) 
Blood samples for CRP assay were collected in lithium heparin coated Vacuette tubes by 
the dialysis nurses and collection was confirmed by the the principal investigator (D.C.). CRP 
was assays were analysed using the Siemens Healthcare Diagnostics ADVIA Chemistry system 
(Tarrytown, New York, USA).  The method to measure wide range CRP in serum and plasma by 
a latex-enhanced immunoturbidimetric assay was applied.  This measure was based on the 
principle that the analyte concentration is a function of scattered light caused by the latex 
aggregates. The latex particles coated with anti-CRP rapidly agglutinating to CRP-forming 
aggregates. The CV% is 3.8 for a mean value of 6.8, and 5.9 for a mean value of 94.5.  
Lipid Profile 
Blood samples for blood lipid assays were collected in lithium heparin coated Vacuette 
tubes. Blood lipids were analysed using the Siemens Healthcare Diagnostics ADVIA Chemistry 
system (Tarrytown, New York, USA). An enzymatic method using cholesterol esterase, 
cholesterol oxidase conversion followed by a Trinder reaction was used to measure concentrated 
cholesterol. HDL-C cholesterol in serum and plasma was measured without prior separation. 
Cholesterol from non-HDL-C particles was released and eliminated in the first step of the 
reaction. Cholesterol in HDL particles was released in the second step by detergent in R2, and the 
HDL-C cholesterol was then measured by a Trinder reaction. The Triglycerides method was 
based on the Fossati three-step enzymatic reaction with a Trinder endpoint. The triglyceride was 
converted to glycerol and free fatty acids by lipase. The glycerol was then converted to glycerol-
3-phosphate by glycerol kinase followed by its conversion by glycerol-3-phosphate-oxidase to 
hydrogen peroxide. A colored complex was formed from hydrogen peroxide, 4-aminophenazone 
and 4-chlorophenol under the catalytic influence of peroxidase. The absorbance of the complex 
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was measured as an endpoint reaction at 505/694 nm. The single-reagent procedure quantitates 
the total triglycerides including the mono and diglycerides and the free glycerol fractions. 
The following equation was then used to calculate LDL cholesterol:  
LDL-C cholesterol = (Total Cholesterol – (Triglycerides/2.2)) – HDL-C cholesterol 
The CV% of the total cholesterol, HDL-C and triglyceride at two different mean concentrations 
is presented in Table 3.4 (CV=1.3-6.3%).  
 
Table 3.4. The associated means and CV% of lipids  
Lipid Mean CV Mean CV 
Total cholesterol 
mmol/L 5.69 4.2 2.94 1.3 
HDL-C mmol/L 1.1 4.8 0.31 6.3 
Triglycerides mmol/L 2.43 4.2 1.09 3.7 
 
3.3.1.3 Anthropometric measures 
Weight and height were measured using a Taylor 5596A scale and a SECA portable 
stadiometer, respectively. Body Mass Index (BMI) was computed as the ratio of weight (kg) over 
height squared (m2).  BMI > 25 kg/m2 was categorised as ‘overweight’, while BMI > 30 kg/m2 
was categorised as ‘obesity’ (15). Waist circumference was measured using calibrated non-
metallic tape, according to standard protocol (Appendix 9) (15).  
 
82 
 
3.3.2 Functional Outcomes 
3.3.2.1 Upper body muscular strength 
A Jamar™ dynamometer was used to measure handgrip strength of both arms. The 
measurement can be used to represent overall upper body muscle strength (16). The Jamar 
dynamometer, adjusted to its second most narrow hand position, was held by a seated subject. 
The participant had the shoulder adducted and in neutral rotation, the elbow flexed to 90 degree 
angle and the forearm and wrist in neutral. The participant was then instructed to grip as hard as 
possible for at least 3 seconds before relaxing. The participant had a 30s rest between each trial 
of each arm, with the best score recorded in kilograms for both the fistula-containing and non-
fistula arms.  
3.3.2.2 Lower body strength  
Muscular strength was assessed using a single leg press.  A three-repetition maximum 
(3RM; i.e. the heaviest weight lifted with proper technique for only three repetitions was 
performed according to standard strength testing protocols (17) using the Maxim™ dialysis 
weight machine. The 3RM for both the left and right leg were added to create a summary score 
for lower body muscular strength.   The protocol for the 3RM test is detailed in Appendix 7.  
3.3.2.3 Six minute walk test 
The six minute walk test is a validated functional measure that reflects aerobic and 
functional capacity in older adults aged 60 – 80 years (18). The six-minute walk enables the 
assessment of a wide range of physical fitness levels including those who cannot run and thus the 
test is appropriate and commonly used in ESRD (18-20). Performance was determined by the 
83 
 
maximun distance walked in six minutes along a circuit.  The protocol for the six-minute walk 
test is detailed in Appendix 8. 
 
3.3.3 Psychological Outcomes  
3.3.3.1 Geriatric Depression Scale  
The GDS (Appendix 10) was used to evaluate depression symptoms with scores ranging 
from 0 to 30 categorised as: ‘normal’ (0 – 9), ‘mild depression’ (10-19), and severe depression 
(20-30) (21). GDS is found to be an internally consistent measure and correlates with the number 
of Research Diagnostic Criteria symptoms for depression (22) and thus is accepted as a reliable 
and valid self-rating depression screening scale for elderly populations.  The GDS has also shown 
to have good internal reliability in adults younger than age 65 (23). The GDS is non-somatically 
focused, and can be easily administered by either an observer or the patient personally. In 
cognitively intact patients older than 65, the GDS is preferred over other depression screening 
instruments including the Beck Depression Inventory and the Center for Epidiomiological 
Studies Depression Scale  (24).  
3.3.3.2 Health-related quality of life (HRQoL) 
The SF-36 Version 1.0 was used to evaluate changes in eight domains of HRQoL, 
including physical functioning, role-physical, bodily pain, general health, vitality, social 
functioning, role-emotional and mental health (25).  In addition, the instrument provides scores 
for a PCS and a MCS calculated from the relevant HRQoL domains. The SF-36 is designed for 
self-administration and has demonstrated a high degree of internal consistency and construct 
validity (26). The SF-36 has been shown to be a valid tool to assess physical functioning in 
84 
 
ESRD (27) and sensitive enough to detect changes over time in response to resistance or aerobic 
exercise training intervention in dialysis patients (12, 28, 29).  
 
3.4 Clinical Co-variates 
The Physical Activity Scale for the Elderly (PASE) (Appendix 10) was used to evaluate 
and quantify leisure and daily activity level at week 0, week 13, and week 26 as a confounding 
variable (30). Additional factors potentially related to the adaptations under investigation were 
extracted during the recruitment and screening process and baseline testing by means of standard 
questionnaires and assessments, and were entered into analytic models as appropriate. These 
factors included demographic characteristics (i.e. age, gender, occupation, marital status, living 
arrangement, income, smoking history, alcohol intake, etc.), medication and supplement usage 
and dosage, adverse events related to medication/supplement intake, and history of medical and 
surgical procedures received (Appendix 10).   
 
3.5 Changes in Health Status, Adverse Events and Compliance 
Changes in health status occurring during the control and intervention periods was 
documented by means of a structured questionnaire of open-ended questions that was 
administered weekly, during dialysis treatment (Appendix 11).  This questionnaire was designed 
to obtain information regarding acute illnesses, falls, changes in medication dose and usage, 
adverse events related to exercise participation and all visits to health care professionals.  An 
adverse event was defined as any injury, impairment or medical condition that was directly or 
suspected to be due to performing the prescribed exercise. In addition, the clinical notes of each 
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patient were reviewed on a week basis to document any dialysis-related adverse events or 
complaints. Overall adherence to training was computed as the total number of exercise sessions 
attempted divided by the total number of exercise sessions offered, multiplied by 100%.  In 
addition, the percentage of each of the 10 prescribed PRT exercises completed was computed as 
the total number of sets completed divided by the total number of sets prescribed, multiplied by 
100%. Reasons for missing or non-attempt of exercise sessions were also documented.  
	
3.6  Assessment protocol 
As mentioned, all outcome measures were assessed at baseline (week 0), after the control 
period (week 13) and after the intervention period (week 26) (Table 2) in the dialysis centers 
participants received hemodialysis treatment. The testing was scheduled on the second or third 
non-dialysis day of the week. Assessments were completed in the following order: 
anthropometric measures (i.e. height, weight, waist circumference), supine blood pressure, 
arterial stiffness (i.e. PWV and AI), six-minute walk, muscular strength (i.e. maximal handgrip 
strength, three repetitions-maximum leg press). The testing session took approximately 1 to 1.5 
hour to complete.  Follow-up testing in week 26 was completed at least 48 hours after the last 
exercise session.  Each assessment was conducted by the principal investigator (D.C.). The 
dialysis nurse collected bloods for haematological measures just prior to the patients’ dialysis 
session at each timepoint and immediately forwarded and assayed by the haematology, 
biochemistry and vascular biology and cell trafficking laboratories of Institute of Medical and 
Veterinary Science. Bloods for EPCs assays were collected on the first dialysis day of the week 
while bloods for CRP and lipid profile were collected on the second dialysis day of the week.  
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Psychological outcome measures and PAL, evaluated using questionnaires (i.e. SF-36, 
GDS and PASE) were self-administered by participants within their own home after instructions 
were provided by the principal investigator. The questionnaires were collected and checked by 
the principal investigator to ensure they were completed correctly.   
 
3.7 Control period 
During the control period (week 1 – 12), participants were provided usual medical and 
dialysis care but were given no instructions to exercise or access to equipment.  
 
3.8 Intervention period 
The RT intervention is fully detailed in Appendix 12.  Six upper-body and four lower-
body exercises were prescribed in each dialysis session (3 sessions per week).  Upper body 
exercises were comprised of shoulder press, chest press, seated row, biceps curl and triceps 
extension and seated back extension. Lower body exercises were comprised of leg press, knee 
flexion, knee extension, supine bent knee hip flexion or leg raise depending on participant’s 
ability (Figure 3.1). Table 3.5 shows the equipment that was used to perform each exercise. 
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Table 3.5. Equipment used for each exercise prescribed 
Equipment Exercises 
Customized weight 
machine 
Chest press,  
Seated row 
Leg press,  
Knee flexion 
Supine bent knee hip flexion/leg raise 
Free weights 
(dumbbells) 
Shoulder press 
Bicep curl 
Tricep extension 
Elastic tubings Back extension 
Knee extension 
Supine bent knee hip flexion/leg raise 
 
Table 3.6. Progression of the resistance training programme 
Week Number of  
sets 
Number of 
repetitions 
RPE 
1 – 2 3 12 – 15 12 – 13 
3 – 4 3 12 – 15 13 – 14 
5 – 12 3 – 4 10 – 12 14 – 15 
RPE, rating of perceived exertion 
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During the intervention period, the participants were prescribed light-to-moderate 
intensity RT three times per week during their routine hemodialysis sessions. The principal 
investigator aimed to have each participant complete their exercises during the first half of their 
dialysis session to avoid any risk of dialysis-induced hypotension. The principal investigator 
guided each participants in increasing the intensity (load) and volume (number of sets) of 
resistance training with strength adaptation.  The rating of perceived exertion of each set was 
assessed using the Borg scale (15) (Appendix 13), and progressed according to Table 3.6. An 
exercise log sheet was used to track the progress of each participant (Appendix 14). The average 
duration of the exercise program was approximately 30 minutes; the efficiency of training was 
enhanced by having participants alternate exercises that use different muscle groups.     
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Figure 3.1.  Specific resistance training exercises  
(a) biceps curl with dumbbell, (b) shoulder press with dumbbell, (c) triceps extension with 
dumbbell, (d) seated row with machine, (e) chest press with machine, (f) seated back extension 
with elastic tubings, (g) leg press with machine, (h) knee flexion with machine, (i) knee extension 
with elastic tubings, (j) supine bent knee hip flexion with machine 
 
 
 
  
 
(a) 
 
 
(b) 
 
 
(c) 
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The exercise program was designed to be performed with the patient in a seated or supine 
position receiving dialysis. A combination of RT equipment was used to optimally target all 
major muscle groups of the body. The equipment included a novel Maxim Fitness™ (Hindmarsh, 
SA, Australia) exercise device (see section 3.9),  Thera-bandTM elastic tubing (Akron, Ohio, 
USA) with handles (Practitioner Supplies, Clovelly Park, SA, Australia) and free weight 
dumbbells (Celsius™, China). As the elastic tubings have up to 5 colour graded resistance, 
progression in resistance was attained by connecting different colours of tubing to handles. A 
guide to the progression of elastic resistance has been developed by the principal investigator 
(31). Standard hemodialysis chairs (Fresenius Medical Care, Scoresby, Victoria, Australia) were 
used during the training sessions. The upper limb containing the vascular access was exercised 10 
- 15 minutes prior to each dialysis session in the patient waiting area.  Patients with a vascular 
catheter access were instructed to perform all the exercises during their dialysis session, unless 
they refused. 
 
3.9  Prototype design and development 
The lead author (D.C.) developed the novel exercise device prototype in consultation with 
Maxim Strength Fitness Equipment Pty. [www.maximfitness.net, Hindmarsh, SA, Australia 
(Figure 3.2)].  The lead author is an accredited exercise physiologist17 who has worked for over 
six years prescribing exercise as standard care in dialysis centers in the Adelaide metropolitan 
area.  In clinical practice, the lead author routinely utilized a custom-designed resistance training 
device (Maxim Strength Fitness Equipment Pty., Adelaide, Australia) developed and tested by 
Bennett et al (32). The device (32) consisted of a weight-adjustable, pulley system that applied 
resistance (up to 32 kg) to the lower body musculature in three movements: leg press (target 
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muscles: quadriceps, gluteal, hamstrings and calves), knee flexion (target muscles: hamstrings) 
and knee extension (target muscles: quadriceps). The prototype designed in the present study 
advanced upon this initial design (32) by enabling the performance of both upper and lower body 
exercises during dialysis with heavier loads.  
The lead author first conceptualized and sketched an equipment design that could provide 
an overload stimulus to all of the major muscle groups, while considering the space available in 
participating dialysis centers and the dimensions of standard hemodialysis chairs (Fresenius 
Medical Care, Scoresby, Victoria, Australia).  Portability and functionality were considered as 
key aspects of the design; i.e. the device would require wheels with a braking mechanism 
allowing for safe positioning during pre-dialysis training (of the fistula containing arm in the 
patient waiting area) and intradialytic exercise training, and need to be stowed when not in use.  
Further, the PRT exercises needed to be administered without complicated set-ups or 
configuration changes, easily used in practice by both exercise physiologists and/or dialysis 
nursing staff.   The concept of a portable device including wheels and brakes was adopted from 
Bennett et al. (32) This design was finalized after several discussions with the production 
manager of Maxim FitnessTM to ensure its feasibility and the mechanics to allow bilateral or 
unilateral movement.  As the device was first of its kind, the process of designing and developing 
it took approximately 4 months.   
The structure was made of steel and measured 1.16 m wide, 0.94 m long and 1.61 m tall. 
The design consisted of a trapezium-shaped base, with two lever arms pivoting from the corners 
of the widest side and the pin-loaded weight stack is positioned on the shorter side (Figure 3.2).  
The lever arms allowed the performance of resistance exercises involving pushing (e.g. chest 
press) and pulling (e.g. seated row, hip flexion) while a plate attachment was connected to a pair 
of steel cables enabling leg press and knee flexion exercises. All exercises performed with the 
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device are presented in Table 1.  Loading of each exercise ranged from 2.5kg to 59kg; the 
weights were pin-loaded and easily adjusted by the supervising exercise physiologist or nurse.  
1kg add-on weights are available for gradual increment (Figure 3.2).  
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 3.10 Statistical Analyses 
Analyses were performed using the Statistical Package for the Social Sciences (IBM©, 
SPSS Version 19.0).  All available data were included regardless of patient compliance to the 
intervention.  All data were inspected visually and statistically for normality at each timepoint 
(weeks 0, 13, and 26).  Normally distributed data were described using mean + standard 
deviation.  Non-normally distributed data were log-transformed across the three timepoints prior 
to entry into parametric statistical models.  Primary analysis incorporated a linear mixed model 
defining individual as the random effect with the outcome measure evaluated across three 
timepoints (weeks 0, 13, 26).  Each model was also adjusted for age, gender, hemodialysis 
vintage, and interactions for time by age, time by gender and time by hemodialysis vintage.   P-
values were reported for the change from week 0 to week 13 and change from week 13 to 26.  In 
addition, the mean difference and effect size were computed comparing the control period (week 
13 – week 0) to the intervention period (week 26 – week 13). 
There are no published data on the effects of RT during hemodialysis on arterial stiffness 
in patients with ESRD.  The sample size estimate was therefore determined by a post hoc sample 
size computation provided by Koh et al. (12) following the completion of a recent RCT 
comparing intradialytic aerobic exercise training to home-based aerobic exercise training and to 
usual care control in a cohort of patients with ESRD. The data collected by  Koh et al. (12) 
suggested that 36 patients per group would be needed to detect a -1.0 m/s statistically significant 
and clinically meaningful change in PWV between the exercise and the control group in a 
parallel arm randomised controlled trial (ES = 0.67; α = 0.05 and 1-β = 80%). Replacing the 
parallel groups design with a cross-over and assuming between measures correlation of 0.5, the 
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required sample size was computed as n=20 to detect the same effect size on this outcome 
measure.  
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Chapter 4 
Resistance Training In End Stage Renal Disease: Systematic Review 
And Clinical Trial Recommendations  
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4.1 Abstract 
Background:  This systematic review provides an overview of the extant literature on 
progressive resistance training (PRT) in patients with ESRD and outlines recommendations for 
future trials.  
Methods:  A non-meta-analytic, systematic review of all published literature evaluating the 
chronic (>6week) application of PRT in patients with ESRD using electronic databases. 
Results:   The search yielded 16 clinical trials, including 11 randomized controlled trials (RCT), 
four uncontrolled trials and one trial involving a within-subjects control period plus RCT.   RCT 
quality ranged from low (4/10) to high (10/10) with a mean quality score of 7.3/10; 7/11 RCT 
had a quality score ≥7.5.  All trials evaluated chronic adaptation to PRT across a range of 
important outcomes.  The evidence suggests that PRT can induce muscle hypertrophy, and 
improve aspects of physical functioning and health-related quality of life (HRQoL) in this 
population.  There is also preliminary evidence to suggest that PRT may reduce protein-energy 
malnutrition and cardiovascular risk factors, including CRP, total cholesterol, triglyceride, and 
measures of insulin resistance in patients with or at-risk of comorbid type 2 diabetes.  The 
evidence base for PRT adapting some of the endpoints investigated to date remains inconsistent 
(e.g. physical performance tests, obesity outcomes), and many other pertinent clinical outcomes 
remain to be investigated. 
Conclusion:  RCT are required to investigate a range of novel research questions related to the 
benefits and application of PRT in this cohort and its patient subgroups (e.g. diabetes, depression, 
dyslipidemia, etc.).  Future studies must be of high methodological quality to inform clinical 
practice guidelines.  
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4.2 Introduction 
The global incidence of end-stage renal disease (ESRD) continues to rise annually (1).  
Accompanying this rise is growth of the prevalent hemodialysis population (1). These trends are 
being driven by an unprecedented burden of hypokinetic, non-communicable diseases, and 
particularly the type 2 diabetes-obesity pandemic (2).  As the ESRD patient population continues 
to grow, greater efforts must be directed toward improving patient outcomes in this cohort, 
including morbidity, mortality and health-related quality of life (HRQoL).  
Progressive resistance training (PRT) is an anabolic form of exercise that involves 
challenging the skeletal muscles with unaccustomed loads, usually in the form of free- or 
machine weights.  Clinical trials in other cohorts have consistently shown that chronic RT 
interventions (>6 weeks) can counteract many impairments that accrue as a consequence of 
ageing and hypokinetic diseases (3).  PRT is a modality of choice for inducing skeletal muscle 
hypertrophy and enhancing bone mineral density (4, 5).  These adaptations often underlie 
improvements in physical functioning (e.g. muscular strength), activities of daily living (6-8) and 
HRQoL (9-11).  Accumulating evidence also suggests that PRT can induce cardiovascular 
system adaptation, including the improvement of cardiovascular disease (CVD) risk factors (e.g. 
hypertension, blood lipids, visceral fat, insulin resistance, glycemic control and circulating c-
reactive protein (CRP)) (12-16).  The many potential benefits of PRT might be particularly 
important for patients with ESRD who suffer from various physiological, functional and 
psychological impairments, contributing to poor HRQoL (17), low physical activity and fitness, 
and high CVD-related and all-cause mortality (18). 
 In 2002, Headley et al (19) conducted the first study of isolated PRT in patients with 
ESRD.  Ten hemodialysis patients were prescribed 12 weeks of PRT during non-dialysis time.  
Each training session consisted of 9 machine-weight exercises targeting all major muscle groups. 
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Participants significantly improved several measures of physical functioning, including six-
minute walk, maximal walking speed, sit-to-stand movement time and leg extension strength 
from pre to post training. Since this initial study (19), numerous investigations have shown that 
chronic PRT (>6 weeks) prescribed within or outside of routine hemodialysis treatment is safe, 
and can induce clinically important adaptations in patients with ESRD (20-22).  
Despite an accumulating evidence base, PRT and exercise training in general are not 
routinely prescribed in clinical practice to enhance health outcomes in this cohort.  Therefore, the 
purpose of the present systematic review to provide an overview of the extant literature on PRT 
in patients with ESRD, and to outline recommendations for robust randomized controlled trials 
(RCT) to investigate a range of novel research questions related to the benefits and application of 
PRT in this cohort.  
 
4.3 Methods 
Search Strategy 
A search of all published literature using the following electronic databases was 
conducted in August 2015: MEDLINE (OvidSP, Wolters Kluwer), PubMed (NCBI, U.S. 
National Library of Medicine), ScienceDirect (SciVerse, Elsevier), SPORTDiscus (EBSCOhost, 
EBSCO), Scopus (SciVerse, Elsevier), Web of Science (Web of Knowledge, Thomson Reuters), 
the Cochrane Library (John Wiley & Sons), Embase (OvidSP, Wolters Kluwer), CINAHL, and 
Google Scholar.  Search syntaxes were developed in consultation with an experienced university 
librarian taking into account a broad range of terms and phrases used in definitions related to 
hemodialysis (e.g. chronic kidney disease, hemodialysis, end-stage renal disease, etc.) and PRT 
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(e.g. resistance training, resistance exercise, weight training, weight lifting, strength training, 
etc.). Reference lists of retrieved full-text articles were examined to identify additional articles 
not found by our search.   
 
Study selection 
A systematic, critical review was undertaken to overview the literature and guides the 
development of future RCT.  The evidence base for PRT adapting many clinically important 
outcomes in this cohort is currently preliminary, and therefore a meta-analytic approach was not 
warranted.  There were also important findings to convey from several uncontrolled trials.  
Therefore, randomized controlled trials (RCT), controlled trials, cross-over trials and 
uncontrolled trials that investigated the independent effect of PRT in adults with ESRD were 
included.  Studies that did not evaluate the isolated effect of PRT within and/or between groups 
were excluded.  PRT interventions included any form of loaded exercise using body weight 
(calisthenics), equipment (machine weights, free weights) or apparatus (elastic bands), prescribed 
during or outside of hemodialysis treatment with the potential to increase muscular strength.  The 
interventions had to be at least six weeks in duration.  Trials prescribing PRT with additional 
neuromuscular, weight-bearing activity (e.g. balance training) were included, while those 
prescribing PRT interventions combined with aerobic training, or prescribing repetitive hand-grip 
(e.g. ball squeezing) exercise only, were excluded.  Outcomes that were potentially responsive to 
PRT based on the evidence in apparently healthy or other chronically diseased cohorts, were 
included.  Citations were compiled in an Endnote X7© (Thomson Reuters) file and duplicates 
were identified and deleted.  Both authors independently reviewed the titles and abstracts of each 
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reference for potential inclusion.  Each reviewer then performed a second screening on the full 
text version of these articles; disagreements were resolved by discussion. 
 
Quality assessment 
A quality checklist was designed based on established criteria for the assessment of RCT 
and was extended for the critique of other study designs as appropriate (23, 24). Quality items 
reviewed, each worth 1.0 numerical point, were as follows: (1) evidence of randomization and 
concealment of treatment allocation, (2) statistical similarity of groups at baseline, (3) 
specification of eligibility criteria, (4) blinding of outcomes assessors, (5) reporting of 
compliance, (6) supervision of exercise sessions, (7) reporting of dropouts, (8) presenting data for 
primary and secondary outcomes, (9) use of intention-to-treat analysis, and (10) reporting of 
adverse events.  Summed scores to range from 0 to 10 points with higher scores reflecting better 
quality.  
 
Data extraction  
The following data were extracted using a standard proforma: study design, study 
population characteristics (inclusion/exclusion criteria), group(s) and sample size, PRT 
intervention (e.g. specific exercises, number of sets per exercise, number of repetitions per set, 
intensity (load), frequency and duration of training), selected outcome measures, and key 
findings. 
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4.4 Results 
Figure 4.1 presents a flowchart summarizing identification of potentially relevant studies, 
and those included.  Our search identified 201 citations after duplicates were removed. Of these, 
168 citations were excluded after the first screening of titles and/or abstracts for inclusion and 
exclusion criteria.  After further assessment of the remaining 33 citations, 8 were excluded for 
reasons listed in Figure 4.1, leaving 24 citations presenting the findings of 16 trials.  A summary 
of these studies is presented in Table 4.1.     
Figure 4.1. Flowchart summarizing identification of studies for review 
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Descriptive data synthesis 
Of the 16 trials, 11 were RCT (25-36), four were single treatment group uncontrolled 
trials (19, 37-41) and one trial by Molsted and colleagues involved both a within-subjects control 
period and an RCT comparing PRT + protein drink to PRT + placebo drink (42-46). 
The studies were published between 2002 and 2014.  Five studies were conducted in the 
USA, four in Europe (i.e. Greece, Switzerland, Denmark, and Wales), three in Brazil, two in Asia 
(Iran, South Korea) and two in Australia.  All studies enrolled exclusively maintenance 
hemodialysis patients with the exception of one study that also enrolled five peritoneal dialysis 
patients (42-46).  In general, studies included patients who were adequately dialyzed (Kt/V>1.2) 
and/or had received hemodialysis treatment for more than three months (26).  Major exclusion 
criteria included uncontrolled cardiovascular diseases and other conditions that would physically 
limit or contraindicate participation in PRT.  Sample sizes ranged from n=10 to n=79.  The mean 
age of participants ranged from 42.8 to 70 years.   All trials were open to both men and women; 
however, two studies recruited no women (28, 31), and one article published by Molsted et al 
(43) was limited to a subgroup of men only.    
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Table 4.1. Summary of studies prescribing progressive resistance training in patients with end stage renal disease 
Study 
Identificati
on 
Inclusion/exclusion criteria 
PRT / 
Comparison 
Group(s) (n) 
PRT Intervention  Selected Outcome Measures Key Findings Qualit
y Score 
Randomized controlled trials  
Kirkman et 
al.,  
2014 
Wales 
Inclusion criteria: ESRD 
receiving HD three times per 
week.  Exclusion criteria: Age 
<18 years, <3 months of HD, 
required support for ambulation, 
hemoglobin <11 g/dL, 
neuromuscular or catabolic 
conditions, anabolic treatment in 
previous 3 mo., uncontrolled 
medical condition 
PRT (n=9) 
Placebo control 
(n=10) 
Intradialytic:  leg press 
utilizing resistance bands, 
loading up to 200 kg.   
3 sets x 8-10 reps, 80% 
predicted 1RM (based on 
5RM), 3x/wk, 12 wk 
- muscle volume (thigh, via MRI)  
- physical functioning:  knee 
extension strength, STS-30s, 8ft ‘get-
up-and-go’, 6-min walk  
- HRQoL: 8 domains 
↑ muscle volume  
↑ knee extensor strength 
no Δ in any other outcome 
8 
de Lima et 
al.,  
2013 
Brazil 
Inclusion criteria: 18-75 yr; HD 
three times per week, sedentary. 
Exclusion criteria: uncontrolled 
hypertension, cardiomyopathy, 
amputation, deep vein thrombosis, 
pallor, severe dyspnea, femoral 
fistula, arrhythmias, precordial 
pain, orthopedic, neurological or 
cognitive condition 
PRT (n=11) 
Aerobic (n=10) 
Control (n=11) 
Intradialytic: knee flexion 
and extension, and hip and 
knee flexion with foot 
dorsiflexion using weighted 
ankle cuffs, 3 sets x 15 reps, 
40% 1RM, 3x/wk, 8 wk 
- sub-maximal exercise capacity (4 
min step test) 
- HRQoL: 11 domains 
In the PRT group over time:   
↑ step test (number of steps achieved)   
↑ HRQoL in 3 domains (social 
support, patient satisfaction, and 
general health)  
no Δ in any other outcome 
5.5 
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Song et al.,  
2012 
South Korea 
Inclusion criteria: Age >18 yr; 
HD >3mo.; permission of 
nephrologist; ability to maintain a 
seated position; independent 
ambulation with or without an 
assistive device; adequate dialysis 
(Kt/V=1.2); stable during dialysis 
PRT (n=20) 
Control (n=20) 
Prior to each HD session: 6 
upper body exercises using 
elastic bands, and 6 lower 
body exercises using 
sandbags, 3 sets x 10-15 
reps, RPE 11-15, 3x/wk, 12 
wk  
- body composition:  muscle mass, 
body fat and visceral fat area (via 
bioelectrical impedance), waist 
circumference, arm circumference 
- physical functioning:  handgrip and 
leg strength, sit ups, sit and reach test, 
shoulder flexibility, single-leg 
balance 
- HRQoL: physical and mental 
component scales 
- blood lipids: TC, triglycerides, 
HDL-C, LDL-C 
↑ in muscle mass 
↑ leg strength 
↑ HRQoL physical and mental 
component scales;  
↓ body fat percentage  
↓ total cholesterol and triglycerides  
no Δ in any other outcome  
8 
Orcy et al.   
2012  
Brazil  
Inclusion criteria: HD >3mo, 
receiving EPO, Hb >9.0 g/dL, 
independent ambulation. 
Exclusion criteria: symptomatic 
ischaemic heart disease, 
myocardial infarction in previous 
6 mo., uncontrolled hypertension, 
pleural or pericardial friction rub, 
aortic stenosis, musculoskeletal 
problem of the legs, vertebral 
fractures, participating in an 
exercise program  
PRT (n=13) 
PRT + Aerobic 
(n=13) 
Intradialytic:  muscles 
groups targeted included: 
elbow/shoulder flexors, hip 
flexors with knees 
flexed/extended, and hip 
abductors.  Equipment: 
elastic bands, dumbbells, 
balls and ankle weights of 1-
2 lbs, 3-4 sets x 10-15 reps, 
3x/wk, 10 wk 
- 6-min walk  no Δ in 6-min walk 10 
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Dong et al.,  
2011 
USA 
Inclusion criteria: Age >18 yr; 
HD >3 mo.; adequate dialysis 
(Kt/V >1.2). Exclusion criteria: 
active inflammatory or infectious 
disease, pregnancy, 
hospitalization within previous 1 
mo., cardiovascular disease and/or 
osteoarthritis and unable to 
exercise 
PRT + Nutritional 
supplement 
(n=10) 
Nutritional 
supplement only 
(n=12) 
PRT prior to each HD 
session: leg press using 
pneumatic equipment, 3 sets 
x 12 reps, 70% 1RM.  1RM 
tested at month 3 for load 
adjustment, 3x/wk, 6 mo. 
- body mass  
- body composition: fat mass, body 
fat percentage, fat-free mass and leg 
fat-free mass (via DEXA)  
- albumin, prealbumin 
- CRP 
- leg strength (1RM)  
no Δ in any outcome 6.5 
Chen et al.,  
2010 
USA 
Inclusion criteria:  Age ≥30 year; 
serum albumin <4.2 g/dl and HD 
3x/week for >3 mo. with ≥80% 
compliance. Exclusion criteria:  
Any unstable chronic condition, 
cardiac surgery, retina laser 
therapy, myocardial infarction, 
joint replacement or lower 
extremity fracture in previous 6 
mo., severe cognitive impairment, 
leg amputation, current strength 
training 
PRT (n=22) 
Placebo control 
(n=22) 
Intradialytic: knee extension, 
dorsi/plantar flexion, leg 
curl, inner leg raises, 
dorsi/plantar flexion with 
straight legs using weighted 
ankle cuffs. First 8 sessions 
with no loading (RPE 2-
4/10) progressed to 1-2 sets 
x 8 reps, RPE 6/10, 2x/week, 
48 sessions 
- physical functioning:  STS-5x, 4m 
gait speed, balance tests, knee 
extension strength 
- body composition:  body fat 
percentage, fat-free mass, leg fat-free 
mass (via DEXA) 
- HRQoL:  physical and mental 
component scales 
- self-reported physical activity  
- self-reported ADL disability 
↓ STS-5x 
↓ ADL disability 
↑ knee extension strength,  
↑ fat-free and leg fat-free mass  
↓ body fat  
↑ HRQoL physical component scale  
↑ physical activity level 
no Δ in balance and gait speed tests 
8 
Afshar et 
al.,  
2010 
Iran  
Inclusion criteria: Age >20 yr; 
HD >3mo., no lower body 
dialysis graft.  Exclusion criteria: 
infection, inflammation, 
autoimmune disorder, 
malignancy, severe muscle 
weakness or skeletal deformity, 
PRT (n=7) 
Aerobic (n=7) 
Control (n=7) 
Intradialytic: knee 
extension/flexion, hip 
abduction/flexion using 
ankle cuffs; 60% of 3RM, 2 
sets x 8 reps. Sets increased 
to 3, as tolerated,  
- BMI 
- blood lipids: TC, triglycerides, 
HDL-C, LDL-C 
- CRP 
 
↓ CRP  
no Δ in any other outcome 
4 
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history of hypoglycaemia, 
cardiopulmonary contraindication 
to PRT (e.g. MI/CVA within prior 
6 mo., angina, congestive heart 
failure), hospitalization in 
previous month, prior regular 
exercise training 
3x/wk, 8 wk 
Segura-Orti 
et al.,  
2009 
Greece 
Inclusion criteria: HD >3mo. and 
medically stable.  Exclusion 
criteria: MI within previous 6 wk, 
uncontrolled hypertension, 
malignant arrhythmias, unstable 
angina, any disorder exacerbated 
by activity. 
PRT (n=17) 
Placebo control 
(n=8) 
Intradialytic:  knee 
extension, hip/knee/ankle 
extension using ankle cuffs, 
3 sets x 15 reps, 
hip/knee/ankle extension 
using elastic band, 1 set x 15 
reps; isometric leg 
contraction (up to 6s), 1 set x 
15 reps, 3x/wk, 24 wk  
- physical functioning:  STS-10x, 
STS-60s, 6-min walk, knee extension 
strength, graded exercise test in 
METS 
- HRQoL: physical and mental 
component scales 
 
Between groups: 
↑ right knee extension strength   
no Δ in any other outcome between 
groups 
 
Within PRT group: 
↑ STS60s  
↓ STS-10x 
↑ 6-min walk 
↑ GXT (METS) 
no Δ in any other outcome within 
PRT group 
 
7.5 
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Cheema et 
al,  
2007(a,b),  
2011 
Australia 
Inclusion criteria: Age >18 yr, 
HD >3 mo., independent 
ambulation, Kt/V≥1.2, stable on 
dialysis, ability to provide 
informed consent, cognition of 
English.  Exclusion criteria:  acute 
or chronic medical conditions that 
would preclude PRT or collection 
of outcome measures 
PRT (n=24) 
 
Waitlist control 
(n=25) 
Intradialytic: shoulder press, 
side shoulder raise, triceps 
extension, biceps curl, 
external rotation using 
weighted dumbbells; knee 
extension, hip flexion, hip 
abduction, straight-legged 
raise using weighted ankle 
cuffs, hamstring curl using 
elastic tubing; bilateral leg 
raises with no load 
performed seated or supine, 
2 sets x 10 reps, RPE 15-17, 
3x/wk, outcomes assessed at 
12 wk and 24 wk 
- muscle area and attenuation (thigh, 
via CT)  
- anthropometric measures:  mid-arm 
and thigh circumferences, BMI, body 
mass  
- physical functioning:  total strength 
(knee extension, hip abduction, 
triceps extension), 6-min walk  
- cytokines:  CRP, TNFα, IL-1b, IL-
6, IL-8, IL-10, IL-12  
- HRQoL:  physical functioning and 
vitality domains 
- depression 
- self-reported physical activity 
After 12 weeks in PRT vs. control: 
↑ muscle attenuation (↓ muscle lipid) 
↑ BMI, body mass, arm and thigh 
circumferences  
↑ total strength 
↑ HRQoL (Physical Functioning and 
Vitality) 
↓ CRP  
no Δ in any other outcome 
9.5 
Kopple et 
al.,  
2007 
USA 
Inclusion criteria:  stable 
hemodialysis patients, HD >6 mo, 
25-65 yr, sedentary.  Exclusion 
criteria: Hospitalization or 
systemic infection in previous 3 
mo., active cancer; severe heart, 
lung, or liver disease, 
uncontrolled hypertension, 
inflammatory disease, insulin-
dependent diabetes, severe 
osteoporosis, neuropathy, or 
musculoskeletal disease, leg 
PRT (n=15) 
 
Aerobic (n=10) 
 
PRT + Aerobic 
(n=12) 
 
PRT prior to each HD 
treatment: knee extension 
and flexion, leg press, calf 
extension using lower body 
machine. Wk 1-4: 1 set x 12-
15 reps at 70% 5RM, Wk 5-
8: 2 sets x 12-15 reps, Wk 
8+:  3 sets x 6-8 reps at 80% 
5RM, 3x/wk,  ~21 wk 
 
- anabolic and catabolic gene 
expression (mRNA and protein via 
muscle biopsy 
- body mass, BMI 
- body composition:  body fat 
percentage, fat-free mass (via DEXA) 
- cytokines:  CRP, TNF-α, IL-6, 
dietary protein and energy intake 
↑ muscle mRNA IGF-IEa  
↑ IGF-I protein.  
no Δ in any other outcome 
5.5 
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amputation, joint infirmity  Control (n=14)  
Johansen et 
al,  
2006 
USA 
Inclusion criteria:  Kt/V≥1.2 and 
compliant with HD treatment. 
Exclusion criteria: Hemodialysis 
<3 mo.; catabolic state (e.g. HIV 
with opportunistic infection, 
malignancy, or infection requiring 
intravenous antibiotics over prior 
2 mo., active intravenous drug 
use, thigh graft, contraindications 
to PRT 
PRT (n=20) 
Nandrolone 
decanoate (n=19) 
PRT + 
Nandrolone 
decanoate (n=20) 
Placebo injection 
(n=20)  
 
Intradialytic: knee extension, 
hip abduction and flexion, 
ankle dorsiflexion and 
plantarflexion using 
weighted ankle cuffs, 2–3 
sets x 10 reps, 60% 3RM, 
weights increased when 
patient could perform 3 sets 
x 10 reps, 3x/wk, 12 wk  
- body mass  
- body composition: fat-free mass, fat 
mass (via DEXA)  
- quadriceps muscle area (via MRI)  
- physical functioning: muscular 
strength (dynamic 3RM knee 
extension, hip abduction, hip flexion, 
isokinetic knee extension at 90 and 
120 degrees/s, gait speed, STS-5x, 
stair climb 
- HRQoL:  physical functioning 
- physical activity (self-report and 
accelerometer)  
- profile of mood states (anger, 
fatigue)  
↑ fat mass 
↑ quadriceps muscle CSA,  
↑ muscular strength (knee extension, 
hip abduction strength, hip flexion)  
↑ HRQoL (physical functioning) 
trend toward ↓ fatigue (p=0.06) 
no Δ in any other outcome 
8 
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Within subjects + randomized controlled trial 
Molsted et 
al., 
2013(a,b,c)  
2014 (a,b) 
Denmark 
Inclusion criteria: Age >18 years, 
>3mo. HD or PD, able to 
participate in the training 
program. Exclusion criteria: 
severe diabetic retinopathy, leg 
amputation, severe peripheral 
polyneuropathy, dementia, 
inability to speak Danish, and 
participation in conflicting trials 
PRT+protein 
drink (n=13) 
PRT+non-protein 
drink (n=16)  
 
 
 
Non-dialysis time: leg press, 
leg extension, leg curl using 
machine weights.  Intensity 
increased from 15RM to 
6RM over time, 5 sets per 
exercise, 3x/wk, 16 wk  
  
 
- muscle composition (via muscle 
biopsy),  
- body mass, BMI 
- insulin resistance:  OGTT, Matsuda 
ISI, HOMA2 
- cytokines: CRP, IL-6 
- anabolic hormones in men only: 
testosterone, luteinizing hormone, 
follicle stimulating hormone, 
estradiol, IGF-1, IGF-binding 
protein, sex hormone binding 
globulin 
- physical functioning: knee 
extension strength and power (rate of 
force development), STS-5x, STS-
30s  
- HRQoL: 8 domains and 2 summary 
scales 
 
↑ Type 2x muscle fiber CSA and ↓ 
proportion 
↑ body mass 
↑ HRQoL domains (physical 
functioning, bodily pain, role 
emotional, mental health) and 
physical component summary scale 
↑ knee extension strength and power 
↑ STS-30s and EMG amplitude and 
RFD 
↓ STS-5x  
↓ insulin concentrations (fasting, 2hr 
of OGTT and total insulin area under 
the curve) in patients with T2DM or 
impaired glucose 
no Δ in any other outcome 
9.5 
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Uncontrolled trials  
Moraes et 
al.,  
2014 (a,b) 
Brazil 
Inclusion criteria:  Age >18 years 
>6 mo. HD. Exclusion criteria: 
autoimmune diseases, cancer, 
AIDS, amputated limb, bariatric 
surgery, regular exercise, taking 
catabolizing drugs, and catheter 
access for HD 
PRT (n=37) Intradialytic:  Knee 
extension, thigh-knee-ankle 
flexion/extension, isometric 
leg extension, hip flexion 
with knee extended, 4 sets of 
10 repetitions at 60-70% 
1RM using elastic tubing, 
3x/wk, 6 mo.  
- protein energy malnutrition: 
subjective global assessment, BMI, 
albumin, arm muscle area 
- fat mass, fat-free mass (skinfold 
calipers/equations) 
-  ICAM-1  
- VCAM-1 
- cytokines: CRP, TNFα, IL-6, irisin,  
- BMI, body fat percentage, FFM,  
- physical functioning: isokinetic 
knee extension/flexion, STS-10x, 
STS-60s 
↓ in proportion of patients with 
protein-energy malnutrition 
↑ nutritional status, BMI, fat-free 
mass, albumin, 
↓ CRP, ICAM-1, VCAM-1,  
↓ STS-10x 
↑ STS-60s 
no Δ in any other outcome 
5 
Bennett et 
al.,  
2012  
Australia 
Inclusion criteria: ESRD, Age 
>18 yr; HD >3mo.  Exclusion 
criteria:  partial/total blindness, 
leg amputation, unable to 
understand English, hospitalized 
in previous month, unable to 
ambulate independently  
PRT (n=24) Intradialytic PRT: hip 
abduction, ankle 
plantar/dorsi flexion, 
straight-leg raise, hip 
flexion, knee extension and 
flexion using elastic band 
and tubing. 
1 set x 10-20 reps at RPE 15-
17. Loads increased when 20 
reps performed, plus 10 
minutes of static and 
dynamic balance exercises 
- falls risk computed from: reaction 
time, lower limb force, contrast 
sensitivity, proprioception, postural 
sway 
↓ in falls risk score 
↓ reaction time  
↑ lower limb force  
no Δ in any other outcome 
5 
117 
pre- or post-dialysis (static 
and dynamic exercises of 
increasing difficulty), 2 
x/wk, 8 wk  
Bullani et 
al.,  
2011 
Switzerland 
 
Inclusion criteria: Age >18 yr; 
HD >3mo., adequate dialysis 
PRT (n=11) Intradialytic: 
flexion/extension at foot, 
knee and hip; hip 
abduction/adduction using 
elastic bands with 7 grades 
of resistance; initial 2-4 wk 
learning phase, then 3 sets x 
20 repetitions at moderate 
RPE, resistance increased as 
tolerated, 2x/wk, 4.5-6 mo. 
- physical functioning measures: 
Tinetti gait and balance instrument, 
‘timed up-and-go’, one-leg balance, 
6-min walk 
↑ Tinetti score (gait and balance);  
↓ ‘timed up and go’  
- trend toward improved one leg 
balance (p=0.084)  
- trend toward improved 6-min walk 
(p=0.064) 
no Δ in any other outcome 
5 
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Nindl et al.  
2004,  
Headley et 
al.  
2004  
USA 
 
Inclusion criteria:  HD patients, 
physician approval. Exclusion 
criteria: renal osteodystrophy, 
recent MI or cardiovascular 
disease symptoms, uncontrolled 
cardiac dysrhythmias, 
hemodynamic instability, 
hypertension 
PRT (n=10) Non-dialysis time: leg press, 
knee extension/flexion, chest 
press, compound row, lateral 
raises, biceps curls, triceps 
extensions and abdominal 
curls. 1 set of 10-15 reps, 
2x/wk, 12 wk 
- anthropometric measures: body 
mass, body fat percentage, waist 
circumference 
- physical functioning: isokinetic 
knee extension strength at 90, 120 
and 150 degrees/s, handgrip strength, 
6-min walk, maximal gait speed, 
STS10x);  
- CRP 
-IGF-1; IGFBP-2, IGFBP-3 
- growth hormone binding protein 
↑ body fat percentage 
↑ isokinetic strength at 90 degrees/s 
↑ 6-min walk 
↑ maximal gait speed 
↓ STS10x, 
↓ in CRP 
↓ total and ternary IGF-1 
no Δ in any other outcome 
7 
Abbreviations: ESRD end stage renal disease, HD hemodialysis, Kt/V=hemodialysis treatment adequacy, PD peritoneal dialysis; PRT progressive resistance training, MI myocardial infarction, 
CVA cerebrovascular accident, HIV human immunodeficiency virus, AIDS acquired immune deficiency syndrome, RM repetition maximum, RPE rating of perceived exertion, MRI magnetic 
resonance imaging, STS sit-to-stand, HRQoL health-related quality of life, HDL-C high density lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol,  DEXA dual energy X-ray 
absorptiometry, CRP c-reactive protein, ADL activities of daily living, BMI body mass index,  TC total cholesterol, CT=computed tomography, METS metabolic equivalent, TNF = tumor 
necrosis factor, IL interleukin, ICAM-1 intra-cellular adhesion molecule 1 (ICAM-1) VCAM-1 vascular cell adhesion molecule-1, IGF insulin-like growth factor 
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Table 4.2. Quality item assessment 
Study Identification 
Treatment 
Allocation 
(each 
worth 0.5 
points): 
(1) 
evidence 
of 
randomiz
ation 
method; 
(2) 
evidence 
of 
concealme
nt of 
treatment 
allocation 
Were 
groups 
similar at 
baseline 
regarding 
the most 
important 
prognostic 
indicators
? 
Were the 
eligibility 
criteria 
specified? 
Were 
outcomes 
assessors 
blinded? 
Was 
complianc
e to the 
interventi
on 
reported? 
Were 
exercise 
sessions 
supervised 
(0.5 for 
partial 
supervisio
n) 
Were 
dropouts 
reported? 
Were 
point 
estimates 
and 
measures 
of 
variability 
presented 
for the 
primary 
outcome 
measures? 
Did the 
analysis 
include an 
intention 
to treat 
analysis? 
Were 
adverse 
events 
reported? 
Total 
quality 
score (out 
of 10) 
Randomized controlled trials 
Kirkman et al.  1 1 1 1 1 0 1 1 0 1 8 
de Lima et al. 1 1 1 0 0 0.5 1 1 0 0 5.5 
Song et al. 0.5 1 1 0.5 1 1 1 1 0 1 8 
Orcy et al. 1 1 1 1 1 1 1 1 1 1 10 
Dong et al. 0.5 1 1 0 1 1 1 1 0 0 6.5 
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Chen et al. 1 1 1 0 1 1 1 1 0 1 8 
Afshar et al. 0 1 1 0 0 1 0 1 0 0 4 
Segura-Orti et al. 0.5 1 1 1 1 1 1 1 0 0 7.5 
Cheema et al. 1 1 1 0.5 1 1 1 1 1 1 9.5 
Kopple et al. 0.5 1 1 0 0 1 1 1 0 0 5.5 
Johansen et al. 1 1 1 0 1 1 1 1 0 1 8 
Within subjects + randomized controlled trial  
Molsted et al. 1 1 1 0.5 1 1 1 1 1 1 9.5 
Uncontrolled trials 
Moraes et al. N/A 
N
/A 
1 N/A 0 1 1 1 0 1 5 
Bennett et al. N/A 
N
/A 
1 N/A 1 1 1 1 0 0 5 
Bullani et al. N/A 
N
/A 
1 N/A 0 1 1 1 0 1 5 
Nindl, Headley et al. N/A N/A 1 N/A 1 1 1 1 0 1 6 
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Quality assessment  
The quality assessment for the trials reviewed is presented in Table 4.2.  RCT quality 
ranged from low (4/10) to high (10/10) with a mean quality score of 7.3/10, while 7/11 (64%) 
RCT had a quality score ≥7.5.  The trial by Molsted and colleagues had a quality score of 9.5/10.  
The four uncontrolled trials had a quality rating ranging from 5/10 to 6/10.  
 
PRT interventions 
Twelve trials prescribed lower body PRT exercises only (25, 26, 29-31, 35-40, 42-47) 
while four trials prescribed both upper- and lower body PRT exercises (19, 27). All studies 
prescribed two to three sessions of PRT per week, and 1 to 5 sets per exercise. Duration of 
training ranged from 8 weeks to 6 months. Four trials prescribed PRT outside of dialysis time 
(27, 28, 33, 34, 41, 48), while 12 trials prescribed PRT during dialysis (25, 26, 28-31, 33, 34, 36-
40, 47, 48).  
 
Outcomes  
The 16 trials retrieved evaluated chronic adaptation to PRT across a range of clinically 
important outcomes, including: (1) skeletal muscle and protein-energy malnutrition, (2) physical 
functioning (i.e. muscular strength and power, and physical performance tests) (3) psychological 
health status, and (4) CVD risk factors (i.e. systemic inflammation, obesity, blood lipids and 
insulin resistance). 
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1.  Skeletal muscle and protein-energy malnutrition   
 Nine trials (25, 27, 29, 30, 33-38, 42-46), including 7 RCT with a mean quality score of 
7.6/10 (25, 27, 29, 30, 33-36), have investigated the effect of PRT on measures of skeletal muscle 
hypertrophy.  Most recently, an RCT by Kirkman et al (25) prescribed three sessions of 
intradialytic PRT per week for 12 weeks performing a single resistance exercise (i.e. leg press) 
on a custom-designed machine providing a resistance of up to 200 kg.  Participants performed 
three sets of 8-10 repetitions at 80% of predicted 1-repetition maximum (1RM) load. Load was 
increased with strength adaptation.  The PRT group experienced a statistically significant 
increase in thigh muscle volume versus the control group [Mean Difference = 193 (95% CI = 63 
to 324 cm3)].  
Additional studies have shown that PRT prescribed for a minimum of 12 weeks, both 
during (30, 36-38) or outside of dialysis treatment (27, 45) can induce statistically significant 
increases in one or multiple measures of skeletal muscle hypertrophy.  The hypertrophy noted in 
one uncontrolled trial (37) was concomitant with an improvement in nutritional status, evaluated 
via an increase in serum albumin (p<0.05) and the subjective global assessment score (p<0.001), 
and a decrease in the proportion of patients suffering from protein-energy wasting (p=0.01).    
An RCT by Cheema et al (33, 34) (quality score = 9.5) prescribed intradialytic resistance 
training three sessions per week and documented a significant improvement in thigh muscle 
attenuation (a measure of muscle quality; p=0.04) and a clinically meaningful increase in thigh 
muscle cross-sectional area [Mean Difference = 2.1 (95% CI -1.9 to 6.1 cm2)].  These changes 
were accompanied by a significant increase in mid-arm (p=0.004) and mid-thigh (p=0.04) 
circumferences. In addition, a trend toward increased muscle cross-sectional area (p=0.04; non-
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significant due to Bonferroni correction for two primary outcomes) was noted with a longer 
versus shorter duration of PRT (24 versus 12 weeks) (34).  
In contrast to these positive findings, Dong et al (29) (RCT, quality score = 6.5) showed 
no change in whole body or leg muscle mass (both evaluated via dual energy X-ray 
absorptiometry) or circulating albumin or pre-albumin in patients prescribed 6 months of PRT 
and nutritional supplementation versus nutritional supplementation only.  It was not clear if the 
PRT regimen in this study provided progressive overload.  Similarly, Kopple et al (35) (RCT, 
quality score = 5.5) found no significant change in whole body muscle mass or thigh muscle 
cross-sectional area by prescribing a low-intensity (70-80% 5RM) PRT regimen for 21 weeks, 
but changes in anabolic genes expression including IGF-IEa mRNA and IGF-I protein (p<0.05) 
were noted.  A controlled trial by Molsted et al. (45) using a biopsy of the vastus lateralis muscle, 
showed selective hypertrophy of the Type 2x muscle fibers concomitant with a reduction in the 
proportion of Type 2x fibers, and no effect on the other fiber types (i.e. Type 1, 2, and 2a).  
Three studies of PRT in ESRD (38, 41, 43) have investigated anabolic hormone 
responses, including changes in circulating irisin, testosterone, luteinizing hormone, follicle 
stimulating hormone, estradiol, IGF-1, IGF-binding protein, sex hormone binding globulin and 
growth hormone binding protein. These studies found no effect except for a reduction in total 
(p=0.039) and ternary IGF-1 (p<0.05) in one small (n=10) uncontrolled trial (41).   
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2.  Physical functioning  
a. Muscular strength and power  
Numerous studies have evaluated the effect of PRT on upper- (19, 27, 34), lower- (19, 25, 
27, 29, 30, 32, 34, 36-38, 42-46, 49) and total body (33, 34) muscular strength in patients with 
ESRD.  Eight of these trials were RCT (25-30, 32, 33, 35-38, 42-46) with a mean quality score of 
7.9/10.   
Cheema et al (33, 34) (RCT, quality score = 9.5) noted significant improvements in total 
body muscular strength (a summary of elbow extension, knee extension and knee abduction, 
assessed bilaterally and summed, p=0.002) in participants prescribed 12 weeks of full body 
intradialytic PRT (33).  The authors also documented a significant increase in each of the isolated 
strength measures in their PRT group over time (all p<0.001) (34).   
Only two additional studies, including one RCT (27) and one uncontrolled trial (19) have 
evaluated changes in upper body strength (i.e. maximal handgrip strength (assessed bilaterally).  
Both studies prescribed a full body PRT regimen, either prior to routine hemodialysis treatment 
(27) or during non-dialysis time (19), and did not elicit a significant change in this outcome 
measure.      
 The effect of PRT on lower body strength has been consistent, with 9 of 11 studies 
(including 5 RCT, mean quality score = 8.2) documenting a significant increase in one or 
multiple measures of lower body strength secondary to PRT prescribed during dialysis (25, 30, 
34, 36, 39, 47), just prior to dialysis sessions (27), or during non-dialysis time (42).  Molsted et al 
(42) noted that the significant increase in 1RM knee extension strength (p<0.001) was 
concomitant with an increase in neuromuscular recruitment (EMG amplitude) and knee extension 
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power (i.e. rate of force development).  Two trials documented no change in lower body strength 
measures (29, 37).  Both studies did not state explicitly if the training loads were progressed with 
adaptation.  In general, studies that have evaluated lower body strength using a dynamic or 
isometric test have shown significant adaptation, while studies utilizing a isokinetic 
dynamometer have shown mixed effects (19) or null (36, 37) effect on these outcomes.  
b) Physical performance tests 
Six trials have evaluated the effect of PRT on six-minute walk in patients with ESRD and 
have produced mixed results (19, 25, 28, 33, 34, 40, 47).  One uncontrolled trial documented a 
significant increase in six-minute walk (p<0.05) (19), while another uncontrolled trial noted a 
trend toward improvement (p=0.064) (40).  Two RCT noted a significant improvement in their 
PRT group over time (34, 47), but no significant group x time effect (33, 34, 47).  Two additional 
RCT found no change in six minute walk secondary to >10 weeks of intradialytic PRT (25, 28). 
 Sit-to-stand performance tests have been evaluated in seven trials, including four RCT 
(19, 25, 32, 36, 37, 45).  One RCT (30) (quality score = 8) noted a group x time effect for sit-to-
stand performance.  This finding has been supported by one controlled trial (45) (quality score = 
9.5) and two uncontrolled trials (19, 37).  Other RCT have documented only a within-group 
effect for their experimental group (47) or no effect (25, 36).    
Additional physical performance tests that have been investigated have included ‘get-up-
and-go’ (or ‘timed up-and-go’) tests (25, 40), gait speed (30, 36), Tinetti gait and balance (40), 
shoulder and waist flexibility (27), balance (27, 30, 40), falls risk (49), stair climbing (36), and 
sit-ups (27).   In an uncontrolled trial, Bullani et al (40) prescribed 4.5 to 6 months of lower body 
intradialytic PRT and documented significant improvements in the Tinetti gait and balance test 
and the ‘timed up and go test,’ and trends toward improved one leg balance (p=0.084).  However, 
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these adaptations have not been noted in RCT assessing ‘get up and go’ (25), gait speed (30, 36), 
or single leg balance (27).  Further, no effects have been noted for stair climbing (36), shoulder 
flexibility, trunk flexibility (sit and reach test) or sit ups (27).  An uncontrolled trial by Bennett et 
al. (49) has provided evidence suggesting that 8 weeks of intradialytic PRT combined with 
balance exercises may significantly reduce falls risk by improving reaction time and lower limb 
strength. 
c) Exercise capacity 
Two studies have evaluated the effect of PRT on submaximal (26) and maximal exercise 
capacity (47).  An RCT by de Lima et al (26)  (quality score = 5.5) noted a significant increase in 
the number of steps achieved during a submaximal stepping test in their PRT group after 8 weeks 
of lower body intradialytic PRT (p=0.0001); however, group x time effects were not reported in 
this study. Similarly, an RCT by Segura-Orti (47) documented a significant increase in the 
metabolic equivalent exercise capacity during a graded exercise test to exhaustion within their 
PRT group following 24 weeks of lower body intradialytic PRT, however the group x time effect 
was non-significant. 
d) Physical activity 
 Three RCT (30, 33, 36) have investigated the effect of intradialytic PRT on self-reported 
physical activity in patients with ESRD.  One of these trials also employed the use of an 
accelerometer (36).  Two of these studies (mean quality score = 8.8) yielded no effect secondary 
to 12 weeks of PRT (33, 36), while one study (30) yielded a significant increase in self-reported 
physical activity, a change driven primarily by a reduction in physical activity in the control 
group.  
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 3.  Psychological health status 
Seven RCT (25-27, 30, 32-34, 36) and one controlled trial (45) (mean quality score = 8.0) 
have investigated the effect of PRT on one or multiple domains of HRQoL and/or other 
psychological outcomes (i.e. self-reported disability, fatigue, anger) in patients with ESRD.  One 
or more domains of HRQoL have significantly increased in response to PRT in all except two 
trials (25, 32).  Domains of HRQoL that have improved have included:  physical functioning, 
(27, 30, 33, 36, 45), mental health (27, 30, 45), bodily pain, role emotional (45), vitality (33), 
social support, satisfaction, and general health (26). 
An RCT by Cheema et al. (33) (quality score = 9.5) prescribed 12 weeks of full-body 
intradialytic PRT and demonstrated a trend toward reduced depression (p=0.11) in patients 
receiving PRT group as compared to usual care.   Two other RCT (mean quality score = 8) have 
documented a trend toward improved fatigue (p=0.06) (36) and significantly reduced self-
reported disability (p=0.02) (30) secondary to 12-24 weeks of lower body intradialytic PRT 
versus control.  
 
4.  Cardiovascular disease risk factors    
a) Systemic inflammation  
Seven trials have investigated the effect of PRT on circulating CRP in patients with 
ESRD (29, 31, 33, 35, 37, 41, 46).  The results have been mixed.  Three trials (31, 33, 37), 
including two RCT (31, 33), have reported significantly reduced CRP after 12 to 24 weeks of 
PRT, while three trials prescribing 16 and 24 weeks of PRT reported no change (29, 35, 46).  
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One uncontrolled trial of 8-week duration reported a reduction in CRP but did not statistically 
analyze this change (41).    
Two trials (mean quality score = 7.5) that reported no change in CRP also reported no 
change in circulating IL-6 (44) or TNF-α (35).  IL-6 and TNF- α also failed to change in two 
trials that noted significantly reduced CRP (37) (33).  Cheema et al. (48) also noted no change in 
other pro- and anti-inflammatory cytokines, including IL-1b, IL-8, IL-10, and IL-12 secondary to 
12 weeks of PRT versus control.  Moraes et al (37) found that reduction of CRP (p<0.001) was 
concomitant with significant reductions in the vascular cell adhesion molecule 1 (VCAM-1) 
(p<0.05) and intra-cellular adhesion molecule 1 (ICAM-1) (p<0.05).  
b) Obesity  
The effect of PRT on obesity outcomes in patients with ESRD has been inconsistent.   
Several trials have shown that PRT significantly increases BMI (37) and body mass (29, 33, 45), 
which is likely to be the product of muscular hypertrophy (33), while other studies including two 
RCT have reported no effect on these outcomes (19, 35, 36). Further, body fat percentage has 
also been shown to increase (19, 36), decrease (27, 30) or remain unchanged secondary to PRT 
(29, 35, 37).  Only three studies to date have investigated the effect of PRT on measures of 
abdominal obesity including waist circumference (19, 27, 33) and visceral fat area (27).  All of 
these studies have shown no effect.   
c) Blood lipids  
Two studies have investigated the effect of PRT on blood lipids in patients with ESRD 
(27, 31).  An RCT by Song et al (27) (quality score = 8/10) prescribed full body PRT three 
sessions per week prior to each hemodialysis treatment for 12 weeks and documented 
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significantly reduced total cholesterol (p=0.017) and triglyceride (p=0.012) in the PRT group 
versus the control group.  However, no change was detected in other blood lipids (i.e. HDL and 
LDL cholesterol).  By contrast, a relatively low quality RCT by Afshar et al (31) (quality score = 
4/10) documented no change in total cholesterol, triglyceride, or HDL or LDL cholesterol in 
participants prescribed 8 weeks of low intensity (60% 3RM) intradialytic PRT versus usual care 
(n=7).   
d. Insulin resistance 
 A controlled trial by Molsted et al (46) completed a sub-group analyses limited to 
participants with impaired fasting glucose or type 2 diabetes and showed that 16 weeks of PRT 
significantly reduced circulating insulin concentrations (i.e. fasting, 2 hour postprandial, and total 
area under the curve, all p<0.05).  However, there was no change in blood glucose or other 
parameters of insulin sensitivity (i.e. HOMA-2 or Matsuda Index). 
 
4.5 Discussion 
Summary and Recommendations 
This systematic review has overviewed the current literature on PRT intervention in 
patients with ESRD.  The evidence suggests that PRT can induce muscle hypertrophy, and 
improve aspects of physical functioning and HRQoL in this patient population.  There is also 
preliminary evidence to suggest that PRT may reduce protein-energy malnutrition and 
cardiovascular risk factors, including CRP, total cholesterol, triglyceride, and measures of insulin 
resistance in patients with or at-risk of comorbid type 2 diabetes.  These adaptations are clinically 
relevant to the ESRD population.  Notably, guidelines for prescribing PRT across the chronic 
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kidney disease continuum have been included within a recent exercise prescription position 
statement (50), and we have recently indicated a need to update clinical practice guidelines to 
inform clinicians on the benefits of PRT in this cohort (51). 
The evidence base for PRT adapting some of the endpoints investigated to date remains 
inconsistent (e.g. physical performance tests, obesity), and many other pertinent clinical 
outcomes remain to be investigated.  Of the 16 clinical trials reviewed, 11 involved an RCT 
design.  Seven RCT were of high methodological quality (>7.5/10), while four yielded a quality 
score <6.5/10. Particular methodological deficits across the lower quality RCT included the lack 
of blinded outcomes assessors, reporting of compliance to PRT intervention, conducting of 
intention-to-treat statistical analyses, and reporting of adverse events.  Standardized reporting is 
required of future clinical trials (24, 52).  It is also essential that PRT interventions be thoroughly 
described with respect to frequency, intensity, delivery (equipment and setting), supervision and 
application of progressive overload. This is particularly important for determining the exercise 
dose required to adapt specific endpoints (i.e. determine dose-response effects).  Future trials also 
need to be limited to certain sub-populations with the ESRD population (e.g. patients with 
clinical depression, type 2 diabetes, hypercholesterolemia) to better elucidate the benefits of PRT 
on outcomes related to these specific comorbidities.   
The majority of studies reviewed demonstrated significant skeletal muscle hypertrophy 
secondary to PRT.  These findings are clinically important given that muscle wasting is common 
and a strong independent predictor of mortality in this cohort (53).  Our findings are also 
supported by a recent meta-analysis showing that PRT can induce a regional hypertrophy (in 
targeted muscle groups) in patients with chronic kidney disease, including those receiving 
hemodialysis (SMD = 0.43 [95% CI = 0.11 to 0.76]) (11).  Studies that have failed to elicit 
change in muscle hypertrophy measures have involved lower intensity training (35) or may have 
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failed to apply ongoing progressive overload (29).  Evidence suggests that PRT with loads 
eliciting 6-12RM (with sets performed to the onset of neuromuscular fatigue and loading 
increased with strength gains) maximizes the hypertrophic response (54).   Unfortunately, the 
equipment used in many trials prescribing intradialytic PRT specifically has been rudimentary 
(i.e. elastic tubing/bands, weighted ankle cuffs with a few kg loading) and may not optimize 
application of progressive overload.  Only one trial reviewed developed a customized leg press 
machine for the dialysis setting with loading up to a maximum of 200kg (25).  The patients 
enrolled in this study experienced similar myogenic adaptation to a group of healthy controls 
engaged in the same training regimen. Cheema et al. (55) have previously commented on the 
need to develop customized equipment, particularly targeting the lower body musculature, to 
deliver robust PRT regimens in the hemodialysis setting.  A novel lower-body PRT device has 
been recently developed for in-center use by an Australian group and trialed in a study involving 
combined aerobic plus PRT (56).  Regimens that maximize muscle hypertrophy through the 
optimal application of progressive overload are likely to target all muscle fiber types, in contrast 
to the findings of Molsted et al (45) which demonstrated only selective muscle fiber hypertrophy.  
Continuous progressive overload will also likely maximize the adaptation of other related 
outcomes, including muscle quality, metabolism, protein-energy malnutrition, and anabolic 
hormone and gene expression.   
PRT-induced muscle hypertrophy may mediate the reduction of cardiovascular disease 
risk factors.  For example, an RCT enrolling older patients with type 2 diabetes has shown that 
gains in muscle mass are significantly associated with reductions in CRP (57).    This finding is 
also supported by the present review.  Trials prescribing higher intensity PRT and demonstrating 
muscle hypertrophy (and reductions in protein-energy malnutrition) noted reductions in 
circulating CRP (33, 37) whereas trials prescribing less intense (35) or potentially non-
progressive training (29) failed to induce muscle hypertrophy and hence reduce CRP.    Greater 
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relative (to body size) muscle mass and quality are also associated with better insulin sensitivity 
and lower risk of type 2 diabetes (58, 59).  Only one trial we reviewed has investigated the effect 
of PRT on insulin sensitivity outcomes (46) and showed some favorable results.  RCT enrolling 
patients with ESRD and comorbid insulin resistance or type 2 diabetes are required to support 
these findings.  
PRT-induced muscle hypertrophy and concomitant increases in energy turnover can also 
likely contribute to reduced body fat outcomes (e.g. body fat percentage and waist 
circumference) (60). To date, only two of seven studies have shown that body fat percentage can 
be significantly reduced secondary to PRT in patients with ESRD (27, 30), whereas none of three 
trials demonstrated a reduction in waist circumference (19, 27, 33) and visceral fat area (27).  
These outcomes require further investigation in a subset of ESRD patients with elevated body fat 
percentages and/or waist circumference.  
Large-scale epidemiological studies have consistently identified low HDL, and high LDL 
and triglyceride as CVD risk factors in the general population (61-63). Dyslipidemia is also a 
significant risk factor for the progression of atherosclerosis and increased mortality (64, 65) in 
ESRD. Song et al (27) have shown that significantly reduced total cholesterol (p=0.017) and 
triglyceride (p=0.012) after PRT were accompanied by a positive shift in body composition (i.e. 
increased muscle mass and reduced body fat percentage).  Hence, any null effect of exercise on 
lipids in several studies may be due to a lack of change in body composition as reported by 
Leehey et al (66). Additional research is required to ascertain the concurrent effect of PRT on 
lipid profile, body composition, arterial health and their interactions. Future studies should also 
investigate the effect of PRT on the usage of lipid-lowering medications as such medication use 
has been shown to be reduced in response aerobic training (67). 
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The effect of PRT on measures of lower body muscular strength have been consistent 
with most studies showing a positive effect (25, 27, 30, 34, 36, 39, 42, 47), however only three 
studies have evaluated changes in upper body strength and their effects have been inconsistent 
(19, 27, 34).  The lack of improvement in upper body strength measured via maximal handgrip 
strength (19, 27) may have been due to the lack of exercises specifically targeting the forearm 
flexors.  Another potential explanation is that the handgrip test is insensitive to changes with 
PRT.  Only one study has documented an improvement in an upper body strength, measured via 
changes in maximal isometric forearm (i.e. triceps) extension (34). Future studies would benefit 
from the inclusion of more comprehensive and robust assessment of upper body muscular 
strength involving the major muscle groups of the upper body (e.g. chest and back muscles).  
Several studies have shown an improvement in sit-to-stand performance secondary to 
PRT (19, 30, 37, 45, 47).  In general, these studies prescribed PRT exercises at a relatively higher 
intensity, and include exercises that strengthen the major muscle groups associated with sit-to-
stand performance (knee extensor, hip extensor and plantar flexor).   
No controlled trials have noted improvements in the following physical performance 
tests: ‘get up and go’, gait speed, single leg balance, stair climbing, shoulder flexibility, trunk 
flexibility (sit and reach test) or sit ups. Many of these tests are highly dependent on motor 
agility, dynamic or static balance abilities (40, 68, 69). Although PRT is effective for improving 
lower body muscular strength (11), there may be a need to supplement PRT with other, more 
task-specific interventions (i.e. static balance, dynamic balance, standing and walking exercises) 
to improve these measures. This notion is supported by one uncontrolled trial (39) which 
combined lower body PRT with balance exercises and showed a reduction in falls risk.  
 134 
Similarly, the effect of PRT on six-minute walk is inconsistent (19, 25, 28, 33, 34, 40, 47) 
and is likely to be a null effect unless the intervention includes more task-specific exercises. Only 
a significant increase of 25m was found in one uncontrolled trial (19). This is less than the 
smallest improvement (~43m to 54m) necessary for a clinically meaningful change in patients 
with chronic obstructive pulmonary disease and heart failure (70). Since six-minute walk is a 
proxy-measure of aerobic exercise capacity (68), the lack of improvement in this outcome  could 
be due to the limited stress of PRT on aerobic fitness.  To date, there is no RCT evidence to 
suggest that isolated PRT can improve aerobic fitness.  Similarly, evidence for PRT increasing or 
changing physical activity levels is also lacking.  
One or multiple domains of HRQoL have been shown to improve in five of seven RCT 
(26, 27, 30, 33, 34, 36). The lack of improvement of HRQoL domains in two trials (25, 47) may 
be due to their patients being similar in HRQoL measures versus their age-matched healthy peers 
(25).  Impaired HRQoL and increased mortality has also been linked with depression in 
hemodialysis patients (71). Patients with ESRD are also prone to depression which are 
commonly undertreated (72). To date, there is very little evidence that PRT can treat depression 
or other psychological impairments.  Therefore, more research trials on PRT in patients with 
ESRD suffering from depressive symptoms and other mental health conditions are needed. These 
studies need to elucidate on the dose-response effects of PRT across a range of psychological 
outcomes in these ESRD subgroups.   
In conclusion, this systematic review has provided an overview of the extant literature on 
PRT in patients with ESRD, and outlined many recommendations future RCT.  Trials are 
required to investigate a range of novel research questions related to the benefits and application 
of PRT in this cohort and its subgroups (e.g. patients with diabetes, depression, dyslipidemia, 
etc.).  Future studies are required to be of high methodological quality to inform clinical practice 
 135 
guidelines to effectively enhance the important patient outcomes, including morbidity, mortality 
and HRQoL.  
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Chapter 5 
Development, Feasibility and Efficacy of A Customized Exercise 
Device To Deliver Intradialytic Resistance Training In Patients with 
End Stage Renal Disease 
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5.1 Abstract 
Introduction:  This study assessed the feasibility and efficacy of a novel training device used 
within an intradialytic progressive resistance training (PRT) intervention.  
Methods: Non-randomized, within-subjects crossover design with outcomes assessed at baseline 
(week 0), post-control (week 13) and post-PRT intervention (week 26).  Twenty-two 
hemodialysis patients (59% men, 71 ± 11 years) performed PRT three sessions per week for 12 
weeks. The resistance training device was developed to enable the performance of 2 upper and 3 
lower body exercises, unilaterally and bilaterally, both before and during dialysis with loads of 
2.5 to 59 kg. Feasibility outcomes included adverse events, adherence and training load 
progression.  Changes in upper and lower body muscular strength, six-minute walk, health-
related quality of life (HRQoL) via the Short-Form 36 and Geriatric Depression Scale were 
evaluated.   
Findings:  The PRT intervention was delivered without serious adverse events, resulted in 71.2 ± 
23.3% adherence and significant adaptation of all training loads from pre to mid to post training 
(83.8% to 185.6%, all p<0.05).  Lower body strength (p<0.001) and HRQoL sub-scales (Role-
Physical, Social Functioning, Role-Emotional) significantly increased (all p<0.01) and a trend 
toward reduced depression was noted (p=0.06).  No significant changes were noted in other 
outcomes.  
Discussion:  PRT using the novel training device was feasible and improved measures of 
physical and psychological health and HRQoL. This device can be utilized in most dialysis 
centers. Future studies are required to evaluate dose-response effects of PRT prescriptions in 
subpopulations, and PRT in standard dialysis practice.   
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5.2 Introduction 
The global incidence of end-stage renal disease (ESRD) continues to rise annually (1).   
This trend is being driven by an unprecedented burden of hypokinetic diseases, particularly the 
type 2 diabetes-obesity pandemic (2). As the ESRD patient population continues to grow, greater 
efforts must be directed toward improving important patient outcomes in this cohort, including 
physical functioning and health-related quality of life (HRQoL).  
Progressive resistance training (PRT) is an exercise modality that can counteract many 
physiological, functional and psychological impairments caused by ageing and disease (3).  
Studies have shown that PRT can treat metabolic diseases, including type 2 diabetes mellitus 
(T2DM) and obesity (4-6). Early studies in patients with ESRD prescribed PRT interventions 
during non-dialysis time and resulted in low participant enrollment and adherence (7).  More 
recently, PRT interventions have been prescribed during dialysis (8-10) in an attempt to 
overcome some of the barriers to exercise participation, including lack of access and time (7). 
This evidence suggests that intradialytic PRT can improve many important aspects of health 
status (11). However, its delivery must be refined to elicit better health adaptations and enable 
seamless translation into standard clinical care (12).    
To date, exercise equipment used for intradialytic PRT within clinical trials had been 
largely rudimentary (12). Lower body exercises have typically been prescribed using weighted 
ankle cuffs (8, 10, 13), and upper body exercises have either been avoided due to perceived 
difficulty (9), or prescribed unilaterally during dialysis in the non-fistula containing arm using 
elastic bands (14) or dumbbells (15), with the fistula-containing arm trained with the same 
exercises just prior to each dialysis session.  Utilizing these rudimentary forms of equipment is 
cost-effective, but can compromise PRT effectiveness (12).  For example, ankle cuffs typically 
have a low loading capacity (up to 10 kg), and patients who have achieved the maximum load for 
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a PRT exercises will experience no further overload and hence limit adaptation (12).  Moreover, 
the use of dumbbells during dialysis restricts a patient to performing only a few exercises that do 
not effectively target the major muscle groups of the upper body, e.g. pectorals or latissimus 
dorsi (12).  Experts have previously suggested a need to develop and evaluate the effects of more 
robust training devices to enhance the delivery of intradialytic PRT (16).   
The purpose of this study was to present the invention of a prototype, customized 
resistance training device and assess its feasibility and efficacy in a comprehensive intradialytic 
PRT intervention in conventional hemodialysis units. Feasibility outcomes in this study included 
the assessment of adverse events, adherence, and training intensity (loads).  Efficacy outcomes 
included measures of physical functioning (i.e. muscular strength and exercise capacity) and 
psychological health status (i.e., HRQoL and depression).  
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5.3 Methods 
Study Design 
This study utilized a within-subjects, non-randomized crossover design comparing the 
outcomes of an initial 12-week usual care control period to a 12-week intradialytic PRT 
intervention period.  Outcome measures were assessed at baseline (week 0), after the control 
period (week 13) and after the intervention period (week 26).  The Western Sydney University 
Human Research Ethics Committee (Research Code: H9651) and the Central Northern Adelaide 
Health Service (RAH Protocol No.: 120507) approved all research procedures, and the trial was 
registered with the Australian New Zealand Clinical Trials Registry (ACTRN12612000496819).  
  
Participants  
Eligibility criteria:  (1) adult aged ≥40 years, (2) medically stable and adequately dialyzed 
(Kt/V ≥1.2) for greater than three months, (3) able to ambulate independently or with an assistive 
device for ≥50m, (4) no amputation, (5) no acute or chronic medical condition that 
contraindicated or prevented the performance of PRT during hemodialysis treatment, (6) 
cognition and English language sufficient to understand research procedures and provide written 
informed consent, (7) sedentary (i.e., less than 120 min of moderate-intensity physical activity 
per week),(17) (8) no recent participation in PRT.  Participants were recruited from four 
outpatient hemodialysis centers in South Australia from 2012 to 2013.  All patients were 
evaluated for eligibility, which involved review of the medical records, clearance from the 
nephrologist, and interview of the patient.  
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Prototype design and development 
The lead author (D.C.) developed the prototype in consultation with Maxim Strength 
Fitness Equipment Pty. (www.maximfitness.net), Adelaide, Australia (Figure 5.1).  The lead 
author is an accredited exercise physiologist (18) who has worked for over six years prescribing 
exercise as standard care in dialysis centers in the Adelaide metropolitan area.  In clinical 
practice, the lead author routinely utilized a custom-designed resistance training device 
developed and tested by Bennett et al. (19). The device consisted of a weight-adjustable, pulley 
system that applied resistance (up to 32 kg) to the lower body musculature in three movements: 
leg press, knee flexion and knee extension (19). The prototype designed in the present study 
advanced upon this initial design (19) by enabling the performance of both upper and lower body 
exercises during dialysis with heavier loads.  
The lead author first conceptualized and sketched an equipment design that was portable 
and could provide an overload stimulus to all major muscle groups. To ensure portability, the 
space available in participating dialysis centers and the dimensions of standard hemodialysis 
chairs (Fresenius Medical Care, Scoresby, Victoria, Australia) were considered. The concept 
from Bennett et al. (19) of a portable device with wheels and brakes was adopted to allow safe 
positioning during pre-dialysis and intradialytic training, or stowed aside when not in use.  The 
exercises needed to be administered without complicated set-ups or configuration changes, easily 
used in practice by either exercise physiologists or dialysis nursing staff.    
The structure was made of steel and measured 1.16 m wide, 0.94 m long and 1.61 m tall. 
The design consisted of a trapezium-shaped base, with two lever arms pivoting from the corners 
of the widest side and the pin-loaded weight stack is positioned on the shorter side (Figure 5.1a 
and 5.1b).  The lever arms allowed the performance of resistance exercises unilaterally or 
bilaterally, involving pushing (chest press) and pulling (seated row, hip flexion) while a plate 
 149 
attachment was connected to a pair of steel cables enabling leg press and knee flexion exercises. 
All exercises performed with the device are presented in Figure 5.2.  Loading of each exercise 
ranged from 2.5 to 59 kg; the weights were pin-loaded and easily adjusted.  One kg add-on 
weights were available for gradual increment increases (Figure 5.1c).  
 
Figure 5.1. Custom-designed training device 
 
 
 
 
 
 
 
(a) Front view                                      (b) Rear view                                    (c) Pin-loaded weights with 1 kg    
                                 yellow add-ons 
plate attachment 
lever arms 
wheels with 
locks 
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Figure 5.2.  Resistance training exercises performed with the customized exercise device. 
 (a) seated row with machine, (b) chest press with machine, (c) leg press with machine,  
(d) knee flexion with machine, (e) hip flexion with machine
	
 
(a) 
 
(b) 
 
(c) 
 
(d) 
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(e)
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Intervention 
Participants were prescribed a full-body PRT program three times per week (36 sessions 
in total) supervised by an exercise physiologist (20).  The upper limb containing the vascular 
access was exercised prior to each dialysis session with the patient seated in the waiting area, 
while all other exercises were performed with the patient in a seated or supine position in a 
standard hemodialysis chair (Fresenius Medical Care, Scoresby, Victoria, Australia).  The 
intradialytic exercises were completed during the first half of each hemodialysis session.  Smaller 
muscle groups that were not isolated by the exercise device, including the biceps, triceps, and 
deltoids were targeted by free weight dumbbells (Celsius™, China) or Thera-bandTM elastic 
tubing (Akron, Ohio, USA).  During the first four weeks of PRT, three sets of 12-15 repetitions 
of each exercise were performed at a rating of perceived exertion (RPE) of 12-14.  During the 
latter eight weeks of PRT, three to four sets of 10-12 repetitions of each exercise were performed 
at a RPE of 14-15 (21). The duration of the training session was approximately 30 minutes by 
alternating, set-to-set, exercises that targeted different muscle groups.   
Feasibility outcomes 
Adverse events  
Adverse events related to exercise participation and all visits to health care professionals 
occurring during the control and intervention periods were documented weekly using a structured 
questionnaire and reviewing the clinical notes.  An adverse event was defined as any injury, 
impairment or medical condition that was directly or suspected to be due to performing the 
prescribed exercise.  
Adherence  
Overall adherence to training was computed as the total number of exercise sessions 
attempted divided by the total number of exercise sessions offered, multiplied by 100%.  In 
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addition, the percentage of each of the 10 prescribed PRT exercises completed was computed as 
the total number of sets completed divided by the total number of sets prescribed, multiplied by 
100%. Reasons for missing or non-attempt of exercise sessions were also documented. 	
Training load (intensity)  
The heaviest training load lifted during the first-, mid- (session 18) and final session 
(session 36) of the 12-week PRT intervention period was collected and noted for each exercise 
performed using the resistance exercise device and dumbbells.    
Physical functioning  
Upper body muscular strength was evaluated using a hydraulic handgrip dynamometer 
(Seahan SH5001, Heanor, UK) and standard procedures (22).  High intra-examiner reliability 
(right: r=0.981, left: r=0.985) for the dynamometer has been reported for both arms (23).  A 
composite measure of lower body muscular strength was evaluated using a three-repetition 
maximum test using the resistance exercise device and standard test protocols (24).  The test was 
performed unilaterally with the right and left leg added to create a summary score. The six-
minute walk test was used as an index of exercise capacity (25).  
Psychological health status  
The Short Form 36 (SF-36) Version 1.0 questionnaire was used to evaluate changes in 
eight sub-scales of HRQoL, including Physical Functioning, Role Physical, Bodily Pain, General 
Health, Vitality, Social Functioning, Role Emotional and Mental Health (26). The instrument 
also provides domain scores for Physical Component Summary (PCS) and Mental Component 
Summary (MCS) calculated from the relevant HRQoL sub-scales.  
The Geriatric Depression Scale (GDS) was used to evaluate depression symptoms with 
scores categorized as: ‘normal’ (0 – 9), ‘mild depression’ (10-19), and severe depression (20-30) 
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(27). The GDS is accepted as a reliable and valid self-rating depression screening scale for 
elderly populations (28) and in adults younger than age 65 (29).  
Statistical Analysis 
Analyses were performed using SPSS (IBM©, Version 19.0).  All data were inspected 
visually and statistically for normality at each time point (weeks 0, 13, and 26).  Normally 
distributed data were described using mean ± standard deviation.  Non-normally distributed data 
were log-transformed (log10) across the three time points prior to entry into parametric statistical 
models.  Primary analysis incorporated a linear mixed model defining individual as the random 
effect with the outcome measure evaluated across three time points (weeks 0, 13, 26).  All data 
were included regardless of participant adherence to the intervention according to the intention-
to-treat principle (n=22).  Each model was also adjusted for age, gender, dialysis vintage, and 
interactions for time by age, time by gender and time by dialysis vintage.   P-values were 
reported for the change from week 0 to week 13 and change from week 13 to 26.  In addition, the 
mean difference and effect size were computed comparing the control period (week 13 – week 0) 
to the intervention period (week 26 – week 13).  Changes in training intensity (loads) over time 
were evaluated by paired t-tests for all exercises performed using the customized exercise device 
and dumbbells.   A p-value of <0.05 and a 95% CI exclusive of zero were accepted as statistically 
significant.  
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5.4 Results 
Participants and recruitment 
Twenty-two eligible participants consented to participate and completed baseline 
assessment, comprising 11% of the patient population reviewed across the four outpatient 
hemodialysis centers (n=195; Figure 5.3). Baseline characteristics of the cohort are presented in 
Table 1 and participant flow chart in Figure 5.3.   
 
Feasibility outcomes 
Adverse Events 
One participant experienced dizziness once while exercising during hemodialysis. 
Although blood pressure was normal, exercise was immediately ceased.  There were no other 
adverse events. 
Adherence 
Adherence to PRT in the 18 participants who undertook the intervention was 71.2 ± 
23.3%.  Eleven of 18 participants achieved at least 75% adherence (i.e., greater than 27 of 36 
sessions attended). Three participants who refused follow-up assessment at week 26 completed 
less than 20% of the PRT intervention.  The main reasons cited by participants for not attempting 
an exercise session included hospitalization or acute illness.  The percentage completion of 
exercises using the resistance exercise device ranged from 61.6%	to	68.6%, while the percentage 
of exercises completed using the dumbbells and elastic bands ranged from 51.4% to 67.7% 
(Table 5.2).  
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Training load (intensity) 
All training loads for all exercises performed using the customized device and dumbbells 
significantly increased from session 1 to session 18, and session 18 to session 36, and from pre to 
post training (session 1 to session 36; all p<0.05; Table 2).  The change in training intensity from 
session 1 to session 36 across all exercises ranged from 83.8 ± 56.5% to 185.6 ± 121.0%.   The 
percentage adaptation in loading was similar between exercises using the customized device and 
the dumbbells. 
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Figure 5.3. Participants flow 
 
 
	
	
  
Medical Review and Screening 
Baseline Assessment  
(week 0) (n=22) 
Post control period Assessment 
(week 13) (n=18) 
 Consented (n=22) 
Post-intervention period 
Assessment (week 26) (n=15) 
Unavailable for week 13 
assessment (n=4):  
Other research study=1  
Medical=1  
Family commitment=1 
Non-compliance=1 
Unavailable for post-
intervention period 
Assessment (week 26) (n=3):  
Medical=1 
Too strenuous= 1 
Work stress= 1 
Ineligible (n=89) 
Eligible but refused (n=84) 
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Physical functioning 
Leg press strength increased significantly from the control to PRT intervention period 
[Mean Difference = 10 (95% CI = -1 to 21); p<0.001, effect size (ES)=0.55]; however, no change 
was noted in the maximal handgrip strength of the fistula or non-fistula containing arm (Table 
5.3).  Six-minute walk did not significantly change from the control to the intervention period 
(Table 5.3).  
 
Psychological health status 
Significant improvements with large relative effect sizes were noted from the control to 
the PRT intervention period in several sub-scales of HRQoL, including:  Role	Physical [Mean 
Difference = 14.6 (95% CI = 8.4 to 20.8); p=0.035, ES=1.41], Social	 Functioning [Mean 
Difference = 24.5 (95% CI = 10.3 to 38.7); p=0.029,	 ES=1.03] and Role	 Emotional	 [Mean 
Difference = 17.4 (95% CI = 12.3 to 22.5);	 p<0.001, ES=2.04]. There were also significant 
decreases in Role Physical and Role Emotional health sub-scales from pre-control to post-control 
time points (Table 4).   There was also a trend toward an increase in the MCS [Mean Difference 
= 6.7 (95% CI = 1.2 to 12.3);	p=0.07, ES= 0.72] and a decrease in GDS	[Mean Difference = -4.3 
(95%	CI	=	-7.7	to	-1);	p=0.061,	ES=	-0.77] from the control and intervention periods.  
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Table 5.1. Baseline characteristics of the total cohort (n=22) 
Age (years) 71.3 + 11.0 
Sex (men: women) 13:9 
Ethnicity  
Caucasian, n (%) 17 (77.3) 
Asian, n (%) 1 (4.5) 
Aboriginal, n (%) 2 (9.1) 
Indian, n (%) 2 (9.1) 
Height (cm) 161.4 + 10.4 
Body weight (kg)  74.6 + 17.9 
Body Mass Index (kg/m2) 28.5 + 5.6 
Dialysis vintage, months (range) 42.5 (7 – 163) 
Systolic blood pressure at rest (mm Hg) 149 ± 24 
Diastolic blood pressure at rest (mm Hg) 68 ± 9 
Dialysis adequacy (Kt/V) 1.72 + 0.26 
Serum creatinine (µmol/L) 706.2 + 141.8 
Serum albumin (g/L) 35.6 + 2.3 
Medications, n (%):  
Erythropoiesis stimulating agents 18 (81.8) 
Beta blockers 11 (50.0) 
Calcium channel blockers 11 (50.0) 
Nitrates 4 (18.2) 
Angiotensin-converting enzyme inhibitors 3 (13.6) 
Alpha blockers 3 (13.6) 
Angiotensin II receptor blockers 1 (4.5) 
Tobacco use history (n) 11 
Etiology of kidney failure  
other, n (%) 12 (54.5) 
diabetes, n (%) 7 (31.8) 
hypertension, n (%) 2 (9.1) 
glomerular diseases, n (%) 1 (4.5) 
Data reported as mean + standard deviation except dialysis vintage (median value and range reported due to non-
normal distribution). Dialysis adequacy (Kt/V) greater than or equal to 1.2 is considered adequate. 
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Table 5.2.  Adherence to specific exercises and training intensity (load)  
Equipment Exercises 
Sets 
Completed 
(%) 
Session 1 load 
(kg) 
Session 18 load 
(kg) 
Session 36 load 
(kg) 
%change  
(session 1 to 18) 
%change  
(session 18 to 36) 
%change  
(session 1 to 36) 
Customized 
device  
 
 
Chest press  
Seated row 
Leg press 
Knee flexion 
Hip flexion 
67.7 ± 29.1 
67.2 ± 28.8 
68.6 ± 28.4 
67.5 ± 28.0 
61.6 ± 29.8 
4.0 ± 2.3 
8.6 ± 6.4 
25.7 ± 5.5 
10.5 ± 3.4 
2.3 ± 1.5 
5.8 ± 3.4a 
13.8 ± 8.1a 
40.9 ± 12.2a 
15.7 ± 2.6a 
5.4 ± 3.3a 
8.8 ± 4.5b,c 
18 ± 9.2b,c 
58.1 ± 19.8b,c 
19.9 ± 3.2b,c 
6.8 ± 3.5b,c 
53.3 ± 69.5 
68.6 ± 47.0 
57.3 ± 38.8 
44.3 ± 40.7 
119.4 ± 134.3 
62.7 ± 72.4 
38.6 ± 41.8 
40.9 ± 23.3 
28.4 ± 17.7 
45.4 ± 32.0 
140.0 ± 131.2 
133.6 ± 90.9 
123.1 ± 74.7 
83.8 ± 56.5 
185.6 ± 121.0 
Dumbbells Shoulder press 
Biceps curl 
65.6 ± 29.6 
67.7 ± 28.4 
2.7 ± 0.9 
3.0 ± 1.0 
4.8 ± 1.0a 
5.2 ± 1.2a 
6.5 ± 1.3b,c 
6.7 ± 1.1b,c 
79.6 ±55.2 
76.3 ± 54.5 
37.7 ± 20.6 
32.3 ± 17.9 
142.8 ± 66.2 
130.2 ± 66.8 
Elastic tubing Triceps extension  
Back extension 
Knee extension 
60.6 ± 25.7 
51.4 ± 30.8 
63.5 ± 27.2 N/A N/A N/A N/A N/A N/A 
Data reported as mean + standard deviations. N/A not applicable. 
asignificant increase from session 1 to 18  
bsignificant increase from session 18 to 36  
csignificant increase from session 1 to 36  
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Table 5.3.  Physical functioning and psychological health status outcomes 
Outcome Measure Week 0 Week 13 Week 26 P  (time) 
P  
(week 13 vs 0) 
P  
(week 26 vs 13) 
Mean Difference 
(95%CI) 
(Intervention - 
Control period) 
Relative ES (95% CI) 
(Intervention period - 
Control period) 
Physical functioning         
  Handgrip strength, fistula (kg) 19 ± 5 19 ± 5 19 ± 6 0.44 0.32 0.93 -1 (-4, 3) -0.13 (-0.72, 0.47) 
  Handgrip strength, non-fistula (kg) 20 ± 6 20 ± 6 21 ± 6 0.92 0.91 0.31 1 (-3, 4) 0.12 (-0.47, 0.71) 
  Lower body strength (kg)  62 ± 18 64 ± 18 77 ± 21 0.69 0.31 <0.001 10 (-1, 21) 0.55 (-0.05, 1.16) 
  Six-minute walk (m) 328 ± 90 331 ± 96 317 ± 108 0.51 0.90 0.49 -16 (-72, 41) -0.17 (-0.76, 0.43) 
         
Psychological health status         
1.  Health-related quality of life         
  Physical Functioning 48.7 ± 25 43.2±25.9 46.5±29 0.11 0.24 0.54 8.7 (-6.8, 24.2) 0.33 (-0.26, 0.93) 
  Role-Physical 14.7 ± 9.9 6.4±10.5 12.7±12.2 0.53 0.002 0.04 14.6 (8.4, 20.8) 1.41 (0.75, 2.07) 
  Bodily Pain 55.8 ± 28 60.6±28.9 62.6±32 0.44 0.32 0.71 -2.7 (-20, 14.6) -0.09 (-0.68, 0.5) 
  General Health 46.7 ± 16.7 52.4 ± 17.4 48.2±19.7 0.68 0.10 0.28 -9.8 (-20.1, 0.6) -0.56 (-1.16, 0.04) 
  Vitality 50.4 ± 23.2 47.9 ± 24.5 54.9±28.1 0.34 0.63 0.25 9.6 (-4.9, 24.2) 0.4 (-0.2, 0.99) 
  Social Functioning 78.0 ± 22.7 68.3 ± 24.0 83.0±27.8 0.61 0.10 0.03 24.5 (10.3, 38.7) 1.03 (0.4, 1.66) 
  Role-Emotional 21.2 ± 8.1 13.6 ± 8.6 23.5±10.1 0.30 0.002 <0.001 17.4 (12.3, 22.5) 2.04 (1.31, 2.77) 
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  Mental Health 83.7 ± 17.9 82.8 ± 19 89.8±22.1 0.27 0.86 0.20 7.8 (-3.4, 19.1) 0.42 (-0.18, 1.01) 
  Physical Component Scale  31.7±7.4 31.7±7.7 31.3±8.5 0.51 0.99 0.80 -0.4 (-4.9, 4.2) -0.05 (-0.64, 0.54) 
  Mental Component Scale 49.8±8.9 47.9±9.4 52.8±10.9 0.41 0.41 0.07 6.7 (1.2, 12.3) 0.72 (0.11, 1.33) 
2.  Depression         
Geriatric Depression Scale 6.8±5.3 8.5±5.7 5.9±6.3 0.19 0.15 0.06 -4.3 (-7.7, -1) -0.77 (-1.39, -0.16) 
         
Data reported as mean + standard deviations.  The mean difference expresses the mean difference in the outcome between the control and intervention periods. The relative 
effect size is the mean difference between the two periods divided by the pooled standard deviation of the outcome at baseline among participants.  A p-value of <0.05 and a 
95% CI exclusive of zero were accepted as statistically significant. 	  
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5.5 Discussion 
This study presents on the development, feasibility and efficacy of integrating a 
customized resistance training device within a conventional hemodialysis unit. The intervention 
was delivered without serious adverse events, resulted in a moderate-to-high level of adherence 
and positive adaptation in training loads.  Exercising patients also significantly increased lower 
body muscular strength and several sub-scales of HRQoL, including Role	 Physical, Social	
Functioning, and Role	Emotional. Trends toward improved Mental	Component	Summary and 
reduced depression evaluated via the Geriatric Depression Scale were noted.  
To our knowledge, there have been only two studies that have implemented the use of 
novel resistance training device in the hemodialysis setting (9, 19). However, both devices could 
only target the lower body musculature with either one (9) or a few movements (19) and this has 
been identified as a major limitation of PRT interventions prescribed to date (12). Hence, this 
study developed a device to exercise both the upper and lower body musculature in the dialysis 
setting. Upper body exercises included the chest press and seated row that targeted the pectoral 
and back muscles. The improvement of training loads for all exercises delivered with our device 
(Table 1) indicated that progressive overload was being applied without a plateau in training 
intensity (loading).  Targeting all muscle groups and providing ongoing application of 
progressive loading are arguably the most critical aspects of effective PRT delivery, and this 
finding therefore highlights the feasibility of using this novel device in the hemodialysis setting.  
The current study is based on recommendations to implement intradialytic exercise to 
enhance exercise uptake and adherence in patients with ESRD (16). However, as intradialytic 
PRT was still uncommon and often unheard of by patients, exercise uptake remained low with 
about 1 out of 4 eligible patients agreeing to participate in the current study (Figure 5.3).  Over 
43% (84/195) of the patients reviewed were not interested in participating in this study. Low 
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enrollment in PRT intervention trials is not uncommon, with recruitment rates ranging between 
17 to 34% of patients reviewed (9, 10, 13-15, 30-32). 
This highlights the difficulty in implementing intradialytic PRT. To sustain such a 
program in clinical practice, it is likely that recommendations for exercise participation will have 
to come from consulting nephrologists and reinforced by other clinicians, including the dialysis 
nursing staff and exercise professionals (33). The literature supports incorporation of exercise 
into dialysis sessions as standard practice, based on 30 years of evidence (34, 35). However, 
barriers to such implementation exist including lack of awareness of benefits by health care 
professionals and patients, fears of injury, perceived burdens of integration with dialysis 
activities, and availability of accessible and affordable equipment and trainers. These aspects of 
translation need to be investigated further, as well as the nexus between exercise professionals 
and dialysis nursing staff to adequately deliver intradialytic PRT.   
The current study has overcome the difficulty of performing upper body exercises in the 
hemodialysis setting by incorporating a customized exercise device and secondary modalities to 
perform the exercises unilaterally during dialysis or prior to hemodialysis. Adding upper body 
exercises did not hamper adherence or increase adverse events compared to earlier trials of lower 
body exercise (10, 13, 14). Consistent with our findings, a recent meta-analysis found no 
evidence of serious adverse events secondary to PRT prescribed across the chronic kidney 
disease continuum, including in patients with ESRD (33) and adherence to PRT across previous 
studies has ranged from 59%(8) to 94% (9).     
The improvement of lower body muscular strength is consistent with the majority of 
studies prescribing PRT interventions during (8-10, 31, 32, 36) or outside (37, 38)  routine 
hemodialysis treatment.  Only two trials have documented no change in lower body strength 
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measures (39, 40) and both studies did not state explicitly if the training loads were progressed 
with adaptation.   The improvement in lower body strength in this study is an important finding 
as poor lower body muscular strength is associated with reduced muscle mass (41) and increased 
risk of falls (42, 43)  Intervention studies prescribing PRT across the chronic kidney disease 
continuum have been shown to increase muscle mass (33), and reduce the risk of falls (32).  
The lack of improvement of handgrip strength is consistent with the literature, as two 
previous studies also reported no change in this outcome secondary to 12 weeks of isolated full 
body PRT (37, 44). The lack of adaptation could be attributed to the lack of exercises for forearm 
flexors. Another potential explanation is that the handgrip test is insensitive to changes with PRT 
as the increments in training load over time did suggest upper body strength gain in the current 
cohort. To date, only Cheema et al (8) have documented an improvement in an upper body 
strength following a 24-week intradialytic PRT intervention in hemodialysis patients, measured 
via changes in maximal isometric forearm (triceps) extension.  Future studies would benefit from 
the inclusion of more comprehensive and robust assessment of upper body muscular strength 
involving major muscle groups.  
Similarly, the lack of improvement in six-minute walk is also consistent with the mixed 
results in the literature. One uncontrolled trial has noted a significant increase in six-minute walk 
(p<0.05) (44), while another uncontrolled trial noted a trend toward improvement (p=0.064) (45).   
Two RCTs have noted a significant improvement in their PRT group over time (8, 36), but no 
significant group x time effects (8, 15, 31, 36). Two additional RCTs found no change in six 
minute walk secondary to >10 weeks of intradialytic PRT (9, 14). Additional studies are 
warranted to determine the relative importance of physiological constructs most limiting to six-
minute walk performance in this cohort (e.g., poor balance, low aerobic capacity, muscle 
weakness, fear of falling, musculoskeletal pain, claudication, etc.), in order to design exercise 
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interventions to more specifically target the relevant deficits. 
As low HRQoL and depression are associated with increased mortality in hemodialysis 
patients (46, 47), HRQoL was also assessed in this study. At baseline (week 0) and post-control 
(week 13), the mean score for all eight health sub-scales of SF-36 except mental health were 
lower than available data for South Australian general population age-matched norms (48). 
Mental health was similar to the age-matched norms at all time points. Among the eight health 
sub-scales measured using the SF-36 health survey, Role Physical (p=0.035; ES=1.41), Social 
Functioning (p=0.029; ES=1.03) and Role Emotional (p<0.001; ES=2.04) were significantly 
improved with a large effect size post-exercise (week 26) compared to post-control (week 13). 
Despite the improvements, these health sub-scales remained lower than the normative data for 
the South Australian population (48). Nevertheless, these improvements plus near-significant 
improvements post-treatment in depression and the Mental	Component	Summary suggest that 
PRT can benefit patient emotional well-being. This is consistent with most PRT studies in ESRD 
that have shown improvements in one or multiple sub-scales or domains of HRQoL (8, 10, 13, 
31, 37).    Future studies should specifically investigate patients who have clinically significant 
levels of depression to determine whether exercise benefits for this condition extend to the 
depressed dialysis cohort. 	
In summary, the findings of this study suggest that PRT using our customized exercise 
device is feasible and can improve aspects of physical functioning and psychological health 
status. The exercise device tested in this study can be utilized in most dialysis centers with 
sufficient space to give patients the option of PRT before or during dialysis. Future studies are 
required to determine dose-response effects of comprehensive PRT prescriptions in various 
subpopulations of ESRD (e.g., in those with type 2 diabetes or clinical depression), and evaluate 
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the staff and training requirements to allow translation of intradialytic PRT into standard clinical 
practice. 
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Chapter 6 
Effect Of Intradialytic Progressive Resistance Training On Arterial 
Stiffness And Associated Biomarkers In Patients With End Stage 
Renal Disease: A Non-Randomized Controlled Crossover Trial
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6.1 Abstract 
Background:  This study investigated the effect of a 12-week intradialytic progressive resistance 
training (PRT) intervention on arterial stiffness (pulse wave velocity, PWV), hemodynamic and 
associated biomarkers in patients with end stage renal disease (ESRD).  
Study design: Non-randomized, within-subjects crossover design comparing change over an 
initial 12-week control period with a 12-week intervention period. All outcomes were assessed at 
baseline (week 0), post-control (week 13) and post-intervention (week 26).   
Setting & Participants: 22 patients with ESRD (59% men, 71.3 ± 11.0 years, 28.5 ± 5.67 kg/m2, 
7 mo. to 13.5 years on hemodialysis) were recruited from four dialysis centers. 
Intervention: Supervised full-body PRT (3 sets, 11 exercises, moderate intensity) was prescribed 
three times per week during routine hemodialysis treatment.   
Outcomes & measurements: The primary outcome was brachial-ankle PWV measured via 
applanation tonometry.  Secondary outcomes included augmentation index (AI), brachial and 
aortic blood pressures, progenitor cells (PCs), endothelial progenitor cells (EPCs), C-reactive 
protein, blood lipid profile (high-density and low-density lipoprotein cholesterol, total 
cholesterol, triglyceride) and anthropometrics.   
Results: Non-normally distributed data were normalized using logarithmic transformation. No 
significant change in log-PWV was detected between control and intervention periods [mean 
difference = 0 (95% CI = -0.1 to 0.1); P=0.58].  Similarly, no significant change was noted in 
any of the secondary outcomes between the control and intervention periods. Post-hoc analyses 
limited to participants who attended ≥75% of the PRT sessions (n=11) did not differ from the 
primary analysis.  
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Limitations: Low number of participants, lack of a parallel arm control group, measurement of 
brachial-ankle PWV rather than central arterial stiffness.  
Conclusions: 12 weeks of low-to-moderate intensity intradialytic PRT did not change PWV, 
hemodynamic, anthropometric or hematologic measures in patients with ESRD. More research is 
needed to determine whether different intensities or durations of PRT can affect vascular health 
or other outcomes related to survival. 
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6.2 Introduction 
Progression of chronic kidney disease is associated with an exponential increase in 
atherosclerotic cardiovascular disease (CVD) and associated mortality (1).  CVD is the leading 
cause of hospitalization and death in patients with end stage renal disease (ESRD) receiving 
maintenance hemodialysis (2).  Data suggest a 10-30 fold higher risk of CVD-related mortality 
versus the general population (3).  As the ESRD population continues to grow (2), greater efforts 
must be directed toward reducing CVD morbidity and mortality in this cohort.  
Progressive resistance training (PRT) is well recognized for inducing muscle anabolism, 
and improving physical functioning and health-related quality of life in patients with ESRD (4).  
Accumulating evidence from other chronically diseased cohorts suggests that PRT can also 
attenuate CVD risk factors [e.g., hypertension, blood lipids, visceral fat, insulin resistance, and 
circulating C-reactive protein (CRP)] (5-9).  There is preliminary evidence that patients with 
ESRD can achieve such adaptations to PRT, however, data remain inconsistent, warranting 
further investigation (10).  
Pulse wave velocity (PWV) is a measure of arterial stiffness that can be assessed non-
invasively using applanation tonometry (11).  Elevated PWV reflects greater arterial calcification 
or arteriosclerosis (i.e., lower arterial compliance) and is a strong predictor of cardiac events and 
CVD mortality in ESRD (12, 13) and other clinical cohorts such as non-dialysis CKD, 
hypertension and coronary artery disease (14).  Previous studies have shown that intradialytic 
aerobic training can significantly reduce PWV (15).  This improvement in arterial stiffness could 
be partially mediated by enhanced vascular repair reflected in the increased number and/or 
function of progenitor cells (PCs) and the more lineage committed endothelial progenitor cells 
(EPCs) (16, 17).  
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Interventions that decrease arterial stiffness (increase arterial compliance) and increase 
circulating EPCs may contribute to better CVD-related survival in patients with ESRD (12, 13, 
18).  Current evidence suggests that PRT may mitigate CVD risk in patients with ESRD by 
mitigating risk factors such as blood lipids (i.e. total cholesterol and triglyceride) (19), CRP (20-
23), and body adiposity (19, 24).  However, there has been no investigation of the effect of PRT 
on arterial stiffness and associated biomarkers (e.g., PCs and EPCs) in patients with ESRD. 
Therefore, the purpose of this study was to investigate the effect of a 12-week intradialytic PRT 
intervention on PWV and secondary relevant outcomes (i.e. hemodynamic, anthropometric, and 
hematologic). We hypothesized that 12 weeks of PRT would significantly reduce PWV, AI, and 
CRP, increase PCs and EPCs, and improve lipid profile.  
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6.3 Methods 
Study Design 
This study utilized a non-randomized, within-subjects crossover design comparing change 
over an initial 12-week control period (usual care [no exercise]; week 1-12) with a 12-week 
intervention period (intradialytic PRT; week 14-25). Primary and secondary outcome measures 
were assessed at baseline (week 0), after the control period (week 13) and after the intervention 
period (week 26). Post intervention testing was completed >72 hours after the final exercise 
session to avoid acute exercise effects. The Western Sydney University Human Research Ethics 
Committee (Research Code: H9651) and the Central Northern Adelaide Health Service (RAH 
HREC No.: 120507) approved all research procedures. 
 
Participants and recruitment  
Eligibility criteria:  (1) adult aged ≥40 years, (2) medically stable and adequately dialyzed 
(Kt/V ≥1.2) for greater than three months, (3) able to ambulate independently or with an assistive 
device for ≥50m, (4) no amputation, (5) no acute or chronic medical condition that 
contraindicated or prevented the performance of PRT during hemodialysis treatment, (6) 
cognition and English language sufficient to understand research procedures and provide written 
informed consent, (7) sedentary (i.e., less than 120 min of moderate-intensity physical activity 
per week) (25), (8) no recent participation in PRT.  Participants were recruited from four 
outpatient hemodialysis centers in South Australia.  All patients were evaluated for eligibility, 
which involved review of the medical and clinical records, clearance from the nephrologist, and 
interview of the patient.  
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Control Period  
 Participants remained sedentary. They were provided usual medical and hemodialysis 
treatments. 
 
Intervention Period  
Participants were prescribed intradialytic PRT three times per week under the direct 
supervision of an exercise physiologist (26). The upper limb containing the vascular access was 
exercised prior to each dialysis session. The intradialytic exercises were completed during the 
first half of each hemodialysis session.  
Table 6.1. Progression of the resistance training program 
Week Number of  
sets 
Number of 
repetitions 
RPE 
1 – 2 3 12 – 15 12 – 13 
3 – 4 3 12 – 15 13 – 14 
5 – 12 3  10 – 12 14 – 15 
RPE, rating of perceived exertion31. 
 
A combination of PRT equipment was used, including: (i) a customized Maxim Fitness™ 
weight resistance machine (Hindmarsh, SA, Australia) for chest press, seated row, leg press, knee 
flexion and bent knee hip flexion, (ii) Thera-bandTM elastic tubing (Akron, Ohio, USA) with 
handles (Practitioner Supplies, Clovelly Park, SA, Australia) for back extension, knee extension 
and bent knee hip flexion (multiples of 5 color-graded elastic tubing were used to increase 
resistance progressively) (27), and (iii) free weight dumbbells (Celsius™, China) for shoulder 
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press, biceps curl and triceps extension.  Exercise volume and intensity based on rating of 
perceived exertion (28) is presented in Table 6.1. The duration of the training session was 
approximately 30 minutes. Exercises that targeted different muscle groups were alternated set-to-
set. 
 
Outcome measures 
Pulse wave velocity and secondary hemodynamic outcomes  
The primary outcome was brachial-ankle PWV.  Secondary outcome measures included 
augmentation index (AI), brachial and aortic blood pressures, progenitor cells (PCs), endothelial 
progenitor cells (EPCs), C-reactive protein, blood lipid profile [i.e. high-density lipoprotein 
cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), total cholesterol, 
triglyceride], and anthropometrics (body weight, waist circumference, body mass index).  AI 
served as a surrogate measure of arterial stiffness (29).   
To minimize the effect of fluid shifts on vascular and hemodynamic measures (30), 
assessments were conducted at the same time of day and on the same day of the week (mid-week 
non-dialysis) for the baseline and follow-up assessments (week 13 and 26) (30-32). The 
assessment of PWV involved electrocardiogram-gated sequential applanation tonometry (SPT-
301; Millar Instruments, Houston, Texas) to acquire waveforms at the brachial and tibial arteries 
(SphygmoCor 7.1; AtCor, www.atcormedical.com).  Aortic blood pressures and AI were 
estimated using radial applanation tonometry (SphygmoCor 7.1) performed on non-fistula arm 
using a validated and reproducible generalized transfer function (31, 33). AI is also normalized to 
a heart rate of 75 beats per minute (34).  A single trained non-blinded operator (D.C.) tested all 
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participants. Participants fasted from food and caffeinated drinks for a minimum of 4 hours prior 
to assessment.  Resting brachial blood pressure was measured after 15 min supine rest using an 
aneroid sphygmomanometer. PWV was derived as distance (meters)/transit time between the 
brachial and tibial arterial sites (seconds). Pulse pressure (PP) was derived from the difference 
between measured systolic blood pressure (SBP) and diastolic blood pressure (DBP) readings. 
The heights of brachial, sternal notch and posterior tibial arterial sites were measured to 
determine the distance for PWV.  
Anthropometric outcomes 
Body Mass Index (BMI) in kg/m2 was computed from measured height and weight. Waist 
circumference was measured according to standard protocol (28).  
Hematological outcomes  
Peripheral blood samples for PCs (CD133+CD34+) and EPCs (CD133+CD34+CD31+) 
were collected prior to the first dialysis session and were processed within 2 hours of being 
collected.  Peripheral blood samples for other hematological measures were collected prior to the 
second dialysis session. 
 Blood samples were diluted 1:1 with sterile phosphate buffered saline (PBS) and 
mononuclear cells (MNCs) isolated via Lymphoprep™ (Axis-Shield, Oslo, Norway) density 
gradient centrifugation.  Cells were washed in HUVE media (Media 199 (Sigma-Aldrich, MO, 
USA); containing 20% FCS (Hyclone, Utah, USA), 1.5% sodium bicarbonate, 2% HEPES buffer 
solution, Penicillin Streptomycin, sodium pyruvate (all Gibco Invitrogen, Gaithersburg, MD, 
USA) and non-essential amino acids (Sigma-Aldrich) prior to staining for flow cytometric 
analysis. Cells were blocked with 10µl of human FcR blocking reagent (Miltenyi Biotec, 
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Bergisch Gladbach, Germany). Cells were washed prior to blocking with 5µl normal mouse 
serum (Sigma-Aldrich) and immediately incubated with panels of mouse anti-human conjugated 
antibodies; anti CD14 PE-Cy7, anti CD144 FITC, anti CD34 Percp-Cy5.5, anti CD45 Amcyan, 
anti CD31 V450 (all BD Biosciences, Franklin Lakes, NJ, USA) and anti-CD133-PE (Miltenyi 
Biotec) used as per manufacturer’s instructions as well as the viability dye eFlour®780 (1:1000, 
eBioscience, San Diego, CA, USA). The cells were then re-suspended in FACS fix (1% 
formaldehyde, 20g/L glucose, 5mM sodium azide, in PBS). Flow cytometric analysis was 
performed on a FACS ARIA II (BD Biosciences) with PCs and EPCs analyzed via FCS Express 
4 (De Novo Software, Glendale, CA, USA) and recorded as percentage of MNCs. 
 Blood samples for CRP assay were collected in lithium heparin coated Vacuette tubes. 
CRP assays were analyzed using the Siemens Healthcare Diagnostics ADVIA Chemistry system 
(Tarrytown, NY, USA) (CV=3.8%). 
Blood lipids, including total cholesterol, high-density lipoprotein cholesterol (HDL-C), 
low-density lipoprotein cholesterol (LDL-C) and triglycerides were analyzed using the Siemens 
Healthcare Diagnostics ADVIA Chemistry system. LDL cholesterol was calculated as LDL-C = 
[Total Cholesterol–(Triglycerides/2.2)]–HDL-C. The CV for total cholesterol, HDL-C and 
triglyceride ranged from 1.3-6.3%. 
 
Compliance and adverse events  
 Compliance to PRT (%) was defined as the number of sessions attempted divided by the 
number offered x 100. Changes in health status, including acute illnesses, falls, changes in 
medication dosage and usage, visits to health care professionals and exercise-related adverse 
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events were documented during the control and intervention periods by means of a structured 
questionnaire and review of clinical notes on a weekly basis.  A PRT-related adverse event was 
defined as any injury, impairment or medical condition persisting that could be attributed directly 
due to the prescribed exercise program.  
 
Statistical analyses 
There are no published data on the effects of PRT on PWV in patients with ESRD.  A 
sample size estimate was informed by a post hoc computation provided by Koh et al. (35).  Their 
data suggested that 36 participants per group would be needed to detect statistical significance for 
a clinically significant reduction of 1.0 m/s in PWV between an exercise and control group 
within a randomized controlled trial (RCT) (ES = 0.67; α = 0.05 and 1-β = 80%) (35). Assuming 
between measures correlation of 0.5, the required sample size for a crossover design was 
computed as n=20 to detect the same effect size on PWV.   
Analyses were performed using SPSS (IBM©, Version 19.0).  All data were inspected 
visually and statistically for normality at each timepoint (weeks 0, 13, and 26).  Normally 
distributed data were described using mean ±standard deviation.  Non-normally distributed data 
were log-transformed (log10) across the three timepoints prior to entry into parametric statistical 
models.  Primary analysis incorporated a linear mixed model defining individual as the random 
effect with the outcome measure evaluated across three timepoints (weeks 0, 13, 26).  All data 
were included regardless of participant compliance to the intervention according to the intention-
to-treat principle (n=22).  Each model was also adjusted for age, gender, dialysis vintage, and 
interactions for time by age, time by gender and time by dialysis vintage.   P-values were 
reported for the change from week 0 to week 13 and change from week 13 to 26.  In addition, the 
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mean difference and effect size were computed comparing the control period (week 13 – week 0) 
to the intervention period (week 26 – week 13).  Linear univariate regression analyses were 
performed using pooled data to determine significant relationships between PWV and all 
outcome measures at baseline.  In addition, regression analyses were performed to evaluate 
relationships between changes in PWV and changes in all outcome measures during the PRT 
intervention period (week 14-week 25).   
 
6.4 Results 
Participant and recruitment  
Twenty-two eligible participants consented to participate and completed baseline 
assessment, comprising 11% of the total patients reviewed (n=195). Participant flow is presented 
in Figure 6.1. 
 
Baseline characteristics 
Patient characteristics for the total cohort (n=22) are presented in Table 6.2. Age ranged 
from 51 to 89 years and dialysis vintage ranged from 7 months to 13.5 years.  The majority of 
participants were overweight (36.4%) or obese (27.3%). All except five participants were on one 
or more anti-hypertensive medications, and baseline blood pressure indicated stage 1 
hypertension in the cohort (36). Half of the participants (n=11, 50%) were prescribed beta-
blockers and/or calcium channel blockers. The ethnicity of the participants was pre-dominantly 
Caucasian (n=17, 77.3%).  
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Compliance and adverse events  
Compliance to PRT in the 18 participants who undertook the intervention was 71.2 ± 
23.3%.  Eleven of 18 participants achieved at least 75% compliance (i.e., greater than 27 of 36 
sessions attended). Three participants who refused follow-up assessment at week 26 completed 
less than 20% of the PRT intervention.  One participant experienced dizziness during one training 
session while exercising during hemodialysis. Blood pressure was found to be normal, however 
exercise was immediately ceased.  There were no other adverse events.  
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Table 6.2. Baseline characteristics of the total cohort (n=22) 
 Total cohort 
Age (years) 71.3 + 11.0 
Sex (men: women) 13:9 
Ethnicity  
Caucasian, n(%) 17 (77.3) 
Asian, n(%) 1 (4.5) 
Aboriginal, n(%) 2 (9.1) 
Indian, n(%) 2 (9.1) 
Height (cm) 161.4 + 10.4 
Body weight (kg)  74.6 + 17.9 
Body Mass Index (kg/m2) 28.5 + 5.6 
Dialysis vintage, months (range) 42.5 (7 – 163) 
Systolic blood pressure at rest (mm Hg) 149 ± 24 
Diastolic blood pressure at rest (mm Hg) 68 ± 9 
Dialysis adequacy (Kt/V) 1.72 + 0.26 
Serum creatinine (µmol/L) 706.2 + 141.8 
Serum albumin (g/L) 35.6 + 2.3 
Medications, n (%):  
Erythropoiesis stimulating agents 18 (81.8) 
Beta blockers 11 (50.0) 
Calcium channel blockers 11 (50.0) 
Nitrates 4 (18.2) 
Angiotensin-converting enzyme inhibitors 3 (13.6) 
Alpha blockers 3 (13.6) 
Angiotensin II receptor blockers 1 (4.5) 
Tobacco use history (n) 11 
Etiology of kidney failure  
other, n (%) 12 (54.5) 
diabetes, n (%) 7 (31.8) 
hypertension, n (%) 2 (9.1) 
glomerular diseases, n (%) 1 (4.5) 
Data reported according to mean + standard deviation except dialysis vintage (median value and range 
reported due to non-normal distribution). Dialysis adequacy (Kt/V) greater than or equal to 1.2 is 
considered adequate.  
 
 
  
 187 
Figure 6.1. Participants flow 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
  
Eligible (n=106) 
Ineligible (n=89) 
Contraindicative conditions 
(n=42) 
Language barrier (n=22) 
Non-sedentary (n=8) 
Other reasons (n=17) 
Not interested (n=84) 
Lack of interest (n=40) 
Lack of time (n=24) 
Other reasons (n=20) 
 Enrolled and completed 
baseline assessment (n=22) 
Reviewed (n=195) 
Completed week 13 assessment, 
i.e. post control period (n=18) 
 
Unavailable for week 13 
testing, i.e. post control (n=4) 
Withdrew and enrolled in a 
drug trial (n =1) 
Medical contraindication (n =1) 
Family reasons (n =1) 
No reason given (n =1) 
 
Unavailable for week 26 
testing, i.e. post PRT (n=3) 
Medical contraindication (n =1) 
Too strenuous (n =1) 
Work-related reasons (n =1) 
 
Completed week 26 
assessment, i.e. post PRT 
period (n=15) 
 
Enrolled and included in 
analysis (n=22) 
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Baseline relationships 
PWV was positively correlated with brachial SBP (r=0.49, P=0.04) and PP (r=0.51, 
P=0.03), and inversely correlated with PCs (r=-0.68, P=0.045). No other relationships were 
noted between PWV and other outcome measures. 
 
Outcomes  
 Linear mixed model analysis results for the primary and secondary outcome measures are 
presented in Table 6.3.   
Pulse wave velocity and secondary hemodynamic outcomes 
Due to non-parametric distribution, the PWV data were normalized using logarithmic 
(log10) transformation. No significant change in log-PWV was detected between control and 
intervention periods [mean difference = 0 (95% CI = -0.1 to 0.1); P=0.58]. Similarly, no 
significant change was noted in any of the secondary hemodynamic outcomes, including AI, AI 
at 75bpm, and aortic and brachial blood pressures (diastolic-, systolic- and pulse pressures), 
between control and intervention periods (Table 6.3).  
Anthropometric outcomes 
No change was noted in any anthropometric outcome, including weight [mean difference 
= -0.95 (95% CI = -10.86 to 8.95); P=0.30], BMI [mean difference = -0.43 (95% CI = -7.87 to 
7.01); P=0.26] or waist circumference [mean difference = -0.41 (95% CI = -9.81 to 8.98); 
P=0.61] between the control and intervention periods (Table 3). 
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Table 6.3.  Primary outcome (PWV) and secondary hemodynamic measures  
Outcome Measures Week 0 Week 13 Week 26 P (time) P (week 13 vs week 0) 
P (week 26 vs 
week 13) 
Mean Difference 
(95%CI) 
(Intervention - Control 
period) 
Relative ES (95%CI) 
(Intervention - Control 
period) 
Primary outcome: 
 
   PWV (m/s) 12.3  (9.1 – 20.8) 
11.5  
(9.7 – 20.0) 
13.0  
(9.3 – 26.7) 0.70 0.45 0.58 0 (-0.1, 0.1) 0.02 (-0.61, 0.57) 
Secondary outcomes: 
  Hemodynamic outcomes 
    AI (%) 34.9±12.6 33.5±13.0 33.9±16.0 0.78 0.60 0.90 1.9 (-5.9, 9.7) 0.14 (-0.45, 0.74) 
    AI at 75 bpm (%) 30.6±10.7 30.3±11.1 32.6±14.0 0.88 0.90 0.46 2.7 (-3.9, 9.4) 0.24 (-0.35, 0.84) 
    Aortic SBP (mmHg) 139±25 133±26 128±32 0.19 0.31 0.48 1 (-14, 17) 0.04 (-0.55, 0.63) 
    Aortic DBP (mmHg) 69±10 68±10 67±12 0.17 0.40 0.71 1 (-5, 7) 0.08 (-0.51, 0.67) 
    Aortic PP (mmHg) 69±23 65±23 61±28 0.22 0.39 0.40 -1 (-15, 13) 0.03 (-0.62, 0.56) 
    Brachial SBP (mmHg) 149±24 143±26 136±30 0.17 0.28 0.25 -1 (-17, 14) 0.05 (-0.64, 0.54) 
    Brachial DBP (mmHg) 68±9 67±10 66±11 0.16 0.55 0.54 -0.2 (-5.8, 5.4) 0.02 (-0.61, 0.57) 
    Brachial PP (mmHg) 80±22 76±23 71±26 0.16 0.32 0.28 -1 (-15, 13) 0.05 (-0.64, 0.54) 
  Anthropometric outcomes 
    Weight (kg)  72.6±16.3 72.9±16.3 72.3±16.4 0.10 0.51 0.30 -0.95 (-10.86, 8.95) 
-0.058  
(-0.649 – 0.534) 
    BMI (kg/m2) 28.2±5.8 28.4±5.9 28.1±5.9 0.10 0.37 0.26 -0.43 (-7.87, 7.01) 
-0.035  
(-0.626 – 0.556) 
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    Waist circumference (cm) 99.6±14.5 99.6±14.6 99.1±14.9 0.84 0.94 0.61 -0.41 (-9.81, 8.98) 
-0.026  
(-0.617 – 0.565) 
  Hematological outcomes 
    Progenitor cells (%) 0.044±0.042 0.054±0.033 0.050±0.038 0.77 0.38 0.68 -0.014 (-0.037, 0.009) 0.36 (-0.96, 0.23) 
    EPC (%) 0.025±0.033 0.044±0.028 0.039±0.033 0.34 0.047 0.53 -0.024 (-0.043, 0.005) 0.77 (-1.38, -0.16) 
    CRP (mg/L) 4.2  (2.2 – 15.7) 
5.0 
(1.6 – 9.3) 
7.4 
(3.6 – 15.5) 0.92 0.08 0.057 0.49 (0.13, 0.86) 0.8 (0.19, 1.42) 
    HDL-C (mmol/l) 1.2±0.3 1.1±0.3 1.1±0.3 0.11 0.34 0.94 0.007 (-0.24, 0.25) 0.02 (-0.81, 0.86) 
    LDL-C (mmol/L) 2.2±0.9 2.1±0.9 2.1±1.0 0.71 0.21 0.64 0.37 (-0.54, 1.29) 0.35 (-0.49, 1.19) 
    Cholesterol (mmol/L) 4.3±0.9 4.1±0.9 4.1±1.0 0.13 0.30 0.81 0.39 (-0.63, 1.40) 0.32 (-0.51, 1.17) 
Triglyceride (mmol/L) 1.6 (1.3 – 2.3) 
1.6 
(1.3 – 2) 
1.4 
(1.05 – 2.1) 0.08 0.61 0.31 -0.03 (-0.23, 0.17)  -0.12 (-0.96, 0.71) 
         
Log PWV, logarithm-transformed pulse wave velocity; AI, augmentation index; AI at 75 bpm, augmentation index normalised to a heart rate of 75 beats per minute; ES, 
effect size; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; BMI, body mass index; EPC, endothelial progenitor cells; Log CRP, logarithm-
transformed C-reactive protein; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol. Data reported according to mean + standard 
deviation except non-normal distributed data [median (range)]. 
The mean difference expresses the mean difference in the outcome between the control and intervention periods. The relative effect size is the mean difference between the 
two periods divided by the pooled standard deviation of the outcome at baseline among participants.  
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Hematological outcomes 
Due to non-normal distribution, both CRP and triglycerides were normalized using 
logarithmic (log10) transformation prior to parametric statistical analyses.  No change was noted 
in any of the hematological measures, including PCs [mean difference = -0.014 (95% CI = -0.037 
to 0.009); P=0.68], EPCs [mean difference = -0.024 (95% CI = -0.043 to 0.005); P=0.53], log 
CRP [mean difference = 0.49 (95% CI = 0.13 to 0.86); P=0.06], HDL-C, LDL-C, total 
cholesterol, and log triglyceride between the control and intervention periods (Table 6.3). 
 
Associations of Adaptation of PWV  
No relationships were noted between change in PWV and changes in any other outcome 
measures.    
 
Post hoc analyses 
Post-hoc analyses were conducted to evaluate the effect of adherence on adaptation. 
Linear mixed model analyses were computed for all outcome measures using data from 
participants who attended ≥75% of the PRT sessions (n=11).  The findings of these analyses 
remained essentially unchanged from the primary analysis. 
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6.5 Discussion 
To our knowledge, this is the first study to assess the effect of a chronic PRT intervention 
on PWV and secondary outcomes (i.e., hemodynamic, anthropometric, and hematologic) 
potentially contributing as mechanisms to the adaptation of arterial stiffness in patients with 
ESRD undergoing maintenance hemodialysis.  Contrary to our hypotheses, the results indicate 
that a 12-week low-to-moderate intensity intradialytic PRT program does not significantly 
change PWV or associated biomarkers of CVD risk.  These findings have implications for the 
development of future clinical trials investigating the cardiovascular benefits of exercise training 
in ESRD. 
To date, three clinical trials have examined the effects of aerobic training on the arterial 
stiffness measures in hemodialysis patients (15, 35, 37). In contrast to the current study, 
Toussaint et al. (15) observed a significant reduction in PWV (P=0.008) and trend toward 
significant improvement in AI (P=0.062) after three months of intradialytic cycling. Similarly, 
Mustata et al. (37) in an uncontrolled trial of 11 patients reported a significant reduction in AI 
and PP secondary to 12 weeks of treadmill and/or recumbent exercise cycling during non-dialysis 
time. Koh et al. (35) compared the outcomes of hemodialysis patients prescribed intradialytic 
cycling, a home-based walking program or usual care and showed no significant change in PWV 
and AI in either of the exercising groups.  The lack of adaptation in that study could be due to its 
lower intensity (RPE of 12-13), lower work or shorter duration sessions compared to the 
intervention prescribed by Toussaint et al (15) (35 kilocalories versus 70 kilocalories) or Mustata 
et al. (37) (60 to 80% maximal heart rate). Therefore, the results of the existing research may 
collectively suggest that aerobic training at a sufficient intensity level and or volume may 
significantly improve PWV and other measures of arterial stiffness.  
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Two systematic reviews suggest that PRT is not as effective as aerobic training in 
improving measures of arterial stiffness (i.e., PWV or AI) (38, 39). Ashor et al (38) conducted a 
meta-analysis of 42 RCTs enrolling 1627 healthy and chronically-diseased participants found that 
isolated aerobic training significantly reduced PWV [weighted mean difference = -0.63 m/s (95% 
CI: -0.90, -0.35); P<0.01] and AI [weighted mean difference = -2.63% (95% CI: -5.25 to -0.02); 
P= 0.05], however isolated PRT did not change these measures.  Interestingly, Miyachi et al. 
(39) conducted a systematic review of 8 RCTs in 193 participants who were apparently healthy 
or had stage 1 hypertension and determined that high-intensity PRT (>70% 1RM) actually 
increased arterial stiffness (carotid β index or PWV).  However, no effect on arterial stiffness was 
noted with moderate intensity (40-70% 1RM) PRT.    
The findings of the present study appear to be congruent with the findings of Ashor et al. 
(38) and the findings for moderate intensity PRT elucidated by Miyachi et al. (39).  We found no 
evidence of a dose-response effect on arterial stiffness; i.e., participants who attended >75% of 
exercise sessions did not achieve results which differed from our primary analyses of the total 
cohort.  Similarly, the meta-analysis by Ashor et al. (38) documented no relationship between 
PRT intervention characteristics (i.e. absolute and relative intensity, exercise duration and 
frequency) on changes in PWV.  Hence, the empirical data suggest that PRT does not improve 
arterial stiffness.     
The vascular endothelium secretes vasoactive substances to regulate vascular smooth 
muscle tone and therefore partially mediates changes in arterial stiffness (40, 41). Recent data 
suggest that exercise-induced shear stress is the mechanism by which endothelial function is 
improved (42).  However, different modalities of exercise can elicit different patterns of shear 
stress (43).  Aerobic exercise (e.g., running, cycling) typically involves rhythmic movements that 
activate a large number of muscle groups.  This form of exercise has been shown to substantially 
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increase both ante-grade and retrograde blood flow, while PRT exercises targeting specific 
muscle groups (e.g., arm flexors) do not produce such effects (44, 45). One study has shown that 
8 weeks of forearm exercise consisting of squeezing a rubber ring for 30 minutes daily can 
induce local changes in the radial artery in endothelial-dependent vasodilation.   However, such 
exercise may more closely resemble aerobic training than PRT due to its rhythmical nature. 
The null effect of PRT on arterial stiffness and associated hemodynamic measures was 
accompanied by no change in CD34+CD133+ PCs or the more vascular committed 
CD34+CD133+CD31+ EPCs.  Patients with ESRD have lower number of circulating EPCs, 
lower endothelial colony forming units (e-CFU) and impaired EPCs mobilization (46). Higher 
quantities of EPCs are required for the maintenance and repair process of the damaged 
endothelium (47-50). Only one exercise study to date has investigated its effect on PCs and EPCs 
in patients with ESRD. Manfredini et al. (16) conducted a controlled trial of a 6-month moderate 
intensity aerobic training intervention. The exercise protocol consisted of two 10-minute walking 
sessions per day at 50% of the patient’s maximum treadmill speed, performed at home on at least 
three non-dialysis days per week.  No difference was found in circulating PCs (CD34+), EPCs 
(CD34+CD133+VEGFR2+) and e-CFU post intervention between the exercise group (n=14) and 
control group (n=8). The lack of change of circulating EPCs numbers in the current study and in 
the aerobic training study by Manfredini et al study (16) may be due to the uremia associated 
with ESRD, as uremia has been shown to increase EPCs apoptosis and reduce progenitor cells 
differentiation into EPCs (51).  
The lack of change in other hematological and anthropometric measures, including log-
CRP, HDL-C, LDL-C, log-triglyceride, weight, BMI and waist circumference is consistent with 
the null effect the intervention had on arterial stiffness.  These secondary hematological and 
anthropometric measures are known to contribute to arterial stiffness, while exercise exerts its 
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benefits on vascular health in other cohorts partially by altering these factors (52-55). The effect 
of PRT on these outcome measures in patients with ESRD remains inconsistent (22, 56-60). 
Limitations of this study include low number of participants and the lack of a parallel arm 
control group. No sample size can be estimated from post-hoc analysis for change in PWV 
between intervention and control period as there is no discernible change in PWV (relative ES = 
0) in the current study. However, post hoc power calculations indicated that it would have 
required a sample size of 138 for the small ES detected in AI to be significant with  β=0.2 
and  α=0.05. Thus, it is possible that a Type II error may have contributed to the lack of statistical 
significance in our sample, at least for this secondary estimate of central aortic stiffness which 
was measured by radial artery applanation tonometry. Thus, future studies powered for small ESs 
would be needed to determine more definitively whether PRT has the ability to maintain or 
decrease arterial stiffness in patients with ESRD, using more precise measures of arterial stiffness 
than the current study. 
An important limitation relates to the specific assessment of PWV in this study.  Previous 
studies (61, 62) have only established central arterial stiffness (aortic PWV) as a strong 
independent predictor of mortality in ESRD. As the current study measured brachial-ankle PWV, 
it is uncertain whether aortic arterial stiffness was unchanged. The PWV measured in the current 
study is considerably faster than previous aerobic training studies (15, 35, 37), making it unlikely 
that this was solely due to peripheral method of measuring arterial stiffness (63). The current 
cohort may thus have had more advanced arterial stiffness than previous cohorts, limiting the 
potential for adaptation to exercise. Arterial stiffening is also associated with ageing (64). The 
current cohort was elderly and comparatively older than most previous exercise studies in this 
population (23, 35, 37, 59). 
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Although PRT can result in increased arterial stiffness in some younger healthy cohorts, 
this is not evident in middle-aged, older cohorts (39), including clinical cohorts such as type 2 
diabetes (65) and chronic heart failure patients (66).  In young cohorts, the magnitude of increase 
in arterial stiffness after PRT is also unlikely to be clinically adverse as the increase still leaves 
them in the normal range (39). 
In conclusion, the current findings suggest that appropriately screened, older patients with 
ESRD can safely participate in a supervised PRT without worsening arterial stiffness. More 
research is needed to determine if different intensities of PRT or longer training durations can 
alter vascular health and other outcomes related to survival.   
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Chapter 7  
Conclusion
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Conclusion and Summary 
The results of this thesis have extended the current understanding in several areas. While 
a few studies have reported the effects of aerobic exercise training on arterial stiffness and other 
cardiovascular outcomes in patients with ESRD, there is limited research evaluating the effects of 
intradialytic PRT in this population group. Conventional hemodialysis centers are not designed 
with space for commercial exercise equipment. Although previous clinical trials were successful 
in implementing exercise training during hemodialysis, they are primarily aerobic exercise or 
light resistance exercise. Rudimentary resistance exercise equipment was often used which had 
limited resistance load for continual positive physiological adaptations. Few studies had 
endeavored to develop, test and report the feasibility of resistance exercise equipment purpose-
built for delivering a comprehensive, intradialytic PRT in conventional hemodialysis setting.  
This thesis sought to fill these gaps in the literature by first conducting a systematic 
review (Chapter 4) and meta-analysis (Appendix 2) to determine the most efficacious PRT 
programming and expected PRT benefits on physiological, functional and psychological 
outcomes. The main findings of this review are that PRT can increase lower body muscular 
strength, muscle mass, physical functioning and HRQoL whilst its effects on other important 
outcome measures remain inconsistent. The following recommendations for future clinical trials 
were also suggested. Future clinical trials should describe thoroughly exercise programming 
including frequency, intensity, modality, supervision and progression to allow detailed synthesis 
of results. The few studies of moderate to high intensity PRT interventions which maximize 
muscle hypertrophy seemed to also mediate cardiovascular disease risk factors such as 
inflammation, insulin sensitivity, body fat and dyslipidemia. It is therefore recommended that 
future trials should ascertain concurrent, dose-response effects of PRT on cardiovascular health 
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and disease risk factors. More PRT intervention should also target both upper and lower body 
muscle groups to maximise its physiological benefits.  
This research program followed some of these recommendations by including the 
development of a purpose-built training device and evaluating the effects of an intradialytic PRT 
intervention delivered using the device on cardiovascular, functional and psychological outcomes 
in patients with ESRD. The research demonstrates that it is feasible to deliver PRT in a 
conventional hemodialysis setting with a purpose-built training device, resulting in improved 
muscular strength and HRQoL (Chapter 5). The research has also found that upper body 
exercises can be incorporated safely in a hemodialysis setting with proper supervision by an 
exercise physiologist. The intervention was conducted in 3 different hemodialysis centers and no 
serious adverse event was reported as a consequence of PRT.  
Although the average age of the cohort is older than previous PRT studies, no serious 
adverse events occurred in the current trial. This indicates that, with appropriate screening, even 
patients who are older but willing to participate can safely perform both upper and lower body 
exercises prior to or during dialysis with proper supervision. As  hemodialysis patients may either 
have to wait for a lengthy period or have low chance of renal transplants, the improvements in 
HRQoL and lower body strength evident in the current intervention are important findings and 
does justify the incorporation of PRT in clinical care. Nephrologists, nurses and exercise 
physiologists need to work closer to design in-center exercise program and should consider the 
use of exercise equipment purpose-built for hemodialysis setting to increase the ease of 
prescribing quality PRT.  
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Lastly, this research also showed null effect of 12 weeks of moderate PRT on arterial 
stiffness measures hemodynamic, anthropometric or hematologic measures in patients with 
ESRD. This is the first study to investigate the effect of PRT on arterial stiffness and endothelial 
progenitor cells in ESRD, and Type II error is likely to contribute to our measure of AI. The null 
effect on arterial stiffness measures and endothelial progenitor cells should therefore be 
interpreted with reservations. As hemodialysis centers have limited number of patients that are 
willing and eligible to participate, a future RCT involving multiple centers will be necessary to 
generate bigger study cohort.  
New studies need to also investigate whether isolated PRT or combined with aerobic 
training can affect these cardiovascular outcomes in patients with less severe chronic kidney 
disease (stage 1 to 4) as they may have better chance of improvement due to less severe renal-
specific cardiovascular risk factors. Future research should also determine whether different 
intensities and longer durations of PRT can affect vascular health or other outcomes related to 
survival. 
In conclusion, the most significant contribution of this research is the first to develop and 
utilize a portable training device for both upper and lower body exercises in a comprehensive 
intradialytic PRT program. Only two studies that used novel resistance training devices were 
limited to lower body exercises. This is also the first trial to assess the effect of intradialytic PRT 
on arterial stiffness and endothelial progenitor cells in patients with ESRD. In conclusion, the 
intervention has expanded the conventional mode of exercise prescription in the hemodialysis 
setting, reproduced common benefits of PRT and investigated novel cardiovascular effects of 
PRT in ESRD. 
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Appendix 1. Publication – Resistance Training in Chronic Renal Failure 
By Dr. Birinder S. Cheema, PhD, and Danwin Chan, BHSci (Hons) 
School of Science and Health, University of Western Sydney, Campbelltown, NSW, Australia 
 
Introduction 
Chronic kidney disease (CKD), also known as chronic renal failure, is an irreversible 
disease characterized by the progressive loss of kidney function over time, usually a period of 
months to years (Eckardt, Berns, Rocco, & Kasiske, 2009; Levey et al., 2005).  Prevalence data 
for CKD are difficult to ascertain given that the early stages of the disease process are typically 
asymptomatic (Dasmahapatra et al., 2011), and given inconsistencies in diagnostic and 
classification systems (Glassock & Winearls, 2008).  However, recent data from the National 
Health and Nutrition Examination Survey (NHANES) suggest that 13.1% of adults (aged >20 
years) living in the United States had Stage 1 to 4 CKD in 2004 (Coresh et al., 2007).  More 
recent estimates by the United States Renal Data System suggest that 15.1% of the adult 
population in the United States has CKD (USRDS, 2011).   
The prevalence of CKD has increased gradually over the past several decades within the 
United States (Coresh et al., 2007) and globally (El Nahas & Bello, 2005) and these trends are 
expected to continue (El Nahas & Bello, 2005; Lysaght, 2002).  Global estimates suggest that the 
prevalence of CKD is threatening to reach epidemic proportions in both developed and 
developing countries, and that much of the burden can be attributed to the obesity-type 2 diabetes 
pandemic (El Nahas & Bello, 2005).  Certain ethnic populations are severely affected by late-
stage CKD.  These cohorts include African Americans (Klag et al., 1997), Hispanic Americans 
(Lora et al., 2009) and the aboriginal people of Canada (Yeates & Tonelli, 2010), the United 
States (Narva, 2008), New Zealand (Collins, 2010) and Australia (Australia and New Zealand 
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Dialysis and Transplant Registry, 2011), amongst others.  The prevention and treatment of CKD 
globally will become a major challenge in the coming decades (El Nahas & Bello, 2005).    
Diabetes and hypertension are currently the leading causes of CKD accounting for almost 
70% of cases (Bakris, Ritz, & On behalf of the World Kidney Day Steering, 2009).  Other causes 
include glomerulonephritis, IgA nephropathy, polycystic kidney disease, analgesic (aspirin, 
ibuprofen, and paracetamol) use, systemic lupus erythematosus, benign prostate hyperplasia, HIV 
infection, amyloidosis, kidney infections, kidney stones, sickle cell disease, heroin use, and 
certain cancers (K/DOQI, 2002). The etiology of CKD is influenced by infectious diseases and 
genetic predisposition only in a minority of cases (e.g. polycystic kidney disease, HIV infection), 
whilst the majority of cases are heavily influenced by lifestyle factors.  Physical inactivity, 
cigarette smoking and associated diseases (e.g. obesity, hypertension, dyslipidemia, diabetes) are 
consistently recognized as major modifiable risk factors for CKD (Hallan et al., 2006; White et 
al., 2011).   
Individuals with a diagnosis of CKD are at significantly elevated risk of cardiovascular 
and all cause mortality versus healthy peers (Tonelli et al., 2006).  Cardiovascular disease 
remains the leading cause of death in this population and the risk of cardiovascular mortality 
increases as kidney function declines (Sarnak et al., 2003).  Notably, mortality rates due to 
cardiovascular disease have been reported to be 10 to 30 times higher in dialysis-dependent CKD 
patients than in the general population (Sarnak et al., 2003).     
 
 
 
Diagnosis and classification  
Healthy kidneys filter approximately 170 L of blood and process 1.5 L of urine each day 
(How Kidneys Work, 2012).  Similar to the lungs, the kidneys can be considered “overbuilt” in 
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that the kidneys can incur tremendous damage and still sustain life without any adverse effects.  
For example, human beings can live normal, healthy lives with just a single kidney and have a 
life expectancy no different to that of the general population (Ibrahim et al., 2009).   
CKD is defined according to the presence of absence of kidney damage and the level of 
kidney function, regardless of disease etiology (K/DOQI, 2002).  CKD presents with no or few 
symptoms until the advanced stages (Dasmahapatra et al., 2011; K/DOQI, 2002).  Therefore, 
diagnosis can only be undertaken via laboratory tests, including urinalysis, blood tests, imaging 
tests and kidney biopsy (K/DOQI, 2002).  Each diagnostic method has limitations and therefore 
multiple methods are typically used (K/DOQI, 2002).  However, definitive diagnosis is based on 
biopsy or imaging studies (K/DOQI, 2002).  The pathophysiology of CKD depends on the 
causative factors.  Vascular changes that occur with disease progression include ischemia and 
stenosis of the small and large vessels of the kidney.  Damage to the glomeruli and renal tubules 
within the kidney may also underlie CKD progression.   
  Urinalysis can be used to detect the presence of urine casts and crystals (K/DOQI, 
2002).  In addition, the urine is analyzed for total protein, albumin, urea nitrogen and creatinine 
concentrations, measures that are all elevated in CKD.  The amount of creatinine and urea in the 
urine serve as markers of renal function and can be used to compute the glomerular filtration rate 
(GFR).  The Kidney Disease Outcome Quality Initiative (K/DOQI) has classified the severity 
(progression) of kidney disease by the decline GFR (Table 1) (K/DOQI, 2002).  The GFR is 
widely accepted as the best overall measure of kidney function (K/DOQI, 2002).      
However, it should be noted that glomerular injury in the early stages of CKD may induce 
compensatory glomerular hypertrophy, hypertension and hyperfiltration, reflected by an increase 
of GFR (K/DOQI, 2002).  However, this rise of GFR is typically followed by the progressive 
decline of GFR if preventative measures are not undertaken.  Hyperfiltration has often been noted 
in individuals with diabetes mellitus, polycystic kidney disease, hypertension and obesity 
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(Brenner, Lawler, & Mackenzie, 1996; Helal, Fick-Brosnahan, Reed-Gitomer, & Schrier, 2012; 
Palatini, 2012)  
In Stage 4 CKD (GFR=15-29 mL/min/1.73 m2), the patient is required to prepare for 
kidney replacement therapy, including hemodialysis, peritoneal dialysis or kidney transplant.  
Stage 5 CKD (GFR<15-mL/min/1.73 m2) is also known as end-stage renal disease (ESRD) or 
end-stage kidney disease.  In Stage 5, the kidneys can no longer function at a level to sustain life 
(K/DOQI, 2002).  Hence, individuals with ESRD are dialysis-dependent for the remainder of 
their lifetime, or until a successful kidney transplant (K/DOQI, 2002).  
 
Conventional hemodialysis treatment 
 Over 91% of patients diagnosed with ESRD will undertake hemodialysis treatment, while 
6% undertake peritoneal dialysis, and only 2% receive a transplant (USRDS, 2011).  Failure to 
undertake dialysis therapy in patients with Stage 5 CKD will result in imminent death (Galla, 
2000).  Conventional hemodialysis treatment is typically received three times per week for 
approximately 3–5 hours per treatment at an outpatient clinic.  Specialist nursing staff is involved 
in administering the dialysis sessions.  Alternatives to conventional hemodialysis include daily 
hemodialysis treatment or nocturnal hemodialysis, which are both typically administered by the 
patient and/or a trained care provider at home.  During conventional hemodialysis, blood is 
continually drawn out of the body at a rate of 200-400 mL/min to the dialysis machine where it is 
filtered and then returned.  The entire blood volume of the patient (approximately 5L) circulates 
through the machine every 15 minutes.  Sodium bicarbonate is often administered during 
hemodialysis to correct blood acidity.  Recombinant human erythropoietin may be administered 
to correct anemia.  Common side effects of hemodialysis treatment include hypotension, fatigue, 
chest pains, leg-cramps, nausea and headaches.  Such symptoms may occur during treatment and 
may persist post treatment.  Hemodialysis patients are typically older and suffer from many 
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comorbid conditions and therefore medication use is often high.  Depression is a common 
comorbidity in this patient population.   
 
Resistance training for the primary prevention of CKD 
Interventions for the primary prevention of CKD must target such risk factors as 
inactivity, overweight-obesity, insulin resistance, diabetes, hypertension, dyslipidemia cigarette 
smoking, and the low-quality westernized diet.  Scientific investigations have shown that RT 
prescribed in isolation can reverse overweight-obesity (Tresierras & Balady, 2009), type 2 
diabetes (Sigal et al., 2007; Sukala, Page, & Cheema, 2012; Tresierras & Balady, 2009; Willey & 
Fiatarone-Singh, 2003) and hypertension (Cornelissen, Fagard, Coeckelberghs, & Vanhees, 
2011; Fagard, 2006; Moraes et al., 2012).  Hence, interventions such as RT have the potential to 
prevent CKD and hence drastically mitigate the rising incidence of CRF globally (El Nahas & 
Bello, 2005).  
 
 
Resistance training in CKD and ESRD  
  Exercise training has been investigated in CKD since the late 1970’s.  Most of these 
investigations have involved hemodialysis patients, and have prescribed aerobic training in 
isolation or in combination with light to moderate strength training (Cheema & Fiatarone Singh, 
2005; Johansen, 2007; Johansen & Painter, 2012).  Investigations that have prescribed RT in 
isolation have all been published after the year 2000 (Balakrishnan et al., 2010; Castaneda et al., 
2004; Castaneda et al., 2001; Cheema et al., 2007a, 2007b, 2011; Headley et al., 2002; Heiwe, 
Clyne, Tollback, & Borg, 2005; Heiwe, Tollback, & Clyne, 2001; Kopple et al., 2007; Leaf, 
Macrae, Grant, & Kraut, 2003; Nindl et al., 2004; Oder, Teodorescu, & Uribarri, 2003; Rus, 
Ponikvar, Kenda, & Buturovic-Ponikvar, 2003). Likewise, the majority of these studies have 
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enrolled hemodialysis patients (Cheema et al., 2007a, 2007b, 2011; Chen et al., 2010; Headley et 
al., 2002; Johansen et al., 2006; Kopple et al., 2007; Majchrzak, Pupim, Flakoll, & Ikizler, 2008; 
Nindl et al., 2004; Oder et al., 2003; Rus et al., 2003), while only a few trials have enrolled pre-
dialysis patients (Balakrishnan et al., 2010; Castaneda et al., 2004; Castaneda et al., 2001; Heiwe 
et al., 2005; Heiwe et al., 2001; Leaf et al., 2003).  We are aware of no studies that have 
prescribed RT in patients receiving peritoneal dialysis or kidney transplants.  
 Research of the therapeutic potential of RT in patients with CKD is in its early stages, and 
many research questions remain to be answered.  Nevertheless, the studies published to date, 
which have prescribed RT in conventional fitness or rehabilitation settings, as well as during 
hemodialysis treatment, have largely been of good quality (Balakrishnan et al., 2010; Castaneda 
et al., 2004; Castaneda et al., 2001; Cheema et al., 2007a, 2007b, 2011; Chen et al., 2010; 
Johansen et al., 2006; Kopple et al., 2007) and have provided convincing evidence that RT is safe 
and can induce a broad spectrum of physiological, functional and psychological adaptations that 
are particularly important for patients with CKD and ESRD.  
 
Kidney function 
RT has been proven effective in targeting the main metabolic risk factors contributing to 
kidney damage (e.g. hypertension, type 2 diabetes, dyslipidemia, obesity, etc.) (Cornelissen et al., 
2011; Fagard, 2006; Moraes et al., 2012; Sigal et al., 2007; Sukala et al., 2012; Thomas, Elliott, 
& Naughton, 2006; Tresierras & Balady, 2009; Willey & Fiatarone-Singh, 2003).  Therefore, it is 
highly likely that RT can also play a significant role in slowing disease progression in those 
already diagnosed with the disease.  Interventions that induce fat loss may be particularly 
important for this purpose.  Many trials have in patients with CKD shown that weight loss 
induced via hypocaloric diet, bariatric surgery, drugs, exercise, or lifestyle modification can 
reduce proteinurea and albuminurea, which indicate improved renal function (Afshinnia, Wilt, 
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Duval, Esmaeili, & Ibrahim, 2010; Navaneethan et al., 2009).  Weight loss can also normalize the 
GFR in overweight and obese individuals with glomerular hyperfiltration (Chagnac et al., 2003; 
Navaneethan et al., 2009; Navarro-Diaz et al., 2006).  There is substantial evidence that regular 
RT can increase total fat-free mass and resting metabolic rate contributing to the 
mobilization/utilization of visceral and subcutaneous adipose tissue and thereby reduce whole 
body adiposity (Tresierras & Balady, 2009).  Hence, RT may potentially reduce proteinuria and 
albuminuria in individuals with CKD by inducing favorable shifts in body composition.  Trials 
are presently required to test this hypothesis. 
There is currently no consensus regarding the effect of preventative therapies on the GFR.  
The data suggest that reducing hypertension is particularly important for slowing CKD 
progression (Ruggenenti et al., 2008; Tresierras & Balady, 2009).  Some studies have actually 
shown that the GFR in patients with CKD can be increased with aerobic training interventions 
involving cycling or swimming (Pechter et al., 2003; Straznicky et al., 2011; Toyama, Sugiyama, 
Oka, Sumida, & Ogawa, 2010).  However, the findings are not always consistent (Boyce et al., 
1997).   
To our knowledge, only one trial has reported on the effect of RT on renal function to 
date.  Castaneda et al. (2001) conducted a randomized controlled trial that enrolled 26 patients 
with pre-dialysis CKD (i.e. Stage 3-4).  All 26 participants (aged >50 years) adhered to a protein-
restricted diet (0.6g/kg/day) during the trial.  Protein restriction is typically prescribed for 
slowing disease progression (Bellizzi et al., 2007).  Fourteen of the participants were assigned to 
a 12-week RT program while twelve participants received sham training (unloaded exercises).  
RT was prescribed three sessions per week and involved five exercises (chest press, leg press, lat 
pull-down, knee extension and knee flexion) performed for three sets at 80% of 1RM.  The 
training loads were adjusted with strength adaptation.  At the end of the 12-week intervention, the 
RT group experienced a statistically significant increase in the GFR from baseline (+1.18 
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mL/min/1.73 m2) versus the sham exercise group (-1.62 mL/min/1.73 m2; p=0.046).  The 
improvement of GFR was also reflected by a trend toward reduced urinary creatinine 
concentration (p=0.074).   
At present, the mechanisms underlying the RT or aerobic exercise-induced improvement 
of GFR (Castaneda et al., 2001; Pechter et al., 2003; Straznicky et al., 2011; Toyama et al., 2010) 
are not known; however, the reduction of sympathetic vasoconstrictor activity and metabolic risk 
factors (e.g. obesity, hypertension, insulin resistance) and improved endothelial function may be 
implicated (Perticone et al., 2010; Straznicky et al., 2011).   Large-scale RCTs are required to 
confirm or refute the findings of Castaneda et al. (2001), and elucidate the physiological 
mechanisms contributing to the improvement of GFR with RT.  Trials are also needed to 
determine the clinical significance of improved GFR in Stage 4 CKD.  It is generally accepted 
that Stages 3-4 CKD progresses to ESRD (The Remission Clinic approach to halt the progression 
of kidney disease, 2011), however, it is possible that this deterioration can be delayed or even 
prevented with RT and other robust forms of exercise training.    
 
Skeletal muscle wasting and inflammation  
Skeletal muscle wasting, also called protein-energy malnutrition, is common in the latter 
stages of CKD (i.e. Stages 3 to 5) (Fouque et al., 2008; Kopple, 1999; Workeneh & Mitch, 2010).  
Factors such as acidosis (Caso & Garlick, 2005), co-morbid illnesses, corticosteroid usage, aging, 
oxidative stress, dialysis treatment (Raj et al., 2004), and very low levels of physical activity can 
all contribute to the loss and atrophy of muscle fibers in this cohort (Diesel et al., 1993; E. Kouidi 
et al., 1998).  Low anabolic gene expression has been noted to underlie the muscle wasting 
observed in ESRD (Kopple et al., 2007).  Muscle wasting can occur despite adequate nutritional 
intake (Rajan & Mitch, 2008) and is associated with an array of physiological consequences 
including insulin resistance and chronic inflammation (Price, Gooch, Donaldson, & Roberts-
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Wilson, 2010; Rajan & Mitch, 2008).  Patients with CKD and ESRD often suffer from low-grade 
inflammation reflected by chronic, two- to four-fold elevations of circulating pro-inflammatory 
cytokines including C-reactive protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor 
alpha (TNF-α), amongst others (Avesani et al., 2006; Carrero, Yilmaz, Lindholm, & Stenvinkel, 
2008; Kalantar-Zadeh, 2006, 2007; Kalantar-Zadeh, Ikizler, Block, Avram, & Kopple, 2003).  
Numerous investigations have shown that muscle wasting and inflammation, also termed the 
“malnutrition-inflammation complex”, are significant predictors of mortality in this cohort 
(Desmeules et al., 2004; K Kalantar-Zadeh, 2006; Shlipak et al., 2005; Wanner & Metzger, 
2002).   
Recent evidence suggests that RT can counteract muscle wasting and inflammation in 
CKD and ESRD.  Castaneda et al. (2001) documented a significant increase in total body 
potassium (p=0.014), type I and type II muscle fiber cross-sectional area (CSA) (p=0.031 and 
p=0.045, respectively), serum prealbumin (p=0.050), leucine oxidation (p=0.046) and trend 
toward increased mid-thigh CSA (p=0.113) in participants prescribed 12 weeks of RT versus 
sham exercise.   The RT group also maintained body weight while the sham exercise group 
reduced body weight (p=0.049).  These adaptations are clinically relevant as they collectively 
indicate a reversal of skeletal muscle wasting despite a low protein diet.  A subsequent report by 
Castaneda and colleagues revealed that the anabolic effect was accompanied by reduced 
inflammation, reflected by reductions of CRP and IL-6 (Castaneda et al., 2004).  Moreover, the 
RT program elicited an increase in skeletal muscle mitochondrial DNA (Balakrishnan et al., 
2010).  This is an important adaptation given that mitochondrial dysfunction is common in CKD 
(Granata et al., 2009) and that associated deficits in energy metabolism contribute to mortality 
(Sietsema, Amato, Adler, & Brass, 2004).  In contrast to these findings, a study by Heiwe et al. 
(2005) found no significant change in type I, type IIa, or type IIb CSA, despite improvements in 
1RM ,in 12 elderly pre-dialysis (GFR ≤25 ml/min) patients prescribed 12 weeks of RT.  Notably, 
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the RT regimen in this study involved only knee extensor exercises at a low intensity (60% of 
1RM) (Table 2).    
Three recent randomized controlled trials have demonstrated that RT can reduce or 
reverse muscle wasting and inflammatory markers in patients with ESRD receiving hemodialysis 
treatment (Cheema et al., 2007a, 2007b; Kopple et al., 2007; Johansen et al., 2006).  Cheema et. 
al. (B Cheema et al., 2007a, 2007b) evaluated the effect of a supervised RT program prescribed 
three sessions per week during routine hemodialysis treatment in 49 patients with ESRD.  The 
regimen has been fully detailed in a recent article (Cheema et al., 2006).  The limb containing the 
vascular access was exercised just prior to the dialysis session while all other exercises were 
performed while the patient was in a seated or supine position receiving dialysis.  During each 
RT session, two sets of 8 repetitions of 10 exercises targeting the major muscle groups of the 
upper and lower extremities were performed at a rating of perceived exertion of 15-17/20 (“hard” 
to “very hard”).  Upper body exercises performed using free-weight dumbbells included the 
shoulder press, side shoulder raise, triceps extension, biceps curl and external shoulder rotation.  
Lower body exercises, performed using weighted ankle cuffs included seated knee extension, 
supine hip flexion, supine hip abduction, and supine straight-legged raise.  Seated hamstring curls 
were performed using Thera-Band tubing (Akron, Ohio, USA) attached to a fixed position on the 
weight trolley.  Abdominal musculature was targeted with bilateral leg raises in a supine position 
or bilateral leg lifts in a seated position, depending on subject preference and level of ability.   
The loading of exercises was progressed appropriately with strength adaptation.  After 12 weeks, 
participants randomized to the intradialytic RT program (n=24) experienced statistically 
significantly improvements in mid-thigh muscle attenuation and clinically significant 
improvements in mid-thigh muscle CSA, evaluated via computed tomography, as compared to 
those randomized to the wait-list control group (n=25) (Cheema et al., 2007a).  This 
improvement of muscle quality and quantity was accompanied by the significant improvement of 
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anthropometric measures (e.g. increases in BMI, mid-thigh and mid-arm circumferences) and the 
reduction of the inflammatory marker CRP (Cheema et al., 2007a).  Notably, the intradialytic RT 
regimen did not change other circulating cytokine concentrations including tumor necrosis factor-
alpha, interleukin-1b, interleukin-6, interleukin-8, interleukin-10, and interleukin-12 (B Cheema 
et al., 2011).   The reduction of CRP has been noted in other additional trials prescribing 8 weeks 
of intradialytic RT (Afshar, Shegarfy, Shavandi, & Sanavi, 2010) and 12 weeks of RT during 
non-dialysis time (Nindl et al., 2004).  This is an important finding given the morbidity and 
mortality associated with elevations of CRP in ESRD (Shlipak et al., 2005).  Cheema et al. 
(Cheema et al., 2007b) have also noted that a longer duration of intradialytic RT can induce 
greater gains in muscle CSA.    
Only a few additional randomized controlled trial has investigated the myogenic potential 
of RT prescribed during hemodialysis treatment (Johansen et al., 2006; Chen et al., 2010)   
Johansen et al. (2006) conducted a 2 x 2 factorial RCT of intradialytic RT and double-blind 
weekly anabolic steroid (nandrolone decanoate) or placebo injections in 79 patients with ESRD.  
Patients randomized to the RT intervention performed five lower body exercises using ankle 
weights (knee extension, hip flexion, hip abduction, plantarflexion and dorsiflexion) during 
thrice-weekly dialysis.  Two to three sets of 10 repetitions of each exercise were performed 
progressing from 60% of 3RM.  Training loads were increased with strength adaptation.  After 12 
weeks, quadriceps muscle CSA evaluated via MRI increased in the patients assigned to both RT 
+ placebo (p=0.02) and RT + nandrolone (p<0.0001) versus control.  The RT intervention did not 
improve total lean body mass, evaluated via DEXA, perhaps due to the fact that RT targeted only 
the lower extremities.  However, using a similar intervention, Chen et al. (2010) did note 
significant increases in leg and whole body fat-free mass and significant reductions in whole 
body fat mass after approximately six months of low-intensity lower-body intradialytic RT. 
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To date, there has been limited exploration of the subcellular mechanisms that contribute 
to muscular hypertrophy in patients with ESRD.  Kopple et al.(2007) investigated changes in 
anabolic and catabolic gene expression in 80 patients with ESRD randomized to four groups: (1) 
aerobic training, (2) RT, (3) aerobic + RT, and (4) control.  All training sessions were 
administered three times per week for 21 weeks.  The isolated RT group performed four lower 
body exercises (leg extension, leg curl, leg press and calf extension) three times per week 
immediately preceding each dialysis session.  One set of 12-15 repetitions at 70% of 5-RM was 
performed during the first four weeks of intervention.  The intervention was then systematically 
progressed, as tolerated, up to 3 sets of 6-8 repetitions of 80% of re-assessed 5-RM.  
Investigation of vastus lateralis biopsy specimens obtained from 15 patients in the RT group 
revealed significant increases in IGF-IEa mRNA and IGF-I protein from pre to post training. 
Additional anabolic genes, including IGF-IEc, IGF-IR, IGF-II and IGFBP-2 and IGFBP-3 also 
increased in expression, while anti-growth factor myostatin mRNA decreased in expression, 
however these changes did not achieve statistical significance in the RT group.  No changes were 
noted in measures of body composition (i.e. lean mass or fat mass) or circulating CRP, TNF-α or 
IL-6 following the intervention.  Overall, these findings suggest that RT can induce changes in 
gene expression that may promote protein synthesis and reduce protein degradation in patients 
with ESRD.  Greater adaptation may have been achieved with a larger sample size and/or more 
potent anabolic intervention.  
 
Physical functioning and quality of life  
Physical functioning, including the ability to engage in activities of daily living (Painter, 
2005), is lower in patients with CKD as compared to age-matched individuals with normal renal 
function (Painter, 2005).  Deficits in physical functioning have also been documented via self-
report surveys (DeOreo, 1997; Painter, 2005), performance-based tests (e.g. six-minute walk, gait 
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speed, strength, sit-to-stand, etc.) (Johansen, Kaysen, et al., 2003; Painter, Carlson, Carey, Paul, 
& Myll, 2000) and maximal exercise tests (Boyce et al., 1997; Castaneda et al., 2001;  Johansen, 
1999; Painter, Messer-Rehak, Hanson, Zimmerman, & Glass, 1986).  Physical inactivity 
(Johansen et al., 2000; O'Hare, Tawney, Bacchetti, & Johansen, 2003) and low physical 
functioning (DeOreo, 1997; Molsted et al., 2007) contribute to reduced quality of life, increased 
hospitalization, and increased mortality in patients with CKD.  Notably, a recent international 
survey has revealed that physical activity levels are directly proportional to survival in patients 
with ESRD (Tentori et al., 2010).  
  Only one study to date has investigated the effect of RT on physical functioning and/or 
quality of life in pre-dialysis CKD patients.  Heiwe et al. (Heiwe et al., 2001) prescribed 
relatively low-intensity (20 repetitions per set) quadriceps muscle training three times per week 
for 12 weeks in elderly patients with a GFR ≤ 25 ml/min and noted significant improvements in 
isometric quadriceps muscle strength, quadriceps endurance, six minute walk distance, and speed 
on the ‘timed up and go test’ from pre to post intervention.  However, these functional 
adaptations were not accompanied by improvements of quality of life.   
 Several studies have noted improvements in physical functioning and quality of life in 
patients with ESRD.  Cheema et al. (Cheema et al., 2007a) noted significant improvements in 
total body strength (p<0.001), and a trend toward improved six-minute walk distance (p=0.16) 
secondary to 12 weeks of high-intensity intradialytic RT versus usual care.  These improvements 
in functioning were concomitant with the enhancement of quality of life domains including 
vitality and physical function (Cheema et al., 2007a).  Cheema et al. (2007b) have also reported 
that greater strength adaptation can be achieved with longer durations of intradialytic RT.  
 Several studies have noted functional adaptations secondary to low-intensity intradialytic 
RT.   Chen et al. (2010) found that patients who engaged in approximately six months of lower-
body RT experienced significant improvements in knee extensor strength, sit-to-stand movement 
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time, leisure time physical activity, and self-perceived physical functioning and activities of daily 
living versus a sham exercise group.  Similar functional and/or quality of life adaptations have 
also been reported in a smaller trials prescribing intradialytic RT (Bullani et al., 2011).  By 
contrast, Orcy et al. (2012) did not observe a significant improvement in six-minute walk 
distance with 10 weeks of isolated, full body RT.  However, the RT intervention may have been 
prescribed at too low an intensity.  For example, leg exercises were performed with very light (1-
2 lb) ankle cuffs.  The exercises prescribed by Chen et al. (2010) involved the use of weighted 
ankle cuffs that could be loaded only up to 20 lbs (9 kg).  Johansen et al. (2006) also prescribed 
relatively low-intensity, lower-body exercises and noted significant improvements in the physical 
function domain of quality of life after 12 weeks of intervention, however, stair climbing, gait 
speed, or rising from a chair did not significantly improve over time versus the placebo-control 
condition.  
 Headley et al. (2002) conducted an uncontrolled trial that evaluated the effect of an RT 
program prescribed during non-dialysis time in 10 patients with ESRD.  RT sessions were 
prescribed twice per week for 12 weeks.  During each session, the patients completed 1-2 sets of 
10-15 repetitions of nine machine weight exercises (leg press, leg extension, leg curl, chest press, 
compound row, lateral raise, biceps curl, triceps extension and abdominal curl).  Loads were 
adjusted accordingly with strength adaptation.  In addition, the patients were also prescribed an 
unsupervised home-based RT program that involved the performance of nine exercises (squat, 
elbow extension, knee flexion, elbow flexion, calf raise, shoulder shrug, hip abduction, scapula 
retraction and ankle dorsiflexion) using Thera-Band tubing (Akron, OH).  The home-based 
exercises were also prescribed at 1-2 sets of 10-15 repetitions, and heavier resistance bands were 
utilized in the latter weeks of training.  The home-based component of the intervention was 
delivered via a prerecorded video.  At the end of the intervention period, the patients significantly 
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improved peak knee extension isometric strength at 90 degrees of flexion, six-minute walk 
distance, maximal walking speed, and sit to stand movement time.     
 
Forearm exercise for AV fistula maturation 
One of three vascular accesses are typically used to access the blood supply for 
hemodialysis treatment in patients with ESRD:  an arteriovenous (AV) fistula, a synthetic graft, 
or an intravenous catheter.  All vascular accesses must be surgically created.  The AV fistula is 
the preferred vascular access for chronic hemodialysis treatment as it is associated with fewer 
complications (e.g. thrombosis, stenosis and infection) and a longer functional lifespan versus the 
synthetic graft (Allon & Robbin, 2002; Churchill et al., 1992; Woods et al., 1997).  The preferred 
site for the creation of an AV fistula or synthetic graft is the forearm (National Kidney 
Foundation, 2006), and the choice of access is influenced by the condition of the vasculature.  
The AV fistula and synthetic graft must be given time to heal and mature.  In the interim, the 
patient will receive dialysis via an intravenous catheter, the least preferable vascular access for 
long-term dialysis given that it is most prone to complications.  
It is a routine practice to instruct patients to perform arm exercises, especially ball 
squeezing prior to, and some time after AV fistula surgery, and empirical data support this 
practice.  Robbin et al. (2002) determined that patients with an AV fistula adequate for dialysis 
had a venous diameter >0.4 cm and flow volume >500 ml/min within four months of fistula 
creation.  Recent trials involving forearm resistance exercises have been shown to acutely and 
chronically increase vessel diameter, cross-sectional area and dilation (Leaf et al., 2003; Oder et 
al., 2003; Rus et al., 2003).  
Oder & Uribarri (Oder et al., 2003) in a trial enrolling 23 hemodialysis patients revealed 
that five minutes of ball squeezing exercise with the AV fistula-containing arm could acutely 
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dilate the fistula diameter by about 9.3%.  This acute effect may contribute to chronic adaptation 
of the blood vessels with prolonged training (Leaf et al., 2003; Rus et al., 2003).   
Leaf et al. (2003) investigated a six-week intervention that combined 10 minutes of pre-
exercise forearm heating and RT in five patients with pre-dialysis renal failure.  The sessions 
were prescribed four times per week and exercises involved isometric handgrip contractions at 
30-40% of maximal voluntary contractions for 80 to 360s.   In addition, the patients repetitively 
squeezed a squash ball and/or racquet ball.  The volume and intensity of isometric exercise was 
adjusted weekly based on the assessment of grip strength using a handgrip dynamometer and 
according to patient tolerance.  At the end of the training program, the cephalic vein, commonly 
used to create an AV fistula, significantly increased in cross-sectional area by approximately two 
fold.  The authors concluded that this increase in vessel size and related increase in blood flow 
might accelerate the maturation of the AV fistula and reduce vascular access-related morbidities.     
Rus et al. (2003) investigated the effect of handgrip exercise prescribed daily for weeks in 
14 hemodialysis patients.  The exercises involved the use of a rubber ring (maximum 
compression force = 50N) and were performed using the non-fistula containing arm.  Twenty 
compressions per minute were performed for a total of 30 minutes.  No information regarding 
training progression was provided. At the end of the intervention period, the participants 
significantly increased measures of radial artery and average vein diameter.  Improvements in 
brachial artery endothelium-dependent vasodilation were also noted.  These effects highlight the 
importance of handgrip training prior to the construction of the AV fistula as a means to 
potentially improve fistula maturation. 
 
Hemodialysis-induced catabolism 
 Hemodialysis treatment, although essential for preserving life in patients with ESRD, also 
has negative consequences.  Recent investigations have shown the hemodialysis treatment itself 
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can induce skeletal muscle protein catabolism (Raj et al., 2004) marked by increases in pro-
inflammatory cytokines (IL-6) and catabolic markers including caspase-3, annexin-V, ubiquitin, 
and BCKAD-E2 (Raj et al., 2003).  Majchrzak et al. (2008) recently evaluated the effect of a 
single session of resistance exercise performed during hemodialysis treatment on protein kinetics 
in patients with ESRD both during and for 2hr post dialysis treatment.  The study employed a 
randomized crossover design.  Eight patients were allocated, in random order, to oral nutritional 
supplementation (NEPRO®) during dialysis and oral nutritional supplementation (NEPRO®) + 
resistance exercise during dialysis.  The investigators hypothesized that the addition of resistance 
exercise would lead to augment increases in skeletal muscle protein accretion as compared to 
nutritional supplementation alone.  Three sets of leg press exercise at 75% 1RM were prescribed 
during the combined (nutrition + resistance) condition. There were no statistically significant 
differences in protein homeostasis between conditions during dialysis treatment; however, in the 
post-treatment phase the condition involving resistance exercises resulted in a positive total 
amino acid balance and a significantly higher forearm muscle net protein balance when compared 
to nutritional supplementation alone.  No differences were noted in whole body protein balance.  
The researchers concluded that resistance training during dialysis might counteract dialysis-
induced protein catabolism.   
 Notably, however, a follow-up study by the same research group employing a nearly 
identical intervention over a 6-month period failed to elicit significant increases in lean body 
mass in patients randomized to oral nutritional supplementation + RT versus those randomized to 
oral nutritional supplementation only (Dong et al., 2011).  The null effect could have been 
attributed to the fact that only one RT exercise (i.e. leg press) was performed over the entire 6-
month intervention.   The authors acknowledged the need to test more rigorous RT prescriptions. 
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The efficacy of intradialytic RT  
 Painter et al. (1986) published the first study to investigate the efficacy of aerobic training 
(e.g. exercise cycling) prescribed during hemodialysis treatment.  This study, and approximately 
60 additional reports to date, have clearly demonstrated that exercise training during maintenance 
hemodialysis treatment is safe, can induce many clinically meaningful and statistically significant 
health-related adaptations and can result in better compliance than training during non-dialysis 
time (Konstantinidou, Koukouvou, Kouidi, Deligiannis, & Tourkantonis, 2002; Kouidi, Grekas, 
Deligiannis, & Tourkantonis, 2004).  The findings of studies prescribing intradialytic exercise 
have been summarized in several recent review articles that provide support for the integration of 
intradialytic exercise as best practice in ESRD (Cheema, 2008; Cheema, Smith, & Fiatarone 
Singh, 2005)     
 Investigations that have prescribed isolated high intensity and low intensity intradialytic 
RT have reported no life-threatening events, and few adverse events or symptoms (Bullani et al., 
2011; Cheema et al 2007a, 2007b, 2011; Chen et al., 2010; Johansen et al., 2006; Kopple et al., 
2007; Orcy et al., 2012).  Cheema et al. (2007a, 2007b) noted that high-intensity intradialytic RT 
did not exacerbate common dialysis-related complaints including headaches, hypotension, 
fistula/cannulation difficulties and cramping during a 24-week trial that prescribed intradialytic 
RT to 49 patients.  These findings have been supported by an additional randomized controlled 
trial (Chen et al., 2010).  Adverse events have generally been musculoskeletal (Bullani et al., 
2011; Cheema, Lassere, Shnier, & Fiatarone Singh, 2007).  For example, Cheema et al. (2007a, 
2007b) documented only one adverse event induced by the intradialytic RT program, a full-
thickness tear of a right supraspinatus muscle in an elderly woman.  Investigation suggested that 
the woman may have been predisposed to this injury (Cheema et al., 2007).   
 Recruitment data presented in recent randomized controlled trials suggest that the 
majority of patients in the conventional dialysis setting are medically eligible to engage in RT.  
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For example, of 278 patients reviewed by Johansen et al. (2006), only 60 (22%) were excluded 
for reasons of illness, medical instability, cognitive impairment, and cancer.  Others were 
excluded due to lower extremity amputation and active drug abuse, however these are not 
absolute contraindications to exercise, and modifications could be applied to the regimen to 
accommodate such individuals.  Cheema et al. (2007a) excluded only 26 of 142 patients (18%) 
due to a medical contraindication to intradialytic PRT, while Chen et al. (Chen et al., 2010) 
indicated that 66 of 250 patients (26%) did not meet their study eligibility criteria, which were 
mostly related to unstable chronic disease.  
Exercising during hemodialysis is often recommended as a more feasible, convenient, and 
time-effective solution to promote exercise adherence in ESRD (Cheema, 2008).  For example, 
delivering RT during dialysis may enhance compliance by removing the common cited barriers 
to exercise participation in this cohort including “lack of motivation,” “lack of time,” and 
“transportation difficulties (Cheema, 2008).  Further, patients are more likely to participate if it is 
considered normal, “part of the woodwork” and reinforced as beneficial to do so by other patients 
and the attending health care professionals.  While clinically trained exercise physiologists 
should ideally deliver the program, the endorsement of nephrologists, dialysis nursing staff and 
renal dietitians is critically important for continued success (Bennett et al., 2010). Unfortunately, 
many nephrologists and health care professionals appear unaware of the benefits and/or are 
indifferent to the idea (Johansen, Sakkas, Doyle, Shubert, & Dudley, 2003).  
Training packages are now available to establish a cost-effective RT program within any 
dialysis unit (Iqbal, 2007).  As programs become more widely practiced, the demand for novel 
equipment will be increased and, accordingly, the effectiveness of the interventions will be 
improved.  For example, a novel lower-body RT device customized for the hemodialysis setting 
has been recently developed by an Australian group (Bennett, Breugelmans, Agius, Simpson-
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Gore, & Barnard, 2007).  Established, training programs also provide a perfect venue for 
continued research.  
 
Exercise Recommendations 
 The research to date suggests that participation in RT is important for patients at high risk 
of developing CKD and for those diagnosed with CKD and ESRD.  RT can play an important 
role in targeting risk factors including type 2 diabetes, hypertension and obesity and hence can 
play a key role in reducing the CKD burden that has been forecast for the decades ahead (El 
Nahas & Bello, 2005).  Preliminary data suggest that RT can reduce the decline, or potentially 
improve renal function (GFR) in patients diagnosed with the CKD, which could potentially 
contribute to reduced growth of the dialysis population and the reduction of health care 
expenditures attributed to dialysis care.  Moreover RT has been shown to improve many 
important outcomes in patients with CKD and ESRD, including skeletal muscle wasting, 
inflammation, physical functioning, and quality of life.  Such adaptations may potentially 
contribute to greater life expectancy in this vulnerable patient population.  At present, more 
robust investigations are required to evaluate the efficacy of RT delivered across the CKD 
continuum, from at-risk individuals to individuals who have received successful kidney 
transplants.  A broad range of clinically relevant outcome measures should be investigated and 
greater efforts must be directed toward elucidating the relationship between these adaptations and 
survival advantage.      
 There are currently no standardized RT guidelines for individuals with CKD.   However, 
Johansen & Painter (2012) have provided general exercise recommendations that align with the 
American College of Cardiology and American Heart Association guidelines for exercise testing 
(Gibbons et al., 2002).  We have adapted and added to these recommendations in light of the 
latest research on RT in patients with CKD and ESRD presented in this chapter:   
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• Patients with CKD and ESRD are typically older, extremely deconditioned and suffer from a 
high burden of comorbidities.  All patients should undergo appropriate medical screening 
prior to participating in any structured RT program.  It is appropriate to refer patients with 
known cardiac disease to cardiac rehabilitation programs.  
• Exercise programs for patients with CKD should be individually tailored to meet the 
expectations, goals, needs and preferences of the individual patient.  Prescriptions should be 
holistic and involve aerobic training, RT, balance training and flexibility training elements.   
• Evidence suggests that the majority of patients with CKD and ESRD are capable of engaging 
in and benefitting from low- to high-intensity RT.  Training programs can be initiated at low 
dosages and progressed according to patient tolerance.     
• Trainers should be aware of drug-exercise interactions and pay vigilant attention to any 
untoward symptoms during training.  RT sessions should not be undertaken during acute 
illnesses. 
• Intradialytic RT can be safely undertaken by most hemodialysis patients and such programs 
can be successfully implemented at low cost with the involvement of exercise physiologists 
and the support of the dialysis nursing staff and nephrologists.       
• Intradialytic RT sessions should be initiated within the first two hours of treatment in 
individuals who commonly experience dialysis-induced symptoms (e.g. hypotension, 
cramping, headache, nausea, etc.).  
• Clinical, health and fitness-related outcomes should be assessed a regular intervals.  The 
findings of such assessments should be shared with the patient and health care providers, 
including the nephrologist and nursing staff.  
• Patients should always be referred to the appropriate allied healthcare professional in cases 
were the RT prescriber is not qualified to deal with the presenting illness or adverse event 
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• All patients with CKD should be encouraged to be as physically active as possible.  RT 
should be implemented to complement an active lifestyle.  Other forms of exercise should be 
encouraged (e.g. walking, cycling, yoga, Pilates, group exercise classes, etc.) 
 
 
Table 1: Stages of Chronic Kidney Disease as defined by the Kidney Disease Outcome Quality Initiative 
(K/DOQI)  
Stage Description GFR (mL/min/1.73 m2) Action 
1 Kidney damage with normal or elevated GFR ≥90  
Diagnosis and treatment, 
Treatment of comorbid 
conditions, slowing progression, 
cardiovascular disease risk 
reduction 
2 Kidney damage with mild decrease in GFR 60-89 Estimating rate of progression 
3 Moderate decrease in GFR  30-59 
Evaluating and treating 
complications 
4 Severe decrease in GFR 15-29 Preparation for kidney replacement therapy 
5 Kidney Failure <15 of dialysis dependent Kidney transplanted or receiving dialysis 
Reference:  K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and 
stratification. Am J Kidney Dis, 39, S1-266, 2002. 
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Table 2. Resistance training interventions in CKD and ESRD 
 
Subject 
Characteristics 
Resistance Type Training Prescription 
Dependent Variables 
of Interest 
Key Findings in isolated 
RT group 
Castaneda et 
al. 2001, 2004 
Balakrishnan 
et al., 2010 
Stage 3-4 CKD 
14 TRN; 12 P  
TRN= knee flexion and extension, lat 
pull-down, chest and leg press;  
P=sham movements 
3 sets of 8 reps at 80% 1RM, 
3x/wk for 12 wks.  1RM 
testedeach month to adjust 
loading 
GFR, muscle CSA, 
pro-inflammatory 
cytokines, mtDNA 
Sig. ↑ in type I, type II 
CSA, GFR, total body 
potassium, leucine 
oxidation, prealbumin, 
mtDNA, Sig. ↓ in CRP and 
IL-6. 
Heiwe et al. 
2001, 2005 
Pre-dialysis CKD 
16 TRN,  
9 CNTL  
TRN = knee extensions  
CNTL= no training 
3 sets of 20 reps of knee ext at 
60% 1RM, 3x/wk for 12 wks.  
1RM tested every 2 weeks to 
adjust loading  
muscle fiber CSA, 
hematological data, 
functional measures, 
QoL  
No Δ in muscle fiber CSA 
or QoL, Sig. ↑ in 1RM, 
muscle endurance, six-min 
walk, Sig. ↓ in ‘timed up 
and go’  
Headley et al. 
2002 
Nindl et al.  
2004 
ESRD 
10 TRN 
During non-dialysis time; machine 
weights: leg press, knee extension and 
flexion, chest press, compound row, 
lateral raises, biceps curls, triceps 
extensions and abdominal curls.  
1 set of 10-15 reps, 2x weekly 
at initiation, gradual increase 
of set/reps every 2-3 weeks.  
Loads increased with 
adaptation 
isometric strength, 
functional measures, 
CRP 
 
Sig ↑ in quad isometic 
strength, six-min walk 
maximal walking speed 
Sig. ↓ in CRP, 
sit to stand time 
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Cheema et al. 
2007a, 2007b 
2011 
ESRD 
24 TRN  
19 WLC 
Intradialytic RT; free weights: shoulder 
press, side shoulder raise, triceps 
extension, bicep curls, external 
shoulder rotation and bilateral leg 
raise/leg lift; ankle weights: knee 
extension, hip flexion and hip 
abduction; elastic tubing: hamstring 
curl.  
2 sets of 8 reps at RPE 15-17, 
3x/wk for 24 weeks. WLC 
group crossed-over to 
intervention at week 13  
thigh muscle CSA and 
attenuation, CRP and 
other cytokines, 
anthropometics,  
functional measures, 
QoL 
 
Sig. improved muscle 
attenuation, CRP, 
anthropometics, total body 
strength, physical function 
and vitality QoL 
No Δ in IL-1b, IL-6, IL-8, 
IL-10, IL-12 and TNF-α  
Johansen et al. 
2006 
ESRD 
19 TRN+ND, 
16 TRN+P, 17 P 
 
Intradialytic RT; ankle weights:  knee 
extension, hip abduction and flexion, 
ankle dorsiflexion and plantar flexion.  
2-3 sets of 10 reps 60% 3RM, 
3x/wk for 12 weeks 
lean body mass, thigh 
muscle CSA, strength 
measures, functional 
measures, QoL  
No Δ in lean body mass 
Sig. ↑ in quadriceps CSA, 
strength measures and 
physical function QoL. No 
Δ in gait speed, sit to stand 
or stair climbing 
Chen et al.  
2010 
ESRD 
22 TRN, 22 P 
Intradialytic RT; ankle weight: knee 
extension and flexion, hip adductor and 
straight leg dorsi/plantar flexion. Seated 
pelvic tilt without free weight.  
2 sets of 8 reps at moderate 
RPE (6/10) 2x/wk for 48 
sessions 
 
functional measures, 
body composition, 
QoL and perceived 
ADL disability 
 
Sig. ↓ in sit to stand, body 
fat and ADL disability 
Sig. ↑ in knee ext strength, 
lean body mass, physical 
functioning QOL 
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Kopple et al. 
2007 
ESRD 
15 TRN, 15 P 
Just prior to dialysis sessions; machine 
weights: knee extension and flexion, 
leg press and calf extension.  
Wk 1–4: 1 set of 12-15 reps at 
70% 5RM; Wk 5–8: 2 sets of 
12-15 reps to tolerance; After 
wk 8: 3 sets of 6-8 reps at 
80% 5RM; 3x/wk for 21 
weeks 
Anabolic and catabolic 
gene expression, body 
composition, CRP, 
TNF-α, IL-6 
Sig ↑ in muscle mRNA 
IGF-IEa; Non sig ↑ in other 
muscle mRNA levels 
except; Non sig. ↓ in 
mRNA myostatin  
Sig ↑ in IGF-I protein.  
No Δ in CRP, TNF- α, IL-6, 
lean body mass or body fat  
Bullani et al.  
2011 
ESRD 
11 TRN 
Intradialytic RT; elastic bands with 7 
graded resistance: flexion and 
extension at foot, knee and hip; hip 
abduction and adduction.  
Initial 2-4 wk learning phase, 
then 3 sets of 20 repetitions at 
moderate RPE, resistance 
increased as tolerated, 2x/wk 
for 4.5 to 6 months 
functional measures 
  
Sig ↑ in Tinetti score (gait 
and balance); Sig ↓ in 
‘timed up and go’; No Δ in 
one leg balance or six-min 
walk  
Orcy 2012 
ESRD 
13 TRN (RT) 
13 TRN (RT+AT) 
 
Elastic bands, dumbbells, and ankle 
weights of 1-2lbs. Elbow flexor, 
shoulder flexors, hip flexors with knees 
flexed/extended, hip abductor. 
Hamstring curl against a therapeutic 
ball.  
3-4 sets of 10-15reps,  3x/wk 
for 10 wk, progression as 
tolerated.  
Six-minute walk  No Δ in six-min walk 
Oder & 
Uribarri 2003 
ESRD 
23 TRN 
Rubber ball for repetitive squeezing 
handgrip 
Single session, 5 min ball 
squeezing.  
Fistula diameter Acute sig ↑ fistula diameter 
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Leaf et al.  
2003 
Stage 3-4 CKD 
5 TRN 
Handgrip dynamometer for isometric 
handgrip 
Squash ball and racquet ball for 
repetitive handgrip 
Handgrip dynamometer: 30-
40% of MVC for 80–360s, 
plus  
repetitive ball squeezing, 
4x/wk for 6 months 
Cephalic vein size 
CSA 
Sig ↑ in vein CSA with/ 
without tourniquet 
Rus et al. 2003 
ESRD 
14 TRN 
Rubber ring (max compression force = 
50N) for repetitive handgrip exercise 
20 compression/min for 
30min, every day for 8 weeks 
Radial and brachial 
arteries blood flow, 
and diameter 
Vein diameter  
sig ↑ in radial artery and 
average vein diameter, and 
brachial artery endothelial 
function 
Majchrzak et 
al. 2008 
ESRD 
8 TRN+oral 
nutrition 
Intradialytic RT; patients ambulated to 
resistance machine for leg press 
Single session. 3sets of 12reps 
at 75%1RM 
total amino acid 
balance, forearm 
muscle protein 
balance, whole body 
protein balance 
Positive total amino acid 
balance post-dialysis (non-
sig ↑); Sig ↑ in forearm 
muscle protein balance; no 
Δ in whole body protein 
balance 
Dong et al  
2011 
ESRD 
10 TRN+oral 
nutrition, 12 oral 
nutrition 
Just prior to dialysis sessions; 
Pneumatic resistance leg press 
3 sets of 12reps at 70%1RM. 
1RM re-assessed at month 3 
and 6, 3x/wk, 6 months   
leg press 1RM, 
body composition 
 
No Δ in 1RM, percent body 
fat or lean body mass 
TRN= training, P=placebo, CNTL = control, CSA=cross-sectional area, 1RM = one repetition maximum, RPE = rating of perceived exertion, ND = Nandrolone decanoate, 
IGF = Insulin-like growth factor, IL= Interleukin, MVC = Maximum voluntary contraction, QoL=quality of life, RT = Resistance Training, AT = Aerobic Training 
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ABSTRACT 
 
Background:  Skeletal muscle wasting resulting in reduced muscular strength and health-related 
quality of life (HRQoL) is common in chronic kidney disease (CKD) and may be reversed with 
progressive resistance training (PRT).  Therefore, we systematically assessed the effect of PRT 
on measures of skeletal muscle hypertrophy, muscular strength and HRQoL in this cohort to 
inform clinical practice and guidelines.  
Design: Systematic review and meta-analysis. 
Inclusion criteria:  Randomized controlled trials (RCTs) that investigated the independent effect 
of PRT (>6 weeks) on measures of skeletal muscle hypertrophy (muscle mass or cross-sectional 
area [CSA]), muscular strength and/or HRQoL in adults with CKD. 
Data extraction and analysis:  The standardized mean difference (SMD) from each study was 
pooled to produce an overall estimate of effect and associated 95% confidence interval (95% CI) 
between treatment and control groups on primary outcomes.   
Results:  Seven RCTs in 271 patients with Stage 3-5 CKD yielded seven studies on muscular 
strength (N=249), six studies on total body muscle mass (N=200), and six studies on HRQoL 
(N=223).  PRT significantly improved standardized muscular strength (SMD = 1.15 [95% CI = 
0.80 to 1.49]) and HRQoL (SMD = 0.83 [95% CI = 0.51 to 1.16]), but not total body muscle 
mass (SMD = 0.29 [95% CI = -0.27 to 0.86]) in our primary analysis.  However, secondary 
analysis of six studies showed that PRT induced significant muscle hypertrophy of the lower 
extremities (leg mass, or mid-thigh or quadriceps CSA) (SMD = 0.43 [95% CI = 0.11 to 0.76]), a 
pertinent analysis given that most studies implemented lower body PRT only.   
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Conclusions:  Robust evidence from RCTs indicates that PRT can induce skeletal muscle 
hypertrophy and increase muscular strength and HRQoL outcomes in men and women with 
CKD.  Therefore, clinical practice guidelines should be updated to inform clinicians on the 
benefits of PRT in this cohort.   
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1.  INTRODUCTION 
 
According to the United States Renal Data System, over 15% of the adult population in 
the United States (US) has chronic kidney disease (CKD) [1], while global estimates reveal a 
burgeoning epidemic (8-16% prevalence) [2].  These trends are being driven largely by escalating 
rates of obesity and type 2 diabetes [3].  The prevention and treatment of CKD will present a 
major challenge for healthcare systems in the coming decades [3].  A major part of this challenge 
will involve providing quality care to patients with advanced CKD, including those with pre-
dialysis (Stage 3-4 CKD) and end-stage renal disease (ESRD) [3].  
Skeletal muscle wasting is common in advanced CKD [4-6] due to factors such as 
sedentary behavior [7], acidosis [8], co-morbid illnesses, corticosteroid usage, aging, oxidative 
stress, dialysis treatment [9], insulin resistance, chronic inflammation and protein-restricted diet.  
This wasting contributes to reductions in muscular strength and associated functional impairment 
[10-12].  Functional impairment, in turn, contributes to impaired health-related quality of life 
(HRQoL), particularly the physical dimension of HRQoL [13].  Many investigations have shown 
that muscle wasting [14], loss of functional activities [15] and/or low HRQoL contribute to 
greater hospitalization and all-cause mortality in patients with CKD [16-18].    
Progressive resistance training (PRT) has been shown to induce skeletal muscle 
hypertrophy and improve functioning and HRQoL in older adults and those with advanced 
chronic diseases [19].  Since there is an association of muscle wasting in CKD with high 
morbidity and mortality, it has been hypothesized that PRT may be important in terms of clinical 
outcomes in this patient population as well [20-24]. In fact, Exercise and Sport Science Australia 
has recently recommended PRT as a central component of the exercise prescription for patients 
with CKD [25].  Since 2001, a number of randomized controlled trials (RCTs) have investigated 
the independent effect of PRT on measures of skeletal muscle hypertrophy and related health 
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outcomes in patients with CKD [26-32].  However, there is currently no consensus regarding the 
effectiveness of PRT for counteracting catabolic disease outcomes in this cohort [25].  
Accordingly, PRT is not routinely prescribed [33] and recommendations for undertaking this 
form of exercise remain absent from CKD clinical practice guidelines [34].  
Our initial analysis of the published literature indicated an absence of high quality 
reviews specifically elucidating the effect of PRT in patients with CKD.  We therefore conducted 
a systematic review of the literature to assess the independent effect of PRT on measures of 
skeletal muscle hypertrophy, muscular strength and HRQoL in patients with CKD to inform 
clinical practice and guidelines.    
 
2.  METHODS 
 
2.1 Search strategy 
A systematic review of all published literature using the following electronic databases 
was conducted in June 2013: MEDLINE (OvidSP, Wolters Kluwer), PubMed (NCBI, U.S. 
National Library of Medicine), ScienceDirect (SciVerse, Elsevier), SPORTDiscus (EBSCOhost, 
EBSCO), Scopus (SciVerse, Elsevier), Web of Science (Web of Knowledge, Thomson Reuters), 
the Cochrane Library (John Wiley & Sons), Embase (OvidSP, Wolters Kluwer), CINAHL, and 
Google Scholar.  Search syntaxes were developed in consultation with an experienced university 
librarian taking into account a broad range of terms and phrases used in definitions related to 
CKD (e.g. chronic kidney disease, hemodialysis, end-stage renal disease, etc.) and resistance 
training (e.g. resistance training, resistance exercise, weight training, weight lifting, strength 
training, etc.).   Sample search strategies (PubMed and Scopus) have been presented in Electronic 
Supplementary Material, Appendix S1.  Reference lists of retrieved full-text articles and recent 
reviews were examined to identify additional articles not found by our search.   
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2.2 Study selection 
Electronic references were compiled in an Endnote X6© (Thomson Reuters) file and 
duplicates were identified and deleted.  Two authors (BSC and DC) independently reviewed the 
titles and abstracts of each reference for potential inclusion.  Each reviewer then performed a 
second screening on the full text version of these articles, and disagreements were resolved by 
discussion.  RCTs that investigated the independent effect of PRT intervention on measures of 
skeletal muscle hypertrophy (muscle mass or cross-sectional area [CSA]), muscular strength 
and/or HRQoL in adults with CKD (Stage 1 to 5) were eligible.  PRT interventions may have 
included, but were not restricted to, any form of resistive type exercise using body weight 
(calisthenics), equipment (machine weights, free weights) or apparatus (elastic bands), and had to 
have been at least six weeks in duration.  There were no language restrictions for articles.    
 
2.3 Primary outcomes 
The primary outcomes were the mean difference in measures of skeletal muscle 
hypertrophy (muscle mass or CSA), muscular strength and HRQoL after intervention (post-
treatment) between the treatment and control (e.g. non-treatment, placebo-treatment) group.  
Where multiple muscular strength outcomes were reported, we prioritized lower body over upper 
body measures, and knee extension over other lower body measures.  Where multiple measures 
of muscle mass or CSA were reported, we prioritized measures of muscle mass over CSA, and 
whole body over regional measures. Where multiple HRQoL outcomes were reported, first we 
prioritized subscales then summary measures of the physical component of HRQoL.  
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2.4 Data extraction  
Data extraction and quality assessment of included studies were performed and/or verified 
independently by three reviewers (BSC, DC and PF).  Discrepancies were resolved through 
discussion.  Authors of relevant studies were contacted, where possible, for data that could not be 
extracted from the published articles.  
 
2.5 Quality assessment 
The following data were extracted from included studies using a standard proforma: study 
design, study population characteristics, PRT intervention (e.g. specific exercises, number of sets 
per exercise, number of repetitions per set, intensity (load), frequency and duration of training 
and loading progression).  Our quality checklist was designed based on established criteria for the 
assessment of RCTs [35].  Quality items for RCT studies reviewed were (each worth 1.0 
numerical point) as follows: (1) evidence of randomization and concealment of treatment 
allocation, (2) statistical similarity of groups at baseline, (3) specification of eligibility criteria, 
(4) blinding of outcomes assessors, (5) reporting of compliance, (6) supervision of exercise 
sessions, (7) reporting of dropouts, (8) presenting data for primary and secondary outcomes, (9) 
use of intention-to-treat analysis, and (10) reporting of adverse events.  Summed scores to range 
from 0 to 10 points with higher scores reflecting better quality.  Data extraction and quality 
assessment were completed and checked by two reviewers (BSC and DC).   
 
2.6 Data synthesis  
Three reviewers (DC, BSC and EA) independently collated and/or verified extracted data 
to present a descriptive synthesis of important study characteristics and a quantitative synthesis of 
effect estimates. 
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2.7 Secondary outcomes 
The secondary outcomes were data about adverse events for a descriptive synthesis. 
 
2.8 Statistical methods  
We pooled and weighted studies first using random effects meta-analysis models, and 
second using fixed effects models for verification [36].  The effect was measured as the 
difference between groups in the improvement in outcome over the treatment period.  Where 
papers did not present the mean and standard deviation of the improvement in outcome, we 
estimated these from the pre- and post-treatment standard deviations [37].  This estimation 
requires an estimate of the pre- post correlation which we obtained from papers which provided 
pre-, post- and change means and standard deviations [37].  As the estimated correlations were 
quite consistent across studies (Electronic Supplementary Material, Table S1) we used the 
average correlation in our calculations.    
In examining the effects of PRT on skeletal muscle hypertrophy, muscular strength and 
HRQoL outcomes, the standardized mean difference (SMD) from each study was pooled to 
produce an overall estimate of effect and associated 95% confidence interval (95% CI) between 
treatment and control groups.  For each meta-analysis model, the degree of heterogeneity in 
SMDs was assessed by visual inspection, the I2 statistic (moderate being < 50%) [38] and the χ2-
test of goodness of fit [39].  Where evidence of heterogeneity was observed, we checked data 
extracted from individual outlier studies, qualitatively investigated reasons for their different 
results, and explored the effects of study exclusion in sensitivity analyses.  
The subset of studies examining the impact of PRT on lean body mass (in kilograms) as 
measured by dual-energy X-ray absorptiometry (DEXA) were pooled to estimate the inverse 
variance weighted mean difference (WMD), including the DerSimonian and Laird 95% CI, 
between cases and controls.  This preserved the original measurement units.  We also used 
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sensitivity analysis to investigate the robustness of the meta-analyses models. We variously 
excluded studies that combined PRT with other therapies (including hemodialysis), studies in 
older patients (> 60 years), studies conducted outside the US, longer duration trials (≥ 12 weeks), 
and studies of lower quality (score < 6.0).  Publication bias, which reflects the tendency for 
smaller studies to be published in the literature only when findings are positive, was assessed 
visually using funnel plots [40].  All calculations were performed in Stata version 12 (StataCorp, 
College Station, TX, USA) using the 'metan' and 'metafunnel' commands.  A two-tailed P-value < 
0.05 was considered statistically significant throughout the analyses.  
 
3.  RESULTS 
 
Figure 6.1 presents a flowchart summarising identification of potentially relevant studies, 
and those included.  Our search strategy identified 187 citations after duplicates were removed. 
Of these, 164 citations were excluded after the first screening of titles and/or abstracts for 
inclusion and exclusion criteria.  After further assessment of the remaining 23 citations, 16 were 
excluded (Electronic Supplementary Material, Appendix S2) for reasons listed in Figure 6.1, 
leaving 7 for inclusion in the review.  Most citations were excluded due to no randomization or 
due to being redundant citations of the same study. 
 
3.1 Descriptive data synthesis 
Table 1 presents study characteristics of the seven RCTs included for review, which were 
published between 2001 and 2013.  Four of seven studies were conducted in the US [26, 28, 30, 
31] with others conducted in Australia [27], Brazil [29], and South Korea [32].  The major 
inclusion criterion was pre-dialysis (Stage 3-4) CKD [30] or ESRD [26-29, 31, 32].  All studies 
in ESRD involved maintenance hemodialysis patients.  In most of these studies it was noted that 
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the patients were adequately dialyzed (Kt/V>1.2) and receiving dialysis treatment for more than 3 
months.  Major exclusion criteria primarily emphasized uncontrolled cardiovascular diseases and 
other conditions that would contraindicate PRT.  Analysed sample sizes ranged from 22 to 68, 
resulting in a total of 271 participants across studies.  Mean age of the samples ranged from 43 to 
69 years.  All studies enrolled both men and women.  PRT interventions were prescribed two to 
three times per week during hemodialysis treatment in four studies with all employing weighted 
ankle cuffs [26-29].  Only three studies targeted both the upper and lower body musculature with 
PRT exercises [27, 30, 32], while four targeted the lower body musculature only [26, 28, 29, 31].  
Two studies prescribed PRT just prior to each hemodialysis treatment session (3 sessions/wk) 
using machine weights [31] or elastic bands and sandbags [32].  Only one study was conducted in 
patients not receiving hemodialysis and prescribed PRT using standard machine weights three 
sessions per week [30].  Three studies compared PRT intervention to usual care (no exercise) [27, 
29, 32], one study compared PRT to stretching exercise using light resistance bands [28], one 
study compared PRT plus nutritional supplementation with nutritional supplementation only [31] 
and one study compared PRT plus a protein restricted diet to protein-restricted diet only.  Further, 
a study by Johansen et al. [26] compared PRT + anabolic steroid (i.e. nandrolone decanoate) to 
anabolic steroid only and PRT + placebo to placebo only.  Hence, this study was included as two 
separate comparisons in relevant meta-analyses.  Trial durations ranged from 8 to 24 weeks.   
Primary outcomes were muscular strength measures evaluated by knee extension [26-28, 
30] and leg press [31, 32], total body muscle mass measures evaluated by total body potassium 
[30], DEXA [26, 28, 31] and bioelectrical impedance analysis (BIA) [32], mid-thigh muscle CSA 
evaluated by computed tomography (CT) [27, 30], quadriceps muscle CSA evaluated by 
magnetic resonance imaging (MRI) [26], lean leg mass evaluated by DEXA [28, 31], and the 
physical dimension of HRQoL evaluated by the Medical Outcomes Trust Short Form-36 (SF-36) 
physical functioning domain [26, 27, 29] and physical component summary scale [28, 32].  Mean 
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quality scores ranged from 5.5 to 9.5, and five studies received a score of 8.0 or higher 
(Electronic Supplementary Material, Table S2).  
 
3.2 Quantitative data synthesis 
Figure 2 presents the SMD for muscular strength outcomes after PRT between the 
treatment and control groups. PRT significantly improved standardized muscular strength 
outcomes compared with control conditions (SMD = 1.15 [0.80, 1.49]), and there was only slight 
evidence of statistical heterogeneity between studies (I2=35.0%, P=0.161).  The sensitivity 
analyses presented in Table 2 shows that the pooled SMD was similarly large in the fixed effect 
model after each of the various studies was excluded (SMD = 0.82 to 1.36).  In addition, a funnel 
plot was produced and showed little evidence of publication bias, since the SMD in muscular 
strength outcomes was consistently medium to large in all studies (Electronic Supplementary 
Material, Figure S1).  
Figure 3 presents the SMD for total body muscle mass outcomes after PRT between the 
treatment and control groups.  Our primary analysis revealed that PRT failed to increase 
standardized total body muscle mass outcomes compared with control conditions (SMD = 0.29 [-
0.27, 0.86]; I2=73.5%, P=0.002).  A funnel plot showed no evidence of publication bias 
(Electronic Supplementary Material, Figure S2).  The sensitivity analyses showed that this null 
effect was comparable after each of the various studies was excluded (Electronic Supplementary 
Material, Table S3).  Conversely, PRT significantly improved total body muscle mass in the 
fixed effect model (SMD = 0.34 [0.05, 0.63]) but the fixed effect assumption was violated given 
the strong evidence of statistical heterogeneity between studies (I2=73.5%, P=0.002).   
Given that the majority of trials reviewed investigated the effect of lower body PRT only 
(Table 1), we pooled studies to investigate the SMD in lower body muscle mass and CSA 
outcomes in a secondary analysis (Figure 4).  This analysis of six studies showed that PRT 
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induced significant muscle hypertrophy of the lower extremities (leg mass, or mid-thigh or 
quadriceps CSA) (SMD = 0.43 [0.11, 0.76]; I2 =26.8%, P=0.234).  A funnel plot showed little 
evidence of publication bias (Electronic Supplementary Material, Figure S3).  Additionally, we 
pooled studies to estimate the inverse variance weighted mean difference (WMD) in muscle mass 
outcomes after PRT between the treatment and control groups.  PRT significantly improved 
quadriceps muscle CSA measured by MRI (pooled WMD for two studies [26] was 3.83 cm2 
[1.73, 5.94]; I2=1.0%, P=0.315), but not total body muscle mass measured by DEXA only 
(pooled WMD for four studies [26, 28, 31] was -0.06 kg [-1.94, 1.83]) or thigh muscle CSA 
measured by CT (pooled WMD for two studies [27, 30] was 3.03 cm2 [-0.15, 6.21]).   
Figure 5 presents the SMD for HRQoL outcomes after PRT between the treatment and 
control groups.  PRT significantly improved standardized HRQoL outcomes compared with 
control conditions (SMD = 0.83 [0.51, 1.16]), and there was little evidence of statistical 
heterogeneity between studies (I2=27.8%, P=0.226).  The sensitivity analyses presented in Table 
3 shows that the pooled SMD was similarly large in the fixed effect model and after each of the 
various studies was excluded (SMD = 0.70 to 0.94).  In addition, a funnel plot was produced and 
showed little evidence of publication bias, since the SMD in HRQoL outcomes was consistently 
medium to large in all studies (Electronic Supplementary Material, Figure S4). 
 
3.3 Adverse events  
 Four studies reported that no adverse events occurred as a consequence of PRT [27, 28, 
30, 32].  One study that prescribed intradialytic PRT reported no statistically significant 
differences between the experimental and control group in the number of dialysis-related 
complaints (i.e. headache, hypotension, cramping, and fistula cannulation difficulties), falls, 
acute illnesses, and number of visits to health care professionals [27].  However, one adverse 
event was documented in this study: A 73-year-old woman in the PRT group sustained a partial 
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tear of the right supraspinatus.  The injury was documented [41] and managed conservatively; the 
patient resumed lower body PRT for the remainder of the trial [27].  One study reported on 
adverse events related to anabolic steroid use, but not in relation to PRT [26].  Two studies did 
not report on adverse events [29, 31].  
 
4.  DISCUSSION 
 
4.1 Summary of the evidence 
Based on RCT evidence in patients with CKD, our results were consistent and indicate 
that PRT significantly improves measures of muscular strength (SMD = 1.15 [0.80, 1.49]) and 
HRQoL (SMD = 0.83 [0.51, 1.16]).  There was an absence of evidence showing that PRT 
significantly increases total body muscle mass (SMD = 0.29 [-0.27, 0.86]).  However, secondary 
analysis of lower body muscle mass and CSA outcomes (i.e. leg mass, or mid-thigh or quadriceps 
CSA) revealed a significant effect for PRT versus control conditions (SMD = 0.43 [0.11, 0.76]), a 
pertinent analysis given that the majority of trials (4/7) were limited to lower body training [26, 
28, 29, 31].  Overall, this robust evidence from RCTs indicates that PRT can induce skeletal 
muscle hypertrophy and increase muscular strength and HRQoL with no risk of serious adverse 
events in men and women with CKD.   
The size of the effect of PRT on these key outcomes is moderate to large, and clinically 
relevant.  For instance, studies have consistently shown that skeletal muscle wasting is a strong 
predictor of mortality in patients with ESRD [14, 42, 43], and a recent observational study noted 
that the loss of muscle is particularly rapid in pre-dialysis CKD [10].  Carrero et al. [43] have 
shown that incident and prevalent hemodialysis patients (dialysis vintage = 8 to 78 months) with 
mild to moderate/severe muscle wasting (SMD = 0.38 to 0.69) suffer a greater risk of systemic 
inflammation (odds ratio = 2.81 [1.33, 5.91]), cardiovascular disease (odds ratio = 3.08 [1.43, 
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6.65]) and all-cause mortality (hazard ratio = 1.29 to 3.04) compared to CKD patients with no 
evidence of muscle wasting.  Similarly, studies have shown that the loss of muscular strength 
(SMD = 0.66) is associated with significantly greater risk of renal endpoint (i.e. pre-dialysis 
mortality or reaching ESRD) in CKD [44] while impairments in the physical component of 
HRQoL (SMD = 0.60) have been shown to predict mortality [45].  Therefore, the results of our 
study suggest that the size of the effect of PRT on skeletal muscle hypertrophy (SMD = 0.43 
[0.11, 0.76]), muscular strength (SMD = 1.15 [0.80, 1.49]) and HRQoL (SMD = 0.83 [0.51, 
1.16]), which could be expected in practice, could theoretically protect against disease-related 
complications and reduce the mortality burden in patients with CKD.  Hence, our findings are 
clinically relevant.    
Notably, the effect of PRT on muscle strength and HRQoL outcomes remained robust in 
fixed effect models and after exclusion of studies that combined PRT with other therapies 
(including hemodialysis), studies in older patients, studies conducted outside the US, longer 
duration trials, and studies of lower quality.  In summary, our results indicate that PRT should be 
considered for inducing muscle hypertrophy and increasing muscular strength and HRQoL 
outcomes in men and women with CKD.  
 
4.2 Limitations  
Several limitations require careful consideration.  Since only a small number of studies 
were included, the findings of this review may not be relevant to other countries and key groups 
within the CKD population.  In particular, most of the RCTs reviewed were conducted in patients 
with ESRD undergoing hemodialysis treatment, while only one trial enrolled patients with pre-
dialysis CKD.   We found no RCTs that tested the efficacy of PRT in patients undergoing 
peritoneal dialysis or kidney transplant and hence research on these unique CKD populations is 
required.  Second, there was heterogeneity with respect to the exercise prescriptions (Table 1).  
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Several studies did not prescribe full body PRT, while others prescribed low-intensity [26, 29] or 
few exercises [26, 29, 31], factors that can potentially reduce the effectiveness of PRT.  It has 
been shown that patients with CKD can safely tolerate higher intensity and more comprehensive 
PRT regimens (i.e. involving a greater number of exercises) [27, 30].  Such programs, involving 
longer training durations, are likely to be most effective in terms of adapting outcome measures.  
However, we did not investigate any dose-response effects in the present review and accordingly, 
the optimal dosages of PRT to adapt the specific outcomes in this cohort remain unknown and 
require further research.  Finally, combined across all studies, the total number of participants is 
relatively modest (n = 200 to 249).   
 
5.  CONCLUSIONS 
 
We believe that our meta-analytic results are sufficiently reliable to recommend that 
clinicians consider prescribing PRT for inducing skeletal muscle hypertrophy and increasing 
muscular strength and  HRQoL outcomes in patients with CKD.  Future high quality research is 
needed to clarify the long-term clinical benefits and risks of PRT in this cohort. 
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Table 1: Characteristics of randomized controlled trials reviewed 
Reference Sample 
(n) 
Population Mean 
age (y) 
Treatments  Control 
conditions 
Trial 
duration 
(wk) 
Outcomes 
(assessments; units) 
Quality 
score (/10) 
    Inclusion criteria Exclusion criteria             
Castaneda et al, 
2001 
USA 
26 Serum creatinine 1.5-5.0 mmol/l; 
physician approval to follow low-
protein diet; confirmed CKD 
diagnosis by nephrologist (via 
renal biopsy and clinical records) 
Myocardial infarction within 
previous 6 mo.; any unstable 
chronic condition, dementia, 
alcoholism, dialysis or 
previous renal transplant; 
current resistance training; 
recent involuntary weight 
change; albumin <30 g/l, 
proteinurea >10 g/l; 
abnormal exercise stress test 
results 
65 Standard PRT using machine 
weights (knee extension, 
knee flexion, lat pull down, 
chest press, leg press) 3 sets 
x 8 reps at 80% 1RM, 3 
sessions/wk, 1RM tested 
each month to adjust loading, 
plus protein-restricted diet 
(0.6 g/kg per day) 
protein-restricted 
diet (0.6 g/kg per 
day) 
12 Muscle (total body 
potassium (kg), mid-
thigh muscle CSA via 
CT (cm2), type I and II 
muscle fibre CSA 
(µm2)); dynamic 1RM 
upper body strength 
(chest press, lat 
pulldown; kg), dynamic 
1RM lower body 
strength (leg press, knee 
extension, knee flexion; 
kg) 
8.5 
Johansen et al, 
2006 
USA 
68 Adequate dialysis (Kt/V≥1.2) and 
compliant with hemodialysis 
treatment (i.e. missing <2 
treatment sessions over previous 
month) 
Hemodialysis <3 mo.; 
catabolic state (e.g. HIV 
with opportunistic infection, 
malignancy, or infection 
requiring intravenous 
antibiotics over prior 2 mo.; 
unable to provide informed 
consent; active intravenous 
drug use; thigh graft; 
contraindications to PRT 
56 (a) PRT during dialysis using 
weighted ankle cuffs (knee 
extension, hip abduction and 
flexion, ankle dorsiflexion 
and plantarflexion), 2–3 sets 
x 10 reps at 60% 3RM, 3 
sessions/wk, weights 
increased when patient could 
perform 3 sets x 10 reps, plus 
placebo injection weekly                                                                                                    
(b) Intervention a + 
nandrolone decanoate 
injection weekly (men=200 
mg/dose; 
women=100mg/dose) 
(a) placebo 
injection weekly                     
(b) nandrolone 
decanoate 
injection 
administered 
weekly (men=200 
mg/dose; 
women=100mg/d
ose)
12 Muscle  (lean body mass 
via DEXA (kg), 
quadriceps muscle CSA 
via MRI (cm2), serum 
creatinine (mg/dl)); 
dynamic lower body 
strength (knee extension, 
hip abduction, hip 
flexion; lb.); isokinetic 
lower body strength 
(knee extension at 90 
and 120 deg/s; Nm); 
HRQoL (SF-36 physical 
function) 
8 
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Cheema et al, 
2007 
Australia 
49 Adult (≥18 yr); hemodialysis >3 
mo.; independent ambulation 
with or without assistive device; 
adequately dialyzed (Kt/V≥1.2); 
stable during dialysis; ability to 
provide written informed 
consent; willingness to be 
randomly assigned and undergo 
protocols 
Acute or chronic medical 
conditions that would 
preclude PRT or collection 
of outcome measures 
63 PRT during dialysis using 
weighted dumbbells 
(shoulder press, side shoulder 
raise, triceps extension, 
biceps curl, external 
rotation), weighted ankle 
cuffs (seated knee extension, 
supine hip flexion, supine hip 
abduction, supine straight-
legged raise), elastic tubing 
(seated hamstring curl) and 
body weight (bilateral leg 
raises - seated or supine), 2 
sets x 10 reps at RPE 15-17, 
3 sessions/wk 
usual care (no 
exercise) 
12 Muscle (mid-thigh 
muscle CSA via CT; 
cm2); total body 
isometric muscular 
strength (knee extensor + 
hip abductor + tricep, 
kg); isometric knee 
extensor strengtha (kg); 
HRQoL (SF-36 physical 
function) 
9.5 
Chen et al, 2010 
USA 
44 Age ≥30 yr; serum albumin <4.2 
g/dl and hemodialysis thrice 
weekly for >3 mo. with ≥80% 
compliance 
Unstable cardiovascular 
disease; any uncontrolled 
chronic condition; cardiac 
surgery, retina laser therapy, 
myocardial infarction, joint 
replacement or lower 
extremity fracture in 
previous 6 mo.; severe 
cognitive impairment; lower 
extremity amputation; 
current strength training 
69 PRT during first 2hr of 
hemodialysis using weighted 
ankle cuffs (knee extension, 
dorsi/plantar flexion, leg curl, 
inner leg raises, dorsi/plantar 
flexion with straight legs, 
seated pelvic tilt) first 8 
sessions with no loading 
(RPE 2-4/10) progressed to 
1-2 sets x 8 reps (RPE 6/10), 
2 sessions/wk  
Stretching 
exercises using 
light resistance 
bands, 2 sets, 20-
30s/stretch 
18 Muscle (lean whole-
body mass and lean leg 
mass via DEXA (kg); 
muscle strength (knee 
extensor; kg), HRQoL 
(SF-36 physical and 
mental component 
summary scales) 
8 
Dong et al, 2011 
USA 
22 Age >18 yr; thrice weekly 
hemodialysis for >3 mo.; 
adequate dialysis (Kt/V >1.2), 
using a biocompatible dialysis 
membrane 
Active inflammatory or 
infectious disease; 
pregnancy, hospitalization 
within previous 1 mo.; with 
cardiovascular disease 
and/or osteoarthritis and 
unable to exercise 
43 PRT prior to each 
hemodialysis treatment using 
pneumatic resistance 
equipment (leg press only), 3 
sets x 12 reps at 70% 1RM.  
1RM tested at month 3 for 
load adjustment, plus same 
nutritional supplement as 
control, 3 sessions/wk 
Nutritional 
supplement: 2 
cans of lactose-
free formula 
(Nephro®) 
containing 240mL 
and 480 kcal (66.8 
kcal from protein, 
211.2 kcal from 
carbohydrates and 
204.3 kcal from 
fat), taken 3 
24 Muscle (lean body and 
leg mass via DEXA (kg, 
%); muscle strength (leg 
press 1RM; lb.) 
6.5 
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times/wk during 
dialysis 
Song et al, 2012 
South Korea 
40 Age >18 yr; hemodialysis for 
>3mo.; permission of 
nephrologist; ability to maintain a 
seated position; independent 
ambulation with or without an 
assistive device; adequate 
dialysis (Kt/V=1.2); stable during 
dialysis; willingness to be 
randomly assigned and undergo 
study protocols 
None specified.  53 PRT prior to each 
hemodialysis treatment using 
elastic bands (6 upper body 
exercises) and sandbags (6 
lower body exercises), 3 sets 
x 10-15 reps at RPE 11-15, 3 
sessions/wk.  
usual care (no 
exercise) 
12 Muscle (lean body mass 
via BIA; kg); muscle 
strength (grip and leg 
strength; kg); HRQoL 
(SF-36 physical and 
mental component 
summary scales) 
8 
de Lima et al, 
2013 
Brazil 
22 Age 18-75 yr; thrice weekly 
hemodialysis; men and women; 
sedentary 
Uncontrolled arterial 
hypertension; ischemic 
cardiopathy; amputation; 
deep vein thrombosis; 
excessive pallor; severe 
dyspnea; femoral fistula; 
arrhythmias; precordial 
pain; orthopedic or 
neurological condition and 
cognitive alterations 
affecting participation 
47 PRT during first 2hr of 
dialysis using weighted ankle 
cuff (knee flexion/knee 
extension, and hip and knee 
flexion with foot 
dorsiflexion), 3 sets x15 reps 
at 40% 1RM, 3 sessions/wk.  
1RM tested every 15 days for 
load adjustment.  
usual care (no 
exercise) 
8 HRQoLa (SF-36 physical 
functioning) 
5.5 
Abbreviations: USA=United States of America; CKD=chronic kidney disease; HIV= human immunodeficiency virus; Kt/V=hemodialysis treatment adequacy; CT=computed tomography; DEXA=dual energy X-ray 
absorptiometry; MRI=magnetic resonance imaging; BIA=bioelectrical impedance analysis; PRT=progressive resistance training; RM=repetition maximum; lat=latissimus dorsi; reps=repetitions; HRQoL=health-
related quality of life; SF-36=Medical Outcomes Short-Form 36 Quality of Life Questionnaire; CSA=cross-sectional area; aData requested and received from authors (not available in publication) 
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Table 2:  Sensitivity analysis of randomized controlled trials investigating muscular strength outcomes 
 
 
SMD=standardized mean difference, LCL=lower confidence interval, UCL=upper confidence interval, I2=I-squared statistic, PRT=progressive resistance training and 
CKD=chronic kidney disease 
 
 
 
Sensitivity analysis  Studies 
(n) 
Sample 
(n) 
SMD LCL UCL P-value  I2 P-value  
Fixed effects model 7 249 1.13 0.86 1.4 <0.001 35 0.161 
Exclusion of 1 study involving PRT + nandrolone decanoate 6 217 1.1 0.72 1.49 <0.001 41.8 0.126 
Exclusion of 3 studies in cohorts >60 yr  4 130 1.06 0.62 1.49 <0.001 24.7 0.263 
Exclusion of 2 studies outside USA 5 160 1.36 0.98 1.74 <0.001 15.3 0.317 
Exclusion of 1 study in non-dialysis CKD 6 223 1.15 0.75 1.54 <0.001 45.8 0.1 
Exclusion of 2 studies on PRT + diet 5 201 1.22 0.79 1.66 <0.001 49.7 0.093 
Exclusion of 2 studies of longer duration 5 183 1.05 0.74 1.37 <0.001 0 0.426 
Exclusion of 4 studies prescribing PRT during dialysis time 3 110 0.82 0.38 1.26 <0.001 0 0.633 
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Table 3:  Sensitivity analysis of randomized controlled trials investigating health-related quality of life outcomes 
SMD=standardized mean difference, LCL=lower confidence interval, UCL=upper confidence interval; I2=I-squared statistic, PRT=progressive resistance training and 
CKD=chronic kidney disease 
Sensitivity analysis Studies (n) 
Sample 
(n) SMD LCL UCL P-value I
2 P-value 
Fixed effects model 6 223 0.83 0.56 1.11 <0.001 27.8 0.226 
Exclusion of 1 lower quality study (score <6.0) 5 201 0.85 0.46 1.23 <0.001 41.9 0.142 
Exclusion of 2 studies in cohorts >60 yr  4 130 0.73 0.38 1.09 <0.001 0 0.474 
Exclusion of 1 study involving PRT + nandrolone decanoate 5 191 0.94 0.63 1.24 <0.001 1.2 0.399 
Exclusion of 3 studies outside USA 3 112 0.87 0.19 1.56 0.012 66.3 0.052 
Exclusion of 1 study of longer duration 5 179 0.7 0.4 1 <0.001 0 0.622 
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Electronic Supplementary Material 
Electronic Supplementary Material, Appendix S1. PubMed and Scopus search syntax 
"kidney diseases"[MeSH Terms] OR kidney disease[Text Word] OR renal disease[Text Word] 
OR "renal insufficiency, chronic"[MeSH Terms] OR "kidney failure, chronic"[MeSH Terms] OR 
Chronic Renal Insufficiency[Text Word] OR End Stage Renal Disease[Text Word] OR chronic 
renal disease[Text Word] OR end-stage renal failure[Text Word] OR "renal dialysis"[MeSH 
Terms] OR renal dialysis[Text Word] OR "dialysis"[MeSH Terms] OR hemodialysis[Text Word] 
OR haemodialysis[Text Word] AND "resistance training"[MeSH Terms] OR Resistance 
Training[Text Word] OR Strength Training[Text Word]OR Resistance exercise [Text Word] OR 
"weight lifting"[MeSH Terms] OR weight training [Text Word] OR Weight-lifting[Text Word] 
OR "weight-bearing"[MeSH Terms] OR weight bearing[Text Word] OR Weight-bearing [Text 
Word] OR Resistance exercise program*[text Word] 
 
 (TITLE-ABS-KEY("Resistance Training" OR "Strength Training" OR "Resistance exercise" OR 
"weight lifting" OR "weight training" OR "weight bearing" OR "Resistance exercise program*")) 
AND ((TITLE-ABS-KEY("kidney disease" OR "renal disease" OR "renal insufficiency" OR 
"kidney failure" OR "chronic renal insufficiency" OR "end stage renal disease" OR "end stage 
renal failure" OR "end stage kidney disease" OR "chronic kidney disease") OR TITLE-ABS-
KEY("renal dialysis" OR "renal Failure" OR  *modialysis OR dialysis OR CKD)) 
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Electronic Supplementary Material, Table S1 
Outcome Paper Computed correlation 
  Treatment group Control group 
Change in muscle mass Castaneda et al, 2001 [30] 
Johansen et al, 2006a [26] 
Johansen et al, 2006b [26] 
Song et al, 2012 [32] 
0.95 
0.97 
0.99 
0.96 
0.91 
0.94 
0.97 
0.98 
Change in knee extension 
strength 
Johansen et al, 2006a [26] 
Johansen et al, 2006b [26] 
Song et al, 2012 [32] 
0.81 
0.74 
0.89 
0.70 
0.63 
0.91 
Change in health-related 
quality of life (HRQoL) 
Johansen et al, 2006a [26] 
Johansen et al, 2006b [26] 
Cheema et al, 2007 [27] 
Song et al, 2012 [32] 
0.87 
0.94 
0.90 
0.66 
0.78 
0.96 
0.89 
0.68 
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Electronic Supplementary Material, Table S2. Quality items checklist for randomized controlled trials 
Study identification 
Treatment Allocation (each worth 0.5 
points): (1) evidence of randomization 
method; (2) evidence of concealment of 
treatment allocation 
Were groups similar at baseline 
regarding the most important 
prognostic indicators? 
Were the eligibility 
criteria specified? 
Were outcomes assessors 
blinded? 
Was compliance to the 
intervention 
reported? 
Castaneda et al, 2001 0.5 1.0 1.0 0.5 1.0 
Johansen et al, 2006 1.0 1.0 1.0 0.0 1.0 
Cheema et al, 2007 1.0 1.0 1.0 0.5 1.0 
Chen et al, 2010 1.0 1.0 1.0 0.0 1.0 
Dong et al, 2011 0.5 1.0 1.0 0.0 1.0 
Song et al, 2012 0.5 1.0 1.0 0.5 1.0 
de Lima et al, 2013 1.0 1.0 1.0 0.0 0.0 
       (continued >>>) 
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Were exercise sessions 
supervised (0.5 for 
partial supervision) 
Were dropouts 
reported? 
Were data presented for 
primary and secondary 
outcome measures? 
Did the analysis 
include an intention 
to treat analysis? 
Were adverse 
events reported? 
Total quality 
score (out of 
10) 
1.0 1.0 1.0 0.0 1.0 8.0 
1.0 1.0 1.0 0.0 1.0 8.0 
1.0 1.0 1.0 1.0 1.0 9.5 
1.0 1.0 1.0 0.0 1.0 8.0 
1.0 1.0 1.0 0.0 0.0 6.5 
1.0 1.0 1.0 0.0 1.0 8.0 
0.5 1.0 1.0 0.0 0.0 5.5 
(<<<continued)
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Electronic Supplementary Material, Figure S1. Funnel plot assessing the symmetry of the 
standardized mean difference in muscular strength outcomes between the treatment and 
control groups 
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Electronic Supplementary Material, Figure S2. Funnel plot assessing the symmetry of the 
standardized mean difference in total body muscle mass between the treatment and control 
groups  
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Electronic Supplementary Material, Table S3. Sensitivity analysis of randomized controlled trials investigating total body muscle mass 
outcomes 
  N studies N sample SMD LCL UCL P-value I2 p-value 
Fixed effects model 6 200 0.34 0.05 0.63 0.02 73.5 0.002 
Exclusion of 1 study of lower quality (score <6.0) 6 200 0.29 -0.27 0.86 0.311 73.5 0.002 
Exclusion of 1 study involving PRT + nandrolone decanoate 5 168 0.38 -0.28 1.03 0.26 76 0.002 
Exclusion of 2 studies in cohorts >60 yr  4 130 0.01 -0.74 0.76 0.98 77.1 0.004 
Exclusion of 1 study in South Korea (and measuring BIA) 5 160 0.14 -0.46 0.74 0.651 71 0.008 
Exclusion of 1 study in non-dialysis CKD 5 174 0.17 -0.46 0.79 0.602 75.4 0.003 
Exclusion of 2 studies on PRT + diet 4 152 0.39 -0.17 0.96 0.171 66.2 0.031 
Exclusion of 3 studies of longer duration 4 134 0.43 -0.2 1.06 0.18 68.8 0.022 
Exclusion of 3 studies prescribing PRT during dialysis time 3 88 0.39 -0.78 1.56 0.515 84.9 0.001 
SMD=standardized mean difference, LCL=lower confidence interval, UCL=upper confidence interval 
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Electronic Supplementary Material, Figure S3. Funnel plot assessing the symmetry of the 
standardized mean difference in lower body muscle hypertrophy measures (i.e. leg mass, or 
mid-thigh or quadriceps CSA) between the treatment and control groups 
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Appendix 3. Letter for doctor clearance 
 
Dr….. 
Level 9 East Wing,  
CNARTs 
Royal Adelaide Hospital 
North Terrace 
Adelaide, SA 5000 
 
Dear Dr…..,  
 
As part of the medical screening process for the research study entitled “Can thrice a week of 
resistance training during dialysis improve cardiovascular health and other outcomes in 
patients with kidney failure?”, the following patients have had their medical records reviewed 
for contraindications to exercise by exercise physiologist Danwin Chan.  
 
1 LAST NAME, First Name (MRN:  XX-XX-XX, DOB:  XX-XX-XXXX) 
 
To further the medical screening process please complete the attached checklist for each of your 
patients and return these forms to me using internal mail to Hampstead Dialysis Centre.  Your 
assistance is greatly appreciated. 
 
As you are aware, the purpose of this study is to evaluate the effects of resistance training during 
haemodialysis sessions on several indicators of health status in patients with ESRD.  The 
variables to be evaluated include arterial stiffness, endothelial progenitor cells, C-reactive 
protein, lipid profile, physical activity level and function, depression, and quality of life.   
 
I am hopeful that you will recommend participation in this research study to all patients meeting 
eligibility requirements.  Please feel free to contact me if you require further information about 
the study. 
 
Sincerely, 
 
_________________________________ 
Danwin Chan, AEP, Doctoral Student 
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Name of patient:  LAST NAME, First Name (MRN:  , DOB:  ) 
 
 
Checklist of conditions and events, which would require temporary 
exclusion from study: 
 
q Acute change in mental status or delirium 
 
q Cerebral haemorrhage within the past 3 months 
 
q Exacerbation of chronic inflammatory joint disease or osteoarthritis 
 
q Eye surgery within the past 6 weeks 
 
q Fracture in healing stage         
 
q Hernia, symptomatic (abdominal or inguinal) 
 
q Myocardial infarction or cardiac surgery within past 3 months 
 
q Other acute illnesses or change in symptoms       
            
       
q Proliferative diabetic retinopathy or severe non-proliferative retinopathy 
 
q Pulmonary embolism or deep venous thrombosis within 3 months 
 
q Soft tissue injury, healing         
 
q Systemic infection          
 
q Uncontrolled blood pressure (>180/100) 
 
q Uncontrolled diabetes mellitus (FBS>14mmol/L) 
 
q Uncontrolled malignant cardiac arrhythmia (ventricular tachycardia, complete heart 
block, atrial flutter, symptomatic bradycardia) 
 
q Unstable angina (at rest crescendo pattern, ECG changes) 
 
q Other            
_______________________________________________________________ 
 
Practitioner Name:  ________________________________ Date:  _____________ 
 
Practitioner Signature: _____________________________  
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Appendix 4. Participant information sheet 
 
 
 
 
 
Participant Information Sheet 
 
Project Title: Can thrice a week of resistance training during dialysis improve 
cardiovascular health and other outcomes in patients with kidney failure? 
This is a research project and you do not have to be involved.  If you do not wish to 
participate, your medical care will not be affected in any way.  Also, you may withdraw 
from the project at any time after you have commenced.  
 
The research will be conducted according to the NHMRC National Statement on 
Ethical Conduct in Human Research, 2007. 
 
This information sheet will allow you to understand what is involved in the study, so as 
to allow you to decide whether or not to take part. Please ask any questions if there is 
still anything you are not clear about.  
 
Who is carrying out the study?  
Mr Danwin Chan, (BHSci(Hons), AEP, ESSAM) 
Email: 17164203@student.uws.edu.au; Mobile: 0402 819 342 
You are invited to participate in this study conducted by Mr Danwin Chan, PhD 
candidate, School of Science and Health, University of Western Sydney. Mr Chan can 
be contacted with the above contact details. This study is in partnership with the Central 
Northern Adelaide Renal and Transplant Service. 
 
What is the study about? 
The purpose of the study is to determine whether a structured resistance exercise 
program, under the supervision of an exercise physiologist, affects arterial stiffness and 
physical function in haemodialysis patients. 
 
What does the study involve? 
Three testing sessions (week 0, 13, 26) to evaluate your vascular health and physical 
fitness will be performed. No invasive procedure is involved. Each testing session will be 
approximately one hour and is conducted by Mr Danwin Chan. You will need to be 
dressed in workout gear (e.g. shorts, t-shirt and running shoes) to perform the testing 
session.  There will be a 12-week period of no-exercise during dialysis between the first 
and second testing. You are requested not to change your physical activity habit at this 
period. This is then followed by a 12-week program of resistance training.  Participants 
will perform about 40 minutes of upper body and leg exercises during haemodialysis 
while exercises involving the fistula arm will be done 15 minutes just before 
haemodialysis. This will occur three times per week at your haemodialysis centre. Some 
Human Research Ethics Committee 
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pictures and video may be taken during the sessions with your consent. You will be 
asked to sign an additional consent form if this is to occur. The third test session is then 
conducted after the exercise program. Samples of blood (45ml in total) for health 
markers are also collected while you are on dialysis at week 0, 13 and 26. Your vascular 
health, physical function, muscle strength will be assessed in a dialysis centre without 
involving any invasive procedure. Assessment of muscle strength will require a 
sustained level of physical exertion and may result in muscle soreness for a day or two. 
You will also be asked questions about your medical history, perception of quality of life, 
mood and physical activity. Transportion cost to the testing location will be covered. 
 
A video may be made when you perform the exercise. The video will then be used to 
train other people on haemodialysis. We will include you only if you agree to be 
videotaped. 
 
Will the study benefit me? 
At your completion of the exercise program, it is expected that your muscle strength, 
ability to carry out day-to-day tasks and sense of well being will improve. However, 
these benefits are by no means assured as individuals may react differently to the 
exercise stimulus. 
 
What are the possible risks and discomfort of participating? 
As with any exercise, injury or adverse event may result but this can be avoided with the 
investigator’s and nurses’ supervision and precautions. We thus believe the risk is very 
small to you. In addition, weight training in older adults, people with chronic diseases 
and patients on haemodialysis has been proven to be safe and has many health 
benefits.  
 
There are minimal risks and discomfort associated with participation in this study, as 
summarized below: 
1. There may be some changes in blood pressure, pulse and blood flow during dialysis 
due to the exercise, which will be closely monitored.  It is anticipated that the nursing 
staff at the dialysis unit will be able to manage these quite easily.  
2. Muscle strength testing may cause slight soreness over the next 1-2 days. Weight 
lifting exercises may cause fatigue, muscle soreness, injury to tendons or ligaments, 
or exacerbation of underlying arthritis or joint pain. Under direct supervision of an 
experienced trainer, such as will occur in this study, these complications are 
uncommon, and usually resolve quickly with modifications of the training regimen. 
3. Blood samples will be drawn from your haemodialysis lines and thus will not cause 
additional pain.  
 
 
How is this study being paid for? 
You will not have to pay for any cost incurred in this study. Any additional tests, 
procedures, supervised weight training program and transportation cost for this study 
will be covered by the University of Western Sydney and Central Northern Adelaide 
Renal and Transplant Service.  
Will anyone else know the results? How will the results be disseminated? 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission or 
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except as required by law.  Data from the study may be published in scientific/medical 
journal or be presented in a conference, but in a way that patients will not be identified. 
Data will be retained on file by the University of Western Sydney in a locked facility for a 
period of 5 years, after which time it will be destroyed in a confidential manner providing 
data analysis and reporting of results is complete. Study data will only be accessible to 
researchers involved in the study. 
 
Can I withdraw from the study? 
Participation is entirely voluntary: you are not obliged to be involved and if you do 
participate, you can withdraw at any time without giving any reason and without any 
consequences.  
 
Your participation may also be ended prematurely for the following reasons:  
 
4. The investigator feels that it is in your best interests to stop your participation 
5. You have a kidney transplant or an unrelated medical illness or complication that 
makes study procedures unsafe or unreliable 
6. The study, or part of the study, may also be stopped at any time at the discretion of 
the investigator or the researchers.  
7. The study may also be stopped by the ethics committee who review the study to 
protect the rights and welfare of the study patients. 
 
Can I tell other people about the study? 
Yes, you can tell other people about the study by providing them with the chief 
investigator's contact details. They can contact the principal investigator to discuss their 
participation in the research project and obtain an information sheet. 
 
What if I require further information? 
When you have read this information, Mr Chan will discuss it with you further and 
answer any questions you may have. If you would like to know more at any stage, 
please feel free to contact Mr Chan via email or telephone; 
17164203@student.uws.edu.au, mobile 0402 819 342. 
 
 
What if I have a complaint?  
This study has been approved by the Research Ethics Committees of both the 
University of Western Sydney (UWS) and Royal Adelaide Hospital (RAH). The RAH 
Protocol number is 120507 and the UWS project number is H9651.  
 
If you have any complaints or reservations about the ethical conduct of this research, 
you may contact:  
 
UWS Ethics Committee through the Office of Research Services  
Tel: (02) 4736 0883    Fax: (02) 4736 0013      Email: humanethics@uws.edu.au. 
and/or 
 Chairperson, Research Ethics Committee, RAH  
 Tel: (08) 8222 4139 
 
Any issues you raise will be treated in confidence and investigated fully, and you will be 
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informed of the outcome. 
 
Further enquiries should be directed to : 
 
Mr Danwin Chan                                                   Phone: 08 8222 1500  
PhD candidate / Exercise Physiologist                         
Hampstead Rehabilitation Centre 
Hampstead Road, Northfield SA 5085 
 
Mr Robert Barnard         Phone: 08 8222 1811 
Chief Exercise Physiologist 
Hampstead Rehabilitation Centre 
Hampstead Road, Northfield SA 5085 
 
Dr Bobby Cheema                                                 Phone: 02 4620 3795 
Head of Sport & Exercise Science Program 
School of Science and Health (Campbelltown) 
Penrith South DC, University of Western Sydney 
 
 
 
If you agree to participate in this study, you will be asked to sign the Participant Consent 
Form. 
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Appendix 5. Participant consent form 
 
 
 
 
 
 
 
 
Participant Consent Form 
 
This is a project specific consent form. It restricts the use of the data collected to the 
named project by the named investigators.  
 
Project Title: Can thrice a week of resistance training during dialysis improve 
cardiovascular health and other outcomes in patients with kidney failure? 
 
Investigators:  Mr Danwin Chan1,2, Dr Birinder S. Cheema1, Mr Robert Barnard2, Dr 
Simon Green1, Prof Maria Fiatarone Singh3 
          (1University of Western Sydney, 2Centre for Physical Activity in Ageing, 3University of 
Sydney) 
 
I,…………………………………….…, consent to participate in the research project titled 
" Can thrice a week of resistance training during dialysis improve cardiovascular 
health and other outcomes in patients with kidney failure?".  
 
I acknowledge that: 
 
I have read the participant information sheet [or where appropriate, ‘have had read to 
me’] and have been given the opportunity to discuss the information and my 
involvement in the project with the researcher/s and with a family member or friend.  
 
The procedures required for the project and the time involved have been explained to 
me, and any questions I have about the project have been answered to my satisfaction. 
 
I understand that I may not receive any health benefit from taking part in this study. 
 
I understand that, while information gained during the study may be published, I will not 
be identified and my personal results will remain confidential. 
 
I agree to truthfully answer all of the questions asked regarding my medical past. I agree 
to cooperate with the instructions for participating in this study as described above 
 
I agree for my usual treating doctor to be contacted for relevant information as part of 
the study and that he/she will be asked to provide information about my suitability for 
inclusion in the exercise program. 
 
I understand that my involvement is confidential and that the information gained during 
Human Research Ethics Committee 
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the study may be published but no information about me will be used in any way that 
reveals my identity. 
 
I understand that transportation to assessments will be provided. If I chose to use 
personal transportation, a reimbursement of $20 will be provided for each day trip.  
 
I understand that I can withdraw from the study at any time, without affecting my medical 
care or my relationship with the researcher/s now or in the future. 
 
Participant’s full name: ________________  
Participant’s signature: ________________ Dated:___________________ 
 
 
I certify that I have explained the study to the participant/volunteer and consider that 
he/she understands what is involved. 
 
 
Investigator’s full name: _______________     
Investigator’s signature: _______________       Dated: __________________ 
 
This study has been approved by the Research Ethics Committees of both the 
University of Western Sydney and the Royal Adelaide Hospital.  
 
The RAH protocol number is: 120507 
The UWS project number is: H9651 
 
If you have any complaints or reservations about the ethical conduct of this research, 
you may contact either: 
 
Ethics Committee   Research Ethics Committee 
Office of Research Services  The Royal Adelaide Hospital 
University of Western Sydney Tel: +61 8 82224139 
Tel: +61 2 4736 0229  Fax: +61 8 82223035 
Fax: +61 2 4736 0013 Email: 
rah.ethics@health.sa.gov.au 
Email: humanethics@uws.edu.au.   
 
 
Any issues you raise will be treated in confidence and investigated fully, and you will be 
informed of the outcome. 
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Appendix 6. Manual for arterial stiffness assessments 
 
PULSE WAVE ASSESSMENT 
 
EQUIPMENT 
 
• Stopwatch or timer 
• Alcohol swabs 
• Surgical razor 
• ECG electrodes 
• Large bone calliper 
• Fine tip marker 
• Small stickers 
• SphygmoCor unit with ECG leads 
• Notebook computer with SphygmoCor software installed 
 
Note: PWA = Pulse wave analysis; PWV = Pulse wave velocity 
 
ORDER OF TESTING 
 
1 Equipment Set-up 
• Connect the SphygmoCor unit to the laptop via USB (use the bottom port, on the right of the 
laptop) 
• Connect the ECG leads and footswitch to the SphygmoCor unit 
• Connect the Laptop to the power and switch on. 
• Log-in; Username: user - Password: sports, and open the SphygmoCor software. 
• Enter patient details (see below) 
• Enter study details (see below) 
 
2 Patient Set-up 
• Patient should be in a gown 
• Check the patient is fasting, and consumed no caffeine 
• Once the patient lies down for the first test of the morning (BIA), a stopwatch or timer should 
be used to ensure they are in the supine position for 10 minutes before commencing data 
collection. 
• Place ECG electrodes and connect the leads in a II lead configuration (see below) 
 
3 Data Collection 
• Enter the diastolic and systolic blood pressure values that have been obtained from the cuff 
sphygmomanometer. Use the mean of two measures taken 1 min apart in the supine position 
• Wait 2 minutes 
• During the PWA data capture, use the tonometer to identify the brachial and posterior tibialis 
(PT) sites to be used in PWV – a site where a clear waveform can be observed should be selected 
• Mark the brachial (fine tip marker), and PT (fine tip marker) sites  
• Conduct PWA (see below) 
• Check quality and repeat if necessary (see below) 
• Remove the patient’s pillow 
• Measure the distances for PWV (see below) 
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• Conduct PWV (see below) 
• Check quality and repeat if necessary (see below) 
• Replace the patient’s pillow 
• Conduct HRV (see below) 
• Remove ECG leads, close down the software and continue with the next assessment 
 
PATIENT ENTRY - SELECT OR ENTER A NEW PATIENT 
 
Open the ‘Patient’ screen by clicking on the ‘Patient’ button. This screen will allow you to 
create a new patient entry or select a patient that is already present in the database. 
 
To create a new patient entry, select the ‘Create New’ button and enter the patient details. 
Once you have finished entering the patient details, click on the ‘Update’ button to add the 
details of the patient to the database. 
 
To select an existing patient from the database, you may choose the patient by one of the 
following means: 
• Scroll down the list of patients and click on the row to select that patient. If you click on the 
heading ‘Family name’ at the top of the browser this will place the patients in alphabetical order. 
When the patient is selected the patient name is highlighted. 
OR 
• Place the curser in the ‘Patient Search’ field and enter the patient’s family name. Click the 
‘Search’ button or press ‘Enter’’ and the system will select the patient whose family name 
is the closest match. Ensure the patient you wish to select has been highlighted. 
 
Note: Before creating a new patient entry, please check that the patient does not already exist in 
the database, as separate patient entries cannot be merged. 
 
PULSE WAVE ANALYSIS (PWA) - ENTERING STUDY DETAILS 
 
While still in the ‘Patient Screen’; select ‘PWA’ mode by clicking on the ‘PWA’ button on the 
left-hand side of the screen. 
 
Open the Study Screen by clicking on the “Study”. This screen will allow you to enter the 
study details and to proceed to ‘Capture data’. 
 
For measurements taken at the radial artery: 
• Click the ‘radial’ check box. 
• Enter the diastolic and systolic blood pressure values that have been obtained from the cuff 
sphygmomanometer. Use the mean of two measures taken 1 min apart in the supine position. 
• The Medication, Notes, Operator and Anthropometric fields are optional. 
 
At least 2 minutes should elapse between taking the blood pressure and performing the tonometry 
reading. 
 
PERFORMING THE DATA CAPTURE 
 
To proceed to the capture data screen, click on the ‘Capture Data’. 
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Placement of the tonometer: 
• Feel for the location of the strongest pulse at the radial artery of the patient’s right wrist, and 
place the tonometer on the skin at this point. The best results are obtained if the patient’s wrist is 
bent slightly downwards, in the ‘dorsiflex’ position. You may wish to support the patient’s wrist 
in your hand or place a small pillow or rolled towel under the patient’s wrist for support. 
• Gently press the tonometer into the skin until a waveform 
signal appears on the screen. If the trace is off the screen, a 
straight line will be drawn across the horizontal axis of either 
the top or bottom of the signal screen, indicating that either 
too much or not enough pressure is being applied, 
respectively. 
• The tonometer should be perpendicular to the wrist and 
adjustments to the position should be made until a strong, 
accurate and reproducible waveform is displayed in the 
‘Signal detail’ window. This signal will be automatically re-
scaled and zoomed to fit the waveform within the signal detail 
window every 5 seconds. 
 
 
At this point you should identify the brachial and PT sites and lightly mark them in 
preparation for PWV testing. A sharp initial upstroke on each wave is most important for these 
sites rather than a large consistent waveform. 
 
Capturing the waveforms: 
• Once you have achieved a consistent radial pressure waveform, hold steady for at least 12 
seconds (equal to approximately 3 screen sweeps of waveforms) press the ‘Space Bar’ on your 
keyboard or press the foot switch. 
 
Examples of typical, good quality radial waveforms 
 
 
Each waveform should have a sharp initial upstroke. The series of waveforms should have 
consistent peaks and troughs, and the contour of the waveform, in particular the peak pressure 
and shoulder, should be identical. 
 
 
 
 
 
 
Examples of poor raw waveform data 
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EXAMINE THE REPORT FOR QUALITY CONTROL 
 
After you have completed the data capture, the ‘Report Screen’ will be automatically displayed. 
This can also be recalled at any time by selecting the patient in the ‘Patient Screen’ and pressing 
the ‘Report’ button. 
 
Operator Index 
The main quality control parameter is the Operator Index. This is displayed on both the Clinical 
and Detailed Screen. The Operator Index is a number that is calculated from a weighting 
equation using four quality indices. 
The Operator Index range is 0-100. As a general guide, if the Operator Index is ≥ 80 it is 
considered acceptable. If the Operator Index is ≤ 79 the recording is unacceptable and should be 
repeated. 
 
PULSE WAVE VELOCITY - ENTERING STUDY DETAILS 
 
While in the ‘Patient Screen’; select PWV mode by clicking on the ‘PWV’ button on the left-
hand side of the screen. 
 
Open the Study Screen by clicking on the ‘Study’. This screen will allow you to enter the study 
details and to proceed to ‘Capture data’. 
 
Mandatory fields to be selected or entered: 
• Click in the box corresponding to the site from where the measurement is to be taken. 
Site A is the brachial site at which the first measurement is to be taken and; 
Site B refers to the PT site at which the second measurement will be taken. 
• Enter the blood pressure (systolic and diastolic) that has been obtained from the cuff 
sphygmomanometer before PWA.  
• The Capture Time is set to a default of 10 seconds for both the Site A and Site B measurements. 
 
Measuring the Sites: 
 
• The Distance should be measured on the right side and entered as the distance to 
the nearest 1 millimetre directly between each artery location and the suprasternal notch 
are entered in the proximal and distal boxes. 
• Palpate for the supra-sternal notch and identify the point immediately superior to the sternum. 
• With the patient standing upright in the anatomical position with the head facing 
straight, using a stadiometer: 
• Measure and record the distance from the sternal notch to the floor (Figure 2). 
• Measure and record the distance from the marked brachial site to the floor (Figure 3). 
• Using a large bone caliper, measure and record the distance from the base of the foot to the 
marked posterior tibial site while the patient is lying supine – ensure 
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that the blade of the calliper runs along the length of the foot and that the foot is dorsi flexed to 
90° (Figure 4). 
 
   
Figure 2. Sternal notch 
height 
Rest corner of the 
stadiometer on the sterna 
notch 
Figure 3. Brachial height 
Bottom edge of stadiometer 
in line with marked site 
Figure 4. Posterior tibialis 
height 
Distance from the base of the 
foot to the marked posterior 
tibialis site 
 
Placement of ECG leads: 
To ensure a stable, artefact free ECG, the skin should be properly prepared (hair removed at 
electrode site and skin cleaned with an alcohol wipe), and the electrodes positioned correctly. 
The ECG leads should be positioned as shown in the diagram. 
This is a Lead II configuration. The leads can be placed either on the limbs or on the chest area if 
required for stronger QRS levels). 
 
 
PERFORMING THE DATA CAPTURE 
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To proceed to the capture data screen, click on the ‘Capture Data’. 
Once the ECG trace is visible on the screen and is steady, proceed as follows: 
• Check that the R wave on the ECG trace is the tallest part of each ECG waveform, noting that 
this may require adjustment of the ECG cables or ECG electrodes. 
• The tonometer should be placed at the artery defined for Site A (brachial). A strong, 
accurate and reproducible waveform should have already been identified during PWA at the 
marked site. 
This signal will be automatically re-scaled and zoomed to fit the waveform within the signal 
detail window every 5 seconds. 
• When you are satisfied that you have a good reading, press the ‘Space Bar’ on your 
keyboard or click the footswitch. 
 
• A prompt window will appear confirming that the signals have been captured successfully. 
When you are ready to proceed to take the reading at Site B, click the OK button or press the 
footswitch. If you wish to take the reading again, click No and repeat the reading at Site A. 
 
• Repeat the process by placing the tonometer on the artery defined for Site B (PT) and 
proceed with the capture when you have obtained a signal of satisfactory quality. A prompt box 
will appear to confirm that the signal was captured successfully. If you are satisfied with the 
reading at Site B and wish to proceed to the report, click OK. If you wish to repeat the reading at 
Site B, click No and repeat the reading at Site B. 
 
EXAMINE THE REPORT FOR QUALITY CONTROL 
 
After you have completed the data capture, the Report Screen will automatically be displayed. 
This can also be recalled at any time by selecting the patient in the Patient Screen and pressing 
the ‘Report’ button. 
 
Check that information was entered correctly on the Study Screen. If the patient data is incorrect, 
click the patient tool-bar button to return to the Patient Screen and update patient details. If the 
study data is incorrect, click the ‘Recalculate’ tool-bar button to open the 
SphygmoCor Recalculate Report window.  
 
Quality Control checks: 
• The tonometry waveforms should be clear and smooth and it is important that the foot of the 
waveform is easily identified. The quality control parameters used in PWA may assist in 
assessing the quality of the tonometry waveform and are displayed to the right of the waveforms. 
 
• The green dots on the waveforms indicate the marker for calculating timing from the waveform 
to the ECG (onset points) and it is important that these are in a similar location on each 
waveform. 
 
• The R wave on the ECG should be the tallest part of the ECG trace and the green dots should be 
located at the top of the R wave and not on any other part of the ECG trace. 
 
• The SD(ms) in the statistical table (i.e. for each of the site A and B measures) should be 
below 6% of the mean time. If the SD is above 6% it will appear in red.  Repeat the reading. 
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Additional comments on performing brachial and posterior tibial measurements: 
 
 
 
Brachial Measurement: 
The operator should feel for the position for the strongest pulse at 
or above the bicipital aponeurosis, medial to the biceps tendon, 
and place the tonometer directly on the top of the skin at this 
point. The operator can be standing or seated to one 
side. A pillow may be placed next to the patient to allow the 
operator to rest their forearm to ensure that the tonometer and 
wrist remain steady during the measurement. On leaner subjects 
a clearer pulse wave may be observed at a slightly more proximal 
site. 
 
 
 
 
 
 
 
 
 
Posterior Tibial Measurement: 
 
The operator should feel for the position for the 
strongest pulse. The posterior tibial artery pulse can 
be palpated posterior and inferior to the medial 
malleolus. The pulse wave can generally be obtained 
with the foot resting at a natural angle, but on certain 
individuals a better wave form may be obtained with 
either the foot in neutral (perpendicular to the bed), 
or with slight external rotation and passive dorsi 
flexion 
provided by the operator. 
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VARIABLES 
 
A description of all variables for PWA, PWV can be found in the SphygmoCor clinical guides. 
 
COPYING A DATABASE  
 
Copying a database is a method to backup or transfer databases from one computer to another.  
 
To Copy the selected database:  
Step 1. Select the database you want to copy.  
Step 2. Click the Copy button. The “Copy To” dialog window opens.  
Step 3. Select the Windows folder that you want to copy the database to, and click the Ok button. 
The selected database is then copied to the folder you selected. 
 
CAUTION  
When copying a database, ensure that you don’t select a location where any database 
already exists. If this occurs, the database will be corrupted and the records will not be 
recoverable.  
 
EXPORTING DATA  
 
You can export data from the SphygmoCor system for use in other programs. Data is exported in 
a Tab-delimited text-file format. This format is easy to import into spreadsheet applications, such 
as Statview or Excel. 
 
DATABASE WARNING  
 
Do not open the SphygmoCor database with Microsoft Access or any other program as it 
may corrupt your data. All database interactions should be performed using the 
SphygmoCor software. For further advice contact AtCor Medical Product Support. 
 
Whenever you export data, the Export window is displayed: This window allows you to specify 
where the data will be exported to, in the Windows folder structure and what the file will be 
called. The comment in the central section of the window changes according to which of the 
export operations is being performed.  
 
EXPORT ALL MEASUREMENTS IN THE DATABASE  
 
Step 1. Click the Export option on the System>Database menu. You must be in the Patient screen 
to do this. The Export window opens 
 
Step 2. Use the Select button to choose the Windows folder and/or file name to which you want 
all the measurements exported.  
 
Step 3. Click the Export button. A progress bar shows you how much of the export has been 
completed. At the end of the operation, a status message appears in the Export window:  
 
Step 4. Click the Close button to close the Export window. 
 
  
 299 
A separate export process must be performed for each study database, as well as for each PWA 
and PWV  datasets (i.e. two exports per study). 
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 Appendix 7. Protocol for 3 repetition-maximum strength test 
 
(Modified from Baechle et al, 2008 p.396) 
 
1. Instruct the participant to warm up with a light resistance that easily allows 5 to 10 
repetitions.  
2. Provide a 1 minute rest period.  
3. Estimate a warm-up load that will allow the participant to complete 5 to 7 repetitions by 
adding 4 – 9 kg for unilateral lower body exercise. 
4. Provide a 2 minutes rest period.  
5. Estimate a conservative load that will allow the participant to completed 3 to 5 repetitions by 
adding 4 – 9 kg for unilateral lower body exercise.  
6. Instruct the participant to attempt a 3RM.  
7. If the participant was successful, provide a 2 minutes rest period and go back to step 5.  
8. If the participant failed, provide a 2 minutes rest period, then decrease the load by subtracting 
2 – 4 kg for lower body exercise. Return to step 6.  9. Continue	increasing	or	decreasing	the	load	until	the	participant	can	complete	3	repetitions	with	proper	technique.	Ideally,	the	participant’s	3	repetitions	maximum	will	be	measured	within	3	to	5	testing	sets.		
 
Reference:  
 
Baechle, TR, Earle, RW & Wathen, D. 2008, ‘Resistance training’, in Essential of strength 
training and conditioning, 3rd edn, ed. TR Baechle & RW Earle, Human Kinetics, Champaign, 
Illinois.  
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Appendix 8. Protocol for 6-minute walk 
 
 
Equipment: Cones/markers, Measure wheel, Stopwatch  
Site: Non-slippery, flat surface outdoor/indoor area with shelter 
Preparation: 
1. Set up the cones according to the figure below by measuring a 20 x 2 metres  rectangular 
area using the measure wheel. The cones should be 5 metres apart from each other.  
 
2. Ensure that participant is wearing appropriate footwear and that no hindering object is on 
the designated walking area. Remove any if there is. 
 
3. Before beginning, instruct the participant to walk as fast as he can around the cones to 
cover as much ground as possible in six minutes. The pace should be within the 
participant’s comfort zone and he must not run. Inform the participant he is allowed to 
rest if necessary but should continue as soon as they are able to. However, if participants 
feel dizzy, pain, angina, nauseous or undue fatigue, the test will be discontinued. 
 
4. Inform the participant you will say, “Ready, Go!”, then the participant should begin 
walking immediately and you will start the timer at the same time. Begin when the 
participant is ready.  
 
5. No verbal encouragement was given during the test but feedback regarding the remaining 
time is to be given every two minutes and when 1 minute is left.  
 
 
 
 
 
 
 
 
 
Figure. 20 by 2 metres walking circuit with cones marking the corners. 
 
6. The tester will measure the total distance walked to the nearest 0.5 metres using a 
measure wheel. Record the distance in the participant’s case report form.  
 
7. At the end of the test, accompany the participant to walk slowly around for a minute to 
cool down.  
 
  
2 m 
20 m 
Start 
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Appendix 9. Protocol for waist circumference measure 
 
Equipment: Non-metallic tape measure with a spring-load handle  
Preparation: 
 
1. With the participant’s waist uncovered, he stands upright with arms relaxed at the sides.  
2. Take the horizontal measure, mid point between the lower costal (rib) border and iliac 
crest. The measurement is taken at the end of a normal expiration.  
 
3. The tape should be placed on the skin surface without compressing the subcutaneous 
adipose tissue 
 
4. The spring loaded handle of the tape measure should be extended to the same marking  
with each trial.  
 
5. Two duplicate measures need to be done. If the measurements are not within 5 mm, retest 
the measurements till they are. Record the measurements and take the average of the last 
two measures.  
 
Risk level based on waist circumference in general population adults : 
 Waist Circumference (cm) 
 Females Males 
Risk category   
Very low <70  <80 
Low 70-89 80-99 
High  90-109 100-120 
Very High >110 >120 
 
Reference:  
 
American College of Sports Medicine. Guidelines for exercise testing and prescription. 
Philadelphia: Lippincott Williams & Wilkins; 2006, pp 58-61 
 
Norton, K & Old, T. Anthropometrica. Sydney: UNSW Press; 2002, pp 58 
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Appendix 10. Case report form 
 
CASE REPORT FORM 
 
 
 
   Age:  
     Research ID Number:  
 MRN: 
 
(Circle) 
Baseline / 13 weeks / 26 weeks 
 
 
Date: 
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Demographic Information 
 Patient details Person for Notification 
 
 
Name   
Relationship  
Address   
 
 
Telephone  H: 
W: 
 
Gender:  Male  /  Female  
Ethnic:   
                Caucasian 
                Asian  
                Aboriginal  
                Middle East 
                Black  
                Indian  
                other  _______ 
Marital Status:  
  married / defacto 
  widowed 
  divorced    
 single/ never married 
  separated  
 
 
Residence  
In what type of accommodation do you live? 
 
 
 
 
 
 
 
 
How long have you lived at this address? 
 
  house (own) 
  house (rented) 
  unit (own) 
  unit (rented) 
  retirement village 
  hostel 
  nursing home 
  board/rooming house 
 
Years ______Months _____ 
 
 
Living Situation 
With whom do you live? 
 
 
 
 
 
Total number of persons in the household 
 
  alone 
  spouse / partner 
  family 
  paid carer  
  friend 
  other residents  
 
___________ people 
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Education 
What is the highest grade or year of school you 
completed? 
  never /kindergarten 
  primary school 
  high school 
  tertiary  
  post graduate 
 
0 
1 2 3 4 5 6 
7 8 9 10 11 
12 
13 14 15 16 
17 18 19 20 
Work 
Do you currently work for pay either for yourself or 
someone else? 
 
How many hours per week do you work for pay? 
 
Do you currently work as a volunteer? 
 
 
How many hours volunteer hours / week do you work? 
 
  yes        
  no 
 
__________hours / week 
 
  yes        
  no 
 
__________hours / week 
 
 
Annual income 
In what range is your annual income? 
 
 
  < $ 15,000   
  $ 15,000- $30,000      
  >$30,000   
 
Pension 
Do you receive a pension? 
  Nil 
  DVA 
  Age pension 
  Widows pension 
  Disability Pension 
 
Hospital admissions 
During the past 12 months, how many different times 
did you stay in hospital over night? 
 
______ number of times 
 
______ number of days in hospital 
 
 
Smoking 
Are you a non-smoker, ex-smoker or current smoker?  
 
 
 
If you are an ex-smoker, how many years has it been 
since you quit?   
 
If you are an ex-smoker or current smoker, how many 
cigarettes, cigars or pipes did/do you smoke on an 
average day?  
20 cigarettes =1 pack 
 
 
  Non-smoker 
  Ex-smoker 
  Current smoker 
 
 
________ years 
 
 
________ per day 
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Alcohol 
 
During the past 7 days, what was the average number 
of standard  drinks of alcoholic beverages you had 
drunk per day?  
 
 
 
 
________ standard drinks/day 
 
      
    
Comments: 
___________________________________________________________ 
 
___________________________________________________________ 
 
___________________________________________________________ 
 
___________________________________________________________ 
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Subject Medical History 
 
Primary Cause of Renal Failure: 
q Glomerulonephritis 
q Hypertensive nephrosclerosis 
q Analgesic nephropathy 
q Polycystic kidney disease 
q Diabetic nephropathy 
q IgA nephropathy 
q Lupus/SLE 
q Reflux nephropathy/ chronic pyelonephritis 
q Aetiology uncertain 
q Other:            
 
Haemodialysis:  
• Date commenced HD:       
• Duration of HD (yr & months):      
• Problems with dialysis over past 6 months: 
 Hypotension 
 Hypertension 
 Arrhythmias (type):        
 Fistula access problems:       
 Subjective symptoms during session:      
          
 Laboratory abnormalities:       
 Other:          
 
• Kt/V (Date, Value):     
 
Other Diagnoses: 
 
q Active malignancy: 
o Type:           
 
q Gastrointestinal disease: 
o Type:           
 
 
 
q History of M.I: 
o Date:      
q History of Cardiac Surgery: 
o Type:      
o Date:      
q History of Hernia Repair: 
o Date:       
q Alcohol or Drug Dependency 
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q Amputation of Limb 
q Inability to use arm or leg (e.g. hemiparesis, stroke, deformity, contracture, 
neuromuscular disease): 
o Cause:         
q Other:            
q             
q             
 
q Number of visits by health care professionals in past 12 months:  
 
 
Medications: 
 
• Prescription Medication 
Drug Name Dosage 
  
  
  
  
  
  
  
  
  
  
  
 
• Non-Prescription Medication (interview): 
Drug Name Dosage 
  
  
  
  
  
  
  
  
 
• Supplements (interview): 
Supplement Name Dosage 
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Current Level of Physical Activity: 
• Aerobic Exercise: 
o Frequency:     
o Intensity:      
o Modality:      
• Resistance Exercise: 
o Frequency:     
o Intensity/Sets/Reps:    
o Modality:      
• Other:       
        
 
 History of exercise related Injuries (specify):     
           
 
 
Comments: 
___________________________________________________________ 
 
___________________________________________________________ 
 
___________________________________________________________ 
 
___________________________________________________________ 
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Anthropometric Measures 
 
Measurements Measure 1 Measure 2 Measure 3 Mean/Median 
Weight (kg) 
 
    
Height (cm) 
 
    
BMI (kg/m2) 
 
    
Waist circumference 
(cm) 
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Arterial Stiffness  
(Baseline / 13 Weeks / 26 Weeks) 
 
All measurements performed on the        right side     left side, reason: __________ 
 
Measurement (mm)   Participant preparation  
Sternal notch height 
 
  Prior 4 hours of fast from food 
& caffeine 
 
  
Brachial artery height Initial 
Measure,  
 
Difference in initial and final 
measures 
 
FINAL distance 
 
  12 hours since last exercise of 
any kind except simple walking 
 
  
Posterior tibialis artery height 
(Dorsal pedis if used) 
  Loose clothing with short 
sleeves  
  
Distance  
(Brachial è Sternal) 
  10 minutes of supinated rest 
prior to testing 
  
Distance  
(Post. Tibial è Sternal) 
    
 
 Date:    Time: 
Measurement Result Comments 
Supine brachial blood 
pressure (mmHg) 
Test 1: 
Test 2: 
Average:  
 
Observed 
Augmentation Index 
 Operation Index 
Trial 1: _____ >80,  <80 repeat  
Trial 2: _____ >80,  <80 repeat 
Trial 3: _____ >80,  <80 repeat 
Normalised Augmentation 
Index 
 
 
 
 
Observed PWV (m/s) 
 
 Quality Control 
1) either SD red(redo) 
2) ECG-proximal green 
3) ECG-distal green 
T1 
  
  
  
T2 
  
  
  
T3 
  
  
  
Normalised PWV (m/s)   
 
Comments:            
           __ 
 
Six Minute Walk Test (Baseline / 13 Weeks / 26 Weeks) 
 
Distance (m): ______________________________________________________ 
 
Comments:            
______           
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Isometric Strength  
(Baseline / 13 Weeks / 26 Weeks) 
 
   
Measurement (kg)  
Trial 1 
 
Trial 2 
 
Trial 3 
 
Trial 4 
 
Trial 5 
Final 
Score 
Right Handgrip       
Left   Handgrip       
Right Leg press 
      (3RM)                                                                     
      
Left Leg press 
      (3RM)                                                                     
      
 
 
Code each test in the comments column of table by using the format below:  
 
1= Protocol completed 
2= Not completed due to death 
3= Not completed due to refusal, drop-out or loss to follow up 
4=  Not completed due to medical illness or incapacity 
5= Not completed due to equipment failure or examiner error 
6= Not completed due to other cause (specify) 
 
 
Comments:            
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SF-36 Health Status Survey  
(Baseline / 13 Weeks / 26 Weeks) 
Date: _____________ 
This survey asks you your views about your health. This information will help keep track of how 
you feel and how well you are able to do your usual activities. 
 
1. In general, would you say your health is:  1. Excellent 
       2. Very Good 
       3. Good 
       4. Fair 
       5. Poor 
 
2. Compared to one year ago, how would you rate your health in general now?     
1. Much better now than 1 year ago 
2. Somewhat better now than 1 year ago 
3. About the same as 1 year ago 
4. Somewhat worse now than 1 year ago 
5. Much worse now than 1 year ago  
 
3. The following items are about activities you might do during a typical day. Does your health 
now limit you in these activities? If so, how much?  
 
Activities Yes, 
Limited A 
Lot 
Yes, 
Limited 
A Little 
No, Not 
Limited At 
All 
a. Vigorous activities, such as running, lifting 
heavy objects, participating in strenuous 
sports 
1 2 3 
b. Moderate activities, such as moving a table, 
pushing a vacuum cleaner, bowling, or 
playing golf 
1 2 3 
c. Lifting or carrying groceries 1 2 3 
d. Climbing several flights of stairs 1 2 3 
e. Climbing one flight of stairs 1 2 3 
f. Bending, kneeling or stooping 1 2 3 
g. Walking more than a mile 1 2 3 
h. Walking several blocks 1 2 3 
i. Walking one block 1 2 3 
j. Bathing or dressing yourself 1 2 3 
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4. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of your physical health?  
 
 Yes No 
a. Cut down on the amount of time you spent on 
work or other activities 
1 2 
b. Accomplished less than you would like 1 2 
c. Were limited in the kind of work or other 
activities 
1 2 
d. Had difficulty performing the work or other 
activities (for example, it took extra effort) 
1 2 
 
5. During the past 4 weeks, have you had any of the following problems with your work or other 
regular daily activities as a result of any emotional problems (such as feeling depressed or 
anxious)? 
 
 Yes No 
a. Cut down on the amount of time you spent on 
work or other activities 
1 2 
b. Accomplished less than you would like 1 2 
c. Didn’t do work or other activities as carefully 
as usual 
1 2 
 
 
6. During the past 4 weeks, to what extent has your physical health or emotional problems 
interfered with your normal social activities with family, friends, neighbours, or groups?    
   
1. Not at all  
2. Slightly  
3. Moderately 
4. Quite a bit 
5. Extremely 
 
7. How much bodily pain have you had during the past 4 weeks?   
1. None 
2. Very mild 
3. Mild 
4. Moderate 
5. Severe 
6. Very severe 
 
8. During the past 4 weeks, how much did pain interfere   
with your normal work (including both work outside the home and housework)?   
    
1. Not at all  
2. A little bit 
3. Moderately 
4. Quite a bit 
5. Extremely 
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9. These questions are about how you feel and how things have been with you during the past 4 
weeks. For each question, please give the one answer that comes closest to the way you have 
been feeling. How much of the time during the past 4 weeks….  
 
 All of 
the 
Time 
Most 
of the 
Time 
A 
Good 
Bit of 
the 
Time 
Some 
of the 
Time 
A 
Little 
Bit of 
the 
Time 
None 
of the 
Time 
a. Did you feel full of pep? 1 2 3 4 5 6 
b. Have you been a very 
nervous person? 
1 2 3 4 5 6 
c. Have you felt so down in 
the dumps that nothing could 
cheer you up? 
1 2 3 4 5 6 
d. Have you felt calm and 
peaceful? 
1 2 3 4 5 6 
e. Did you have a lot of 
energy? 
1 2 3 4 5 6 
f. Have you felt downhearted 
and blue? 
1 2 3 4 5 6 
g. Did you feel worn out? 1 2 3 4 5 6 
h. Have you been a happy 
person? 
1 2 3 4 5 6 
i. Did you feel tired? 1 2 3 4 5 6 
 
10. During the past 4 weeks, how much of the time has your physical health or emotional 
problems interfered with your social activities (like visiting with friends, relatives etc.)?  
 
1. All of the time 
2. Most of the time 
3. Some of the time 
4. A little of the time 
5. None of the time 
 
 
11. How TRUE or FALSE is each of the following statements for you? 
 
 Definitely 
True 
Mostly 
True 
Don’t 
Know 
Mostly 
False 
Definitely 
False 
a. I seem to get sick a little 
easier than other people 
1 2 3 4 5 
b. I am as healthy as 
anybody I know 
1 2 3 4 5 
c. I expect my health to get 
worse 
1 2 3 4 5 
d. My health is excellent 1 2 3 4 5 
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Geriatric Scale 
(Baseline / 13 Weeks / 26 Weeks) 
Date: _____________ 
 
Choose the best answer for how you have felt in the past week (7 days):       
          
         YES NO 
1. Are you basically satisfied with your life?    1. o o 
2. Have you dropped many of your activities and interests?  2. o o 
3. Do you feel that your life is empty?     3. o o 
4. Do you often get bored?       4. o o 
5. Are you hopeful about the future?     5. o o 
6. Are you bothered by thoughts you can’t get out of your head?  6. o o 
7. Are you in good spirits most of the time?    7. o o 
8. Are you afraid something bad is going to happen to you?  8. o o 
9. Do you feel happy most of the time?     9. o o 
10. Do you often feel helpless?      10. o o 
11. Do you often get restless and fidgety?     11. o o 
12. Do you prefer to stay at home, rather than going out  
and doing new things?       12. o o 
13. Do you frequently worry about the future?    13. o o 
14. Do you feel you have more problems with memory than most? 14. o o 
15. Do you think it is wonderful to be alive now?    15. o o 
16. Do you often feel downhearted and blue?    16. o o 
17. Do you feel pretty worthless the way you are now?   17. o o 
18. Do you worry a lot about the past?     18. o o 
19. Do you find life very exciting?      19. o o 
20. Is it hard for you to get started on new projects?   20. o o  
21. Do you feel full of energy?      21. o o 
22. Do you feel that your situation is hopeless?    22. o o 
23. Do you think that most people are better off than you are?  23. o o 
24. Do you frequently get upset over little things?    24. o o 
25. Do you frequently feel like crying?     25. o o 
26. Do you have trouble concentrating?     26. o o 
27. Do you enjoy getting up in the mornings?    27. o o 
28. Do you prefer to avoid social gatherings?    28. o o 
29. Is it easy for you to make decisions?     29. o o 
30. Is your mind as clear as it used to be?     30. o o    
Record number of answers: 
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PASE 
Physical Activity Scale for the Elderly  
(Baseline / 13 Weeks / 26 Weeks) 
 
© New England Research Institute 
 
LEISURE TIME ACTIVITIES 
 
1. Over the past 7 days, how often did you participate in sitting activities such as reading, 
watching TV or doing handcrafts? 
[0] never   [1] seldom  [2] sometimes  [3] often 
      (1-2 days)      (3-4 days)   (5-7 days) 
 
 
Go to Q.2 
 
 
 
 
 
 
 
 
 
2. Over the past 7 days, how often did you take a walk outside your home or yard for any 
reason? For example for fun or exercise, walking to work, walking the dog etc? 
[0] never   [1] seldom  [2] sometimes  [3] often 
      (1-2 days)      (3-4 days)   (5-7 days) 
 
 
Go to Q.3 
 
 
 
 
 
 
 
 
b) On average, over the past 7 days, how many kms/miles/blocks have you walked? 
 (1 mile = 12 blocks: 1km = 0.625miles).   
 
Number  of blocks _________, or km ________, or miles _________ . 
 
[1] less than 1 mile 
[2] 0ne but less than 2 miles 
[3[ two to 4 miles 
[4] more than 4 miles 
  
1a. What were these activities? 
      _________________________________________ 
1b. On average, how many hours per day did you engage in   
      these sitting activities? 
      [1] less than 1 hour  [2] 1 but less than 2 hours 
      [3] 2 – 4 hours   [4] more than 4 hours 
2a. On average, how many hours per day did you spend  
      walking? 
      [1] less than 1 hour  [2] 1 but less than 2 hours 
      [3] 2 – 4 hours   [4] more than 4 hours 
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3. Over the past 7 days, how many flights of stairs have you climbed up? (one flight = 10 
steps)  Number of steps __________, or flights of steps _________. 
[1] less than 1 flight 
[2] 0ne but less than 2 flights 
[3] two to 4 flights 
[4] more than 4 flights 
 
 
4. Over the past 7 days, how often did you engage in light sport or recreational activities such 
as lawn bowls, bowling, water aerobics, golf with a cart, yoga, tai chi, fishing from a boat or 
pier or other similar activities? 
[0] never   [1] seldom  [2] sometimes  [3] often 
      (1-2 days)      (3-4 days)   (5-7 days) 
 
 
Go to Q.5 
 
 
 
 
 
 
 
5. Over the past 7 days, how often did you engage in moderate sport or recreational activities 
such as doubles tennis, ballroom dancing, golf without a cart, softball or other similar 
activities? 
[0] never   [1] seldom  [2] sometimes  [3] often 
      (1-2 days)      (3-4 days)   (5-7 days) 
 
 
Go to Q.6 
 
 
 
 
 
 
 
 
6. Over the past 7 days, how often did you engage in strenuous sport and recreational activities 
such as jogging, swimming, cycling, singles tennis, aerobic dance, skiing (downhill or cross 
country) or other similar activities? 
[0] never   [1] seldom  [2] sometimes  [3] often 
      (1-2 days)      (3-4 days)   (5-7 days) 
 
 
Go to Q.7 
 
 
 
 
 
 
4a. What were these activities? 
      _________________________________________ 
4b. On average, how many hours per day did you engage in  
      these light sport or recreational activities? 
      [1] less than 1 hour  [2] 1 but less than 2 hours 
      [3] 2 – 4 hours   [4] more than 4 hours 
5a. What were these activities? 
      _________________________________________ 
5b. On average, how many hours per day did you engage in  
      these moderate sport or recreational activities? 
      [1] less than 1 hour  [2] 1 but less than 2 hours 
      [3] 2 – 4 hours   [4] more than 4 hours 
6a. What were these activities? 
________________________________________ 
6b. On average, how many hours per day did you engage in  
      these strenuous sport or recreational activities? 
      [1] less than 1 hour  [2] 1 but less than 2 hours 
      [3] 2 – 4 hours   [4] more than 4 hours 
  
 319 
7. Over the past 7 days, how often did you any exercise specifically to increase muscle 
strength and endurance such as lifting weights or pushups etc? 
[0] never   [1] seldom  [2] sometimes   [3] often 
      (1-2 days)      (3-4 days)   (5-7 days) 
 
 
Go to Q.8 
 
 
 
 
 
 
 
 
 
HOUSEHOLD ACTIVITIES 
 
8. During the past 7 days, have you done any light housework such as dusting or washing 
dishes? 
[1] No [2] Yes 
 
9. During the past 7 days, have you done any heavy housework or chores such as vacuuming, 
scrubbing floors, washing windows or carrying wood? 
[1] No [2] Yes 
 
10. During the past 7 days, did you engage in any of the following activities? 
Please answer Yes or No and give the total time over the past 7 days spent engaging in the 
activities. 
 No Yes Hours/wk 
 
a. Home repairs like painting, wallpapering, 
electrical etc 
1 2  
b. Lawn work or yard care including snow or leaf 
removal, wood chopping etc 
1 2  
c. Outdoor gardening 1 2  
d. Caring for another person such as a 
dependent child, dependent spouse or another 
adult 
1 2  
 
  
7a. What were these activities? 
      _________________________________________ 
7b. On average, how many hours per day did you engage in            
exercise to increase muscle strength and endurance? 
      [1] less than 1 hour  [2] 1 but less than 2 hours 
      [3] 2 – 4 hours    [4] more than 4 hours 
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WORK-RELATED ACTIVITIES 
 
11. During the past 7 days did you work for pay or as a volunteer? 
[1] No [2] Yes 
 
 
 
 
 
 
 
 
 
 
 
 
	
11a. How many hours per week did you work for pay and/or as a volunteer?    
_________hrs/wk 
11b. Which of the following categories best describes the amount of physical 
activity required on         your job and /or volunteer work? 
(1) Mainly sitting with light arm movements (eg. Office work, watch maker, 
seated assembly line worker, bus driver etc) 
(2) Sitting or standing with some walking (eg. Cashier, general office 
worker, light tool and        machinery worker) 
(3) Walking with some handling of materials generally weighing less than 
50 pounds (eg. Mailman, waitress, construction worker, heavy tool and 
machinery worker) 
(4) Walking and heavy manual work often requiring handling of materials 
weighing over 50 pounds (eg. Lumberjack, stone mason, farm or 
general labourer. 
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PASE Score 
 
PASE Activity Score PASE 
weight 
PASE 
score 
Muscle strength/endurance* h/d 30  
Strenuous sports* h/d 23  
Moderate sports* h/d 23  
Light sports* h/d 21  
Job involving 
standing/walking* 
h/d 21  
Walking*           h/d 20  
Lawn work or yard care  36  
Caring for another person  35  
Home repairs  30  
Heavy housework  25  
Light housework  25  
Outdoor-gardening  20  
PASE Total   
* determine the average number of hours/day (h/d) over a 7-day period 
  1= engaged in activity during the previous 7 days 
  0= did not engage in activity during the previous 7 days 
 
 
 
Paffenberger Score 
 
 Blocks walked/wk X 4 kcal / block = kcal 
 Flights climbed/wk X 8 kcal / flight = kcal 
 Minutes light sport/recreation/wk X 5 kcal / min = kcal 
 Minutes moderate sport/ 
recreation or muscle strength/wk 
X 7.5 kcal / min = kcal 
 Minutes heavy sport/ 
recreation/wk 
x 10 kcal / min = kcal 
total             kcal 
/ week 
 
 
Comments : 
q protocol completed 
q not completed due to death 
q not completed due to refusal, drop-out or loss to follow-up 
q not completed due to medical illness or incapacity 
q not completed due to examiner failure or error 
q not completed due to other : _______________________________________________ 
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Appendix 11. Weekly Status Check 
Study ID #    
Date:_________________   Week #:     
Interviewer:______________________Telephone___In-person___ 
During the past week have you had any of the following? 
       Yes   No 
 
1.  Acute illnesses     r   r 
 Specify___________________________  
_______________________________________  
2.  Change in medication (prescribed, over-the- 
counter, herbal, nutritional supplement)  r   r 
 Specify       
        
3.  Visits to a health care professional  r   r 
Kind__________________________ 
Indication______________________ 
Treatment______________________ 
4.  New physical, mental, or emotional 
symptoms of any kind    r   r 
Describe:________________________________ 
_______________________________________ 
_______________________________________ 
5.  Falls      r   r 
Number________ 
Circumstance(s)________________________ 
_____________________________________ 
Injury________________________________ r   r 
 
6.  Have you attended all exercise sessions?  r   r 
If not, number attended___________________ 
Reason for missed session(s)______________ 
_____________________________________ 
8.  Other Questions or Comments of subject: 
______________________________________________________________________________
______________________________________________________________________________
_____________________________________________________________________  
 Comments : 
q protocol completed 
q not completed due to death 
q not completed due to refusal, drop-out or loss to follow-up 
q not completed due to medical illness or incapacity 
q not completed due to examiner failure or error 
not completed due to other : __________________
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Appendix 12. Protocol for exercise intervention 
 
Seated Bicep Curl with dumbbell 
This exercise strengthens the upper arm muscles which flex the elbow. 
 
1. Sit erect and towards the front of the chair. Hold a dumbbell at the side, and the palm of 
your hand facing forward. 
 
2. Lift the dumbbell towards the shoulder by bending at elbow.  
 
3. Lower the dumbbell slowly to the starting position. 
 
Tips: 
§ Sit forward in the chair for this exercise to allow full ROM. 
 
§ Use the arm to move the weight – not the shoulder. 
 
§ Maintain good posture by sitting upright and not arching or slouching the back. 
 
 
Seated Shoulder Press with dumbbell 
This exercise strengthens the muscles of the shoulder and back of the upper arm which 
required to reach overhead. 
 
1. Sit upright holding the dumbbell at shoulder level with palms facing forward. 
2. Slowly lift the dumbbell so that it is over the head. 
3. Lower the dumbbell following the same path and repeat. 
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Tips: 
§ Don’t arch the back during the lift. 
 
§ Keep lifting arm close above the body when lifting or lowering the weights. 
 
 
Seated Tricep Extension with dumbbell 
This exercise will strengthen the muscles at the back of the upper arm which straighten out the 
elbow. 
 
1. Sit upright and extend the arm straight up (pre-dialysis training), with the palms facing 
towards the body.  
 
2. Slowly bend at elbow so that the elbow is lowered behind and slightly to the side of the head. 
 
3. Return the dumbbell slowly to starting position.  
 
Tips: 
§ Ensure the elbow stays as close to the ear as possible throughout the motion. 
 
When training your fistula arm prior to dialysis, use your non-fistula arm to hold just below the 
elbow to help support the fistula arm throughout the exercise. During dialysis the trainer will 
support the training arm. 
 
Seated Row with machine 
This exercise will strengthen the muscles at the back of the upper torso needed to lift objects up 
or towards the body. 
 
1. Sit upright with the back supported by the chair. The exercise machine’s wheels should be 
locked prior to exercising. 
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2. Start with the arm extended away from the body with the palms facing down towards the 
floor.  
 
3. Slowly pull back by bending at elbow back and to the side so that the elbow is slightly below 
the shoulder. 
 
4. Return slowly to starting position.  
 
Tips: 
§ Ensure the whole arm is always below shoulder level at all times when performing the 
action.  
 
§ Do not bend at the wrist to avoid placing undue strain on it.  
 
Keep the legs on the leg rest to stable yourself. 
 
Seated Chest Press with machine 
This exercise will strengthen the muscles at the chest needed to push objects away from the body 
or the body off the floor.  
 
1. Sit upright with the back supported by the chair. The theraband should be secured to the back 
of the chair.  
 
2. Start with the arm bent, elbow to the side and with the palm facing down towards the floor. 
The theraband should be taut before beginning.  
 
3. Slowly push forward by straightening at elbow fully before return slowing to starting 
position. 
 
Tips: 
§ Ensure the whole arm is always below shoulder level at all times when performing the 
action.  
 
Do not bend at wrist to avoid placing undue strain on it. 
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Seated Back Extension with elastic tubings  
This exercise will strengthen the muscles at lower backed needed to stand up straight.  
 
1. Sit leaning forward towards the knee on the chair but still keeping the back straight as much 
as one can. The elastic tubing was wrapped around the upper back and below the armpits 
with the exercise physiologist holding the elastic tubing in front.   
 
2. Secure the theraband and keep it taut at the beginning position.  
 
3. Sit back before returning to the earlier position.  
 
Tips:  
 
§ Ensure the spine remain close to neutral position when bending forward and backward.  
 
 
Leg press with machine 
This exercise strengthens the muscles that are required to stand up from a chair.  
 
1. Put both feet on the lower leg rest of the machine, shoulder width apart.  
 
2. Push forward with both feet and straighten your legs.  
 
3. Slowly return to original position.   
 
Tips:  
If the maximum weight available on the machine is too light, use single leg to do the exercise and 
start with a weight about as heavy as the maximun weight. 
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Seated Knee Flexion with machine 
This exercise strengthens the muscles at the back of the thighs which brings the lower legs behind 
the thighs.   
 
1. Sit upright, put both feet on the top leg rest of the machine, shoulder width apart.  
 
2. Elevate the chair so that the legs are rested on the leg rest just behind the ankles.   
 
3. Bend at your knees and bring both feet towards your chair. Then slowly return to original 
position.   
 
Tips:  
§ If the maximum weight available on the machine is too light, use single leg to do the 
exercise and start with a weight about as heavy as the maximum weight. 
 
§ Lean forward slightly to avoid slipping off the chair.   
 
Seated Knee Extension with theraband 
This exercise strengthens the muscles at the front of the thighs which straighten the legs.   
 
1. Sit upright, elevate the chair and position the top leg rest just on top of the ankle, legs 
shoulder width apart.  
 
2. Straighten the legs at the knees with a slow kicking motion against the leg rest. Then 
slowly return to original position.   
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Supine bent knee hip flexion with machine 
This exercise strengthens the muscles of the lower abdomen that bring the thigh closer to the 
chest. 
 
1. Secure the exercise machine by locking its wheels, secure the strap to one ankle and lie 
flat on the back. The exercise cable secured to the ankle should be taut before beginning.  
 
2. Bring the knee towards the chest till it is bent around 90 degree angle. 
 
3. Lower to starting position slowly following the same path. Complete a set before 
changing to the other leg. 
 
Tips: 
§ Maintain controlled movements, and keep upper body still during the lift. 
 
§ Don’t continue lift if back pain occurs. 
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Appendix 13. Borg Scale for Rating of Perceived Exertion 
Rating of Perceived Exertion 
“During exercise, we want you to pay close attention to how hard you feel the exercise 
work rate is. This feeling should reflect your total amount of exertion and fatigue, 
combining all sensations and feelings of physical stress, effort, and fatigue. Don’t 
concern yourself with any factor such as leg pain, shortness of breath or exercise 
intensity, but try to concentrate on your total inner feeling of exertion. Try not to 
underestimate or overestimate your feelings of exertion; be as accurate as you can.”  
      (Borg, 1998) 
 
Reference:  
Borg G. Borg's Perceived Exertion and Pain Scales. Human Kinetics. 1998. (Figure 7.3 page 49) 
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 Appendix 14. Exercise Log Sheet 
 
  
 
 
